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Abstract 
 
Rab25 is a small GTPase of the Rab11 family that is known to control endosomal 
trafficking and the return of internalised receptors to the plasma membrane. 
Recent reports that Rab25 can act as either a promoter or suppressor of 
tumourigenesis highlight the need for greater understanding of how it controls 
integrin trafficking. In this thesis I show data indicating that Rab25 permits the 
sorting of ligand-occupied, active conformation α5β1 integrin to late 
endosomes/lysosomes. Novel photoactivation and biochemical approaches show 
that integrins thus sorted are not degraded, but rapidly recycled from late 
endosomes/lysosomes to the plasma membrane. This requires the Chloride 
Intracellular Channel 3 (CLIC3); a protein resident in late endosomes/lysosomes 
of previously unknown function, that is upregulated in Rab25-expressing cells. 
Here I show that CLIC3 exists in close proximity with active α5β1 in late 
endosomes/lysosomes and is required for cancer cell invasion into fibronectin–
containing three-dimensional matrices. Clinical data indicate that CLIC3 is 
expressed in ovarian cancers, pancreatic ductal adenocarcinoma (PDAC) and 
pancreatic intraepithelial neoplasea (PanIN), but is absent from normal pancreas 
and tumour-associated stroma.  Moreover, Kaplan-Maier analyses demonstrate a 
strong correlation between high levels of CLIC3 (at both mRNA and protein 
levels) and poor prognosis in operable cases of PDAC.  
 
Taken together, the findings presented in this thesis identify CLIC3 both as a 
regulator and component of a novel vesicular transport route that returns 
lysosomally-targetted integrins to the plasma membrane, and as an independent 
prognostic indicator in pancreatic cancer.   
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1 Introduction 
1.1 Cancer cell invasion and metastasis 
1.1.1 Features of cancer 
Cancer is a multi-faceted disease represented by more than a 100 distinct types 
and subtypes originating from various organs in the body. It is believed that 
cancer development and progression mimics the process of evolution, in that 
successive genetic aberrations accumulate overtime and gradually lead to 
transformation of normal cells into tumour cells. Tumorigenesis requires the 
acquisition of six hallmarks, which allow the progressive transformation of 
normal tissue into malignancy (Fig. 1.1). Firstly, cells have to display growth 
signal autonomy, which removes their dependence on exogenous signals 
transmitted into the cell by transmembrane receptors, and that in turn allows 
them to progress from a quiescent into a proliferative state. Secondly, tumour 
cells acquire insensitivity to antiproliferative signals, which are also received by 
cell surface receptors and are utilised to maintain cellular quiescence and hence 
need to be circumvented in order for tumour cells to thrive. Thirdly, cancer cells 
have to acquire resistance towards programmed cell death – apoptosis - a 
process during which cellular components are being disrupted and cell remnants 
are being engrossed by the surrounding cells. Apoptosis allows for the 
elimination of cells harbouring activating oncogenic mutations, which if not 
eradicated, can proliferate to form a tumour mass.  An additional prerequisite 
for the transformation of a normal cell to its cancerous counterpart is 
immortalisation, which is defined as the ability to replicate indefinitely, a 
feature, which normal cell populations lack since they enter the state of 
senescence after a certain number of doublings. Moreover, aberrant cells 
forming the initial neoplasia have to induce and sustain angiogenesis if they are 
to expand to bigger tumours. The proximity of vasculature is necessary to 
maintain oxygen and nutrient supply, which is indispensible for cell function and 
survival. Lastly, most tumours will acquire the ability to invade and spread to 
distant sites of the body, in a process called metastasis, which accounts for 90% 
of cancer-related deaths (Hanahan and Weinberg 2000). 
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Figure 1-1 The six acquired capabilities of cancer.  
Adapted from (Hanahan and Weinberg 2000). 
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1.1.2 Cancer metastasis  
Metastatic spread is a multi-step process and involves a number of stages, such 
as alterations in cell adhesion, acquisition of invasive capabilities, entry into the 
circulation and transit to distant tissues, followed by exit into new sites and 
ultimately colonisation of new niches (Fig. 1.2). A primary step in the metastatic 
cascade is the detachment of cancer cells from a solid tumour mass, which is 
mediated by their decreased adhesive potential. Changes in the expression of a 
number of different protein classes can contribute to the loss of cellular 
adherence to both the surroundings and also to one another. These proteins 
include cell-cell adhesion molecules (CAMs) that mediate cell-cell interactions, 
and integrins, which provide a link between the extracellular matrix and the cell 
interior (Hanahan and Weinberg 2000). One of the most prominent changes 
occurring upon malignant epithelial transformation is the mutational inactivation 
of E-cadherin, which under normal circumstances provides a bridge between 
adjacent epithelial cells and also serves as a scaffold for anti-growth signalling 
to its downstream effectors such as β-catenin and Tcf transcription factor 
(Christofori and Semb 1999). Upon E-cadherin loss and detachment from the 
primary tumour mass, invasive cells need to breach the basement membrane, 
which underlies epithelial cell layers. The basement membrane is a well-
organised, dense meshwork of glycoproteins and proteoglycans (such as type IV 
collagen and laminins), which maintains epithelial structure and provides a 
physical boundary for epithelial tumour invasion into the surrounding stroma. To 
disrupt the structure of this barrier, cancer cells employ matrix-degrading 
proteases. Under normal circumstances, the activity of extracellular matrix 
proteases is subject to tight regulation through both autoinhibition and secreted 
inhibitors. However, in tumours that exhibit metastatic capabilities, protease 
expression is elevated and accompanied by a decrease in the abundance of 
protease inhibitors, thus facilitating the invasion of cancer cells through the 
basement membrane and the adjacent extracellular matrix. Having invaded 
through the basement membrane and the surrounding matrix, tumour cells must 
penetrate the tumour-associated vasculature in a process referred to as 
intravasation. This is usually preceded by the activation of angiogenic processes, 
which result in the establishment of neo-vasculature, and which allow the 
tumour to grow beyond what would be possible if tumour cells relied only on 
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nutrient and oxygen supply from pre-existing blood vessels. The exact 
mechanism by which intravasating cells breach the boundaries of tumour-
associated vessels is unclear, but it is believed to result from enhanced 
mesenchymal motility of invasive cell sub-populations and their responsiveness 
to chemoattractive gradients originating from the vasculature. When in 
circulation, disseminated cells must be able to avoid anoikis, oppose shear 
forces that could lead to physical damage and they also need to evade being 
targeted and killed by immune cells (Gupta and Massague 2006). Having 
intravasated and survived in the circulation, invasive cells must mechanically 
lodge themselves in the walls of capillaries and escape the vasculature to enter 
secondary sites: a process referred to as extravasation. Vascular endothelial 
growth factor (VEGF) released by metastatic cells is thought to yield vascular 
permeability by activating Src family kinases in the endothelial cells and thus 
disrupting endothelial cell junctions. This in turn can facilitate extravasation of 
circulating tumour cells and metastatic spread (Criscuoli, Nguyen et al. 2005). 
When out of the blood vessels and at a secondary site, cancer cells face yet 
another rate-limiting step, the hostility of the new environment. It is interesting 
to note that disseminated tumour cells will likely only colonise niches that are 
compatible with their growth requirements, and most cancer types have their 
preferred recurrence sites. Indeed, breast cancer will metastasise to the bones, 
lungs, liver and brain, even though no direct vasculatory connection exists 
between these sites and breast tissue. Prostate cancer on the other hand, will 
predominantly show metastatic outgrowth in the bones, whilst sarcomas tend to 
target the lungs (Gupta and Massague 2006). One mechanism, which is 
postulated to aid in the metastatic colonisation of target niches, is 
preconditioning of these sites by VEGFR1-positive bone marrow cells, which are 
recruited to these sites in response to factors released by the primary tumours 
and create a permissive environment for the incoming disseminated tumour cells 
(Kaplan, Riba et al. 2005). Once metastatic cells have adapted to the new site 
by overcoming possible quiescence, by establishing interactions with the 
microenvironment and by initiating angiogenetic cues, the colonisation of the 
secondary organ can proceed through the formation of micrometastases and be 
successfully completed by their outgrowth into macrometastatic lesions.  
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Figure 1-2 Cancer metastasis.  
Formation of metastases is a multistep process, during which cancer cells disseminate from the 
primary tumour, enter the circulation with which they travel to distant sites of the body, where they 
extravasate to then populate new niches and form secondary lesions. Figure adapted from 
http://cancer.scripps.edu/research.aspx. 
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1.1.3 Modes of tumour cell migration  
The process of metastasis, as it was described in the previous section, requires 
cancer cells to be motile. The acquisition of a motile phenotype by epithelial 
cells often requires a myriad of transcriptional alterations, which lead to 
epithelial-mesenchymal transition (EMT), a process mainly driven by the 
activation of AP1 and SMAD2 transcription factors and Snail/slug transcription 
repressors (Thiery 2002). When invading through three dimensional 
environments, tumour cells can exhibit two major and mutually interchangeable 
modes of migration: mesenchymal and amoeboid, and migration can occur 
individually or collectively (Fig. 1.3) (Pankova, Rosel et al.).  
1.1.3.1 Individual cell migration 
The mesenchymal mode of migration is characterised by an elongated 
morphology with well-established front-to-back cellular polarity (represented by 
the presence of a leading and trailing edge), and it relies on proteolytic 
degradation of the extracellular matrix (ECM) by proteases such as MMPs. Cells 
utilising this mechanism of movement extend actin rich protrusions, in the form 
of a flat lamellipod, a cylindrical or rounded pseudopod or spiky filopodia. These 
protrusions form integrin-mediated focal contacts with the ECM, and these 
attachment sites can progress to form larger focal adhesions, which are capable 
of transmitting actomyosin contractile force to the ECM. This in turn facilitates 
the forward movement of the cell body, which follows the leading edges and 
allows for the retraction of the trailing edge. Velocities achieved by cells 
adopting this migratory behaviour are relatively low and in the range of 0.1-
1µm/min. This migratory behaviour is frequently triggered by the activation of 
receptor tyrosine kinases, such as EGFR1 or c-Met, which is followed by the 
generation of phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) at the 
cell front, where a GTPase Rac undergoes activation and recruits other 
components of mesenchymal migratory machinery, such as Scar/WAVE proteins 
and the Arp2/3 complex. Arp2/3 then nucleates monomeric G-actin into F-actin 
filaments. Alternatively, this cascade can be initiated either by the activation of 
Cdc42 or by oncogenic Ras proteins, which contribute to the augmentation in 
PtdIns(3,4,5)P3 by activating PI-3 kinase. Conversely, tumour suppressor PTEN 
can, by dephosphorylating PtdIns(3,4,5)P3, antagonise this process (Sahai 2005). 
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The mesenchymal mode of migration requires downregulation of the activity of 
RhoA and its effectors (Rho-associated coiled-coil containing protein kinases, 
ROCK1 and ROCK2), which in turn can activate Rac to drive polarised F-actin-rich 
protrusion formation (Vial, Sahai et al. 2003). 
Another mode of migration, which is thought to resemble the crawling 
movement of leukocytes and the lower eukaryote Dictyostelium discoideum, can 
occur with speeds up to 4µm/min and is referred to as amoeboid motility. In 
contrast to mesenchymal motility, this mode of migration relies on the activity 
of the RhoA-ROCK pathway and does not require ECM proteolysis, but rather 
forces cells to squeeze through existing gaps in the matrix. Moreover, amoeboid 
motility is not characterised by the presence of large cell-ECM contacts, instead 
receptors mediating adhesion formation are diffusely distributed on the cell 
surface (Sahai 2005). This type of movement is thought to occur due to actin 
polymerisation around the cell cortex. This is driven by active RhoA, which 
recruits ROCK family of kinases to phosphorylate a number of cytoskeletal 
substrate proteins thus leading to stress fibre formation and generation of 
contractile force that drives amoeboid, bleb-like movement (Sahai and Marshall 
2003) 
1.1.3.2 Collective tumour cell migration and motility mode-switching 
In contrast to individual cell motility modes described in the previous paragraph, 
collective cell movement involves migration of whole clusters, sheets or strings 
of invasive cells and is frequently employed by cancer lesions for tissue invasion 
in vivo. This requires the maintenance of adhesion contacts between migrating 
cells and relies on the cells that lead the invading sheet to release matrix-
degrading enzymes, and thus create a migratory path for the remaining cells. 
During invasive migration, cells employ a number of different matrix remodelling 
proteases, which are capable of cleaving numerous ECM substrates, such as 
collagen, laminins, fibronectin or vitronectin. These ECM-degrading enzymes 
include matrix metalloproteinases (MMPs), serine proteases as well as 
cathepsins, and can be released by both tumour cells and tumour associated 
fibroblast at the leading edge of the migrating sheet. Microtracks, resulting from 
ECM-degradative activity of individual cells are formed and subsequently filled 
by adjacent cells from the migrating sheet thus leading to track widening, local 
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matrix regression and tissue macropatterning, which allows for collective gliding 
of the entire sheet. Although synergistic action of a number of proteolytic 
enzymes capable of breaking down collagen type I and type III fibres, such as 
MMP-1, MMP-2, MMP-13, MMP-14 and cathepsin B, K and L, is necessary for 
effective disruption of tissue integrity, it is MMP-14 that could potentially be 
targeted by anti-invasive therapy. This is due to the loss of function of MMP-14 
not being easily compensated for by the activity of other proteases (Friedl and 
Wolf 2008).  
An interesting feature of some disseminating tumour cells is their ability to 
switch between different modes of migration. Unlike EMT, mesenchymal-
amoeboid transition (MAT), amoeboid-mesenchymal transition (AMT) and 
collective-to-amoeboid transition (CAT), can be triggered in response to 
changing tumour microenvironments during different stages of the metastatic 
cascade, and can occur as a consequence of differential control of specific 
signalling pathways (Pankova, Rosel et al.). This plasticity of motile tumour cells 
can allow evasion of anti-metastatic treatments that are targeted at one 
molecular pathway only. A successful anti-spread regimen in vivo is therefore 
likely to require a simultaneous anti-protease and anti-Rho/ROCK therapy, that 
would inhibit both types of motility and would prevent switching between the 
varying migratory modes (Sahai and Marshall 2003). 
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Figure 1-3 Depiction of different migration modes. 
A. Individual cell migration can occur through the adaptation of two main phenotypes. Amoeboid 
cells are rounded and migrate through the ECM in a proteolysis-independent manner, whilst 
mesenchymal cells are elongated and require matrix degradation for their migration. Cell migration 
can also be collective and takes form of either strands or clusters. B. Tumour cells can switch 
between varying modes of migration in response to changing environment. Adapted from (Friedl 
and Wolf 2003). 
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1.2 Integrin receptors 
1.2.1 An overview of integrins 
The ability of cells to detect their environment is crucial for the development of 
multicellular organism and for maintaining its homeostasis. Cells can sense their 
surroundings by establishing interactions with neighbouring cells or with the 
extracellular matrix (ECM). These interactions are required for a range of 
processes such as cell growth, proliferation, differentiation and migration. The 
communication between the extracellular matrix and the cellular interior is 
primarily mediated by the integrin family of adhesion receptors. 
Integrin receptors are transmembrane and heterodimeric glycoproteins, each 
composed of an α and a β subunit. Integrin expression is restricted to metazoan 
organisms and no homologues are detected in prokaryotes, plants or fungi. In 
mammals, 18 α (α1- α11, D, E, L, M, V, X, IIb) and 8 β (β1- β8) subunits are 
known, and they can assort to form 24 distinct heterodimers (Hynes 2002). Some 
integrins are specific to certain tissue or cell types, like αIIbβ3 to platelets or 
α6β4 to keratinocytes, while others, such as αvβ3 or α5β1 are more widely 
expressed. α subunits share approximately 30%, and β subunits approximately 
45% sequence identity, thus indicating that they could have arisen from gene 
duplication events. With respect to ligand specificity, integrins can be divided 
into laminin- or collagen-binding, those that recognise RGD sequences and 
leukocyte-specific integrins (Fig. 1.4). Most integrins recognise a short peptide 
sequence within their ligands, and the recognition and binding requires both 
subunits of the heterodimer (Hynes 2002; Takada, Ye et al. 2007). Each integrin 
subunit spans the plasma membrane once, and contains a short cytoplasmic 
domain (20-50 amino acids), with the majority of the polypeptide residing in the 
extracellular portion. The cytoplasmic tail of most integrins connects via a 
number of adaptor molecules, to the actin cytoskeleton, which these receptors 
can modulate (Hynes 2002). With regard to the connection to actin filaments and 
the size of cytoplasmic domain, integrin α6β4 is an exception. It is unique in that 
its cytoplasmic domain is much larger and extends over 1000 amino acids 
(Tamura, Rozzo et al. 1990), whilst making connections not to the actin 
cytoskeleton but to intermediate filaments (Homan, Martinez et al. 2002).  
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Figure 1-4 The integrin adhesion receptor family.  
Integrins are composed of α and β subunits. There are 18 mammalian α and 8 β isoforms and they 
assemble to form 24 distinct heterodimers with defined ligand specificities. Asterix indicates 
subunits with alternative splice variants. Figure taken from (Hynes 2002). 
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1.2.2 Extracellular domain of integrins 
In their extracellular portion, almost half of the mammalian α subunits (α1, 2, 
10, 11, M, L, D, X) contain the I/A domain, which forms a Rossmann fold 
composed of parallel β-sheets within the core of this motif, and α-helices on its 
periphery. The I/A fold in the α subunit associates with the corresponding I/A 
domain in the β subunit (Lee, Bankston et al. 1995). This fold belongs to the 
group of von Willebrand factor A domains (VWA), which are approximately 180 
amino acids long and mediate protein-protein interactions, and in the case of 
integrins, are responsible for ligand binding (Tuckwell 1999). The upper surface 
of the I/A motif contains a metal ion coordination site, which is formed by amino 
acids from three separate loops within that domain. The placement of the metal 
ion within the metal ion-dependent adhesion site (MIDAS) is thought to 
determine the conformation of the I/A domain, which can be either open or 
closed. The other half of mammalian α subunits, which lack the inserted I/A 
domain, contains seven sequence repeats that span over 440 amino acids and 
fold into a 7-bladded β-propeller, and this motif forms complexes with the I/A 
domain in the β subunit of the heterodimer (Springer 1997). More detailed 
insights into integrin structures were gained in 2001, when Xiong and colleagues 
solved the crystal structure of αvβ3 integrin. These studies confirmed that the 
propeller contained within the α subunit complexes with the I/A domain in the β 
subunit to form the ligand binding pocket (Fig. 1.5). This N-terminal, 
extracellular tail of the integrin heterodimer has been shown to rest on two 
legs, each belonging to one of the subunits. Within the leg of the α subunit 
reside three domains termed: thigh, calf1 and calf2, each formed by β-sandwich 
motifs. Between the thigh and the first calf domain lies a high flexibility region, 
which is thought to allow for bending of the integrin head, and to take part in 
integrin activation and conformational change. The organisation of the β subunit 
is a little more complex, in that the most membrane distal extracellular part of 
the molecule, which forms the ligand-binding head, does not constitute its most 
N-terminal primary sequence. It is instead inserted into a β-sandwich loop and 
forms a so called hybrid-I/A domain, which in its primary sequence is preceded 
by a 54-amino acid stretch that forms the PSI domain. This domain, in the three-
dimensional structure, lies beneath the head domain and is linked to the distal 
terminus of the β-subunit leg by a disulphide bond. The leg is composed of four 
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cystine-rich repeats, which form EGF-like folds. At the C-terminus of the EGF-
like folds resides the β-sheet-rich motif, termed the β-tail domain (Xiong, Stehle 
et al. 2001).  
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Figure 1-5 Schematic structure of an integrin heterodimer. 
The α subunit contains in its extracellular part: two calf domains and a thigh domain, which form its 
leg. Positioned on the leg is β-propeller domain, which interacts with I/A domain of the β subunit. β-
propeller and I/A domain form the head of the heterodimer, which contains the ligand binding site. 
The leg of the β subunit is composed of the PSI domain and four EGF repeats. Each subunit 
contains one transmembrane domain and a cytoplasmic tail. 
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1.2.3 Integrin cytoplasmic domain 
The cytoplasmic domains of integrin receptors are much shorter than their 
extracellular portions and they only comprise approximately 50 amino acids. 
Even though they reside approximately 180Å away from the ligand binding site 
(Weisel, Nagaswami et al. 1992), truncations in the cytoplasmic domains of some 
integrins, for example α2 (Kawaguchi and Hemler 1993) or β2 (Hibbs, Xu et al. 
1991) have been shown to modulate their ligand binding affinity. This suggested 
that the integrin cytoplasmic tail is not only key for transducing ligand 
occupation and conformational changes to the cell interior, but it also controls 
the conformation of the extracellular domain and activity status of the receptor 
from within the cell.  
The β integrin cytoplasmic tails have been described to exist in alternatively 
spliced forms and this contributes to the variety of biological functions played by 
these rceptors. β1 integrin, for example, is thought to have 4 distinct 
cytoplasmic splice variants: β1A, β1B (Balzac, Belkin et al. 1993), β1C (Languino 
and Ruoslahti 1992) and β1D (Zhidkova, Belkin et al. 1995), and these are 
expressed in different tissues or cell types. The β1A integrin is the most 
ubiquitously expressed isoform and is involved in a wide range of biological 
processes (Almeida, Huovila et al. 1995; Fassler, Rohwedel et al. 1996), is 
capable of clustering, forming cell-matrix adhesions and mediating signalling. 
The β1B and β1C isoforms are minor variants and are expressed in some human 
cells and tissues, such as hematopoietic cell lines, platelets and osteosarcoma 
cells (Languino and Ruoslahti 1992), and differentiated epithelium (Fornaro, 
Tallini et al. 1996), respectively. The β1D isoform is specifically expressed in 
heart and skeletal muscle and is the most prominent β1 integrin in these tissues 
(van der Flier, Kuikman et al. 1995). The functional differences between the 
different isoforms are exemplified by their varying affinity for binding of 
cytoskeletal proteins such as talin and filamin. Indeed, talin binding is inhibited 
in splice variants β1B and β1C, whilst the β1D isoform binds talin more tightly 
than does β1A (Pfaff, Liu et al. 1998). In agreement with this, is the inability of 
the β1B variant to bind fibronectin, form cell-matrix adhesions and induce 
downstream signalling (de Melker and Sonnenberg 1999). 
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The highly conserved β1 integrin cytoplasmic tail contains three amino acid 
sequences, which have been found to be necessary for integrin targetting to 
focal adhesions, heterodimer formation and binding of cytoplasmic partners. 
These conserved clusters include: cyto-1 (AA 764-774), cyto-2 (AA 785-788) and 
cyto-3 (AA 797-800), and they are conserved amongst β subunits, with the 
exception of β4. Cyto-1 region is thought to mediate adhesion and to affect 
integrin affinity and specificity. Cyto-2 and cyto-3 contain NPXY and NXXY motifs 
(X represents a non-conserved amino acid), respectively, which function to 
recruit integrins to focal contacts and allow their binding to cytoskeletal 
proteins. Additionally, phosphorylation at conserved serine790 or tyrosine788 is 
thought to affect integrin function (Reszka, Hayashi et al. 1992). The β1A and 
β1D variants are very similar and only differ by 13 amino acid residues, half of 
which reside in the region that links cyto-2 and cyto-3 domains (Hannigan, 
Leung-Hagesteijn et al. 1996).  
Surface plasmon resonance (Vallar, Melchior et al. 1999) and NMR spectrometry 
(Vinogradova, Velyvis et al. 2002) of αIIbβ3 cytoplasmic tails have revealed an 
interaction between the α and β subunits within their membrane proximal 
regions. This association has been shown to require the presence of the 
conserved GFFKR sequence in the α subunit (Loh, Qi et al. 1996), and the cyto-1 
domain of the β1 integrin (which contains KLLMIIHDRR sequence) has been 
proposed to be involved in this interaction (Briesewitz, Kern et al. 1995). 
Mutations in the above mentioned region of β1 have been shown to ablate this 
association (Hayashi, Haimovich et al. 1990; Marcantonio, Guan et al. 1990). 
Additionally, heterodimerisation of the cytoplasmic tails has been proposed to 
occur via the hydrophobic stretches within the cyto-1 and GFFKR regions of β 
and α subunits, respectively (Williams, Hughes et al. 1994). 
The cytoplasmic tails of integrins mediate their cell biological functions by 
binding to cytoplasmic proteins and this is thought to occur through a 
structurally conserved mechanism. Most β integrins contain one or two NPXY or 
NPXY-like motifs. The NPXY sequence has a propensity to form a β-turn (Ulmer, 
Yaspan et al. 2001), and such reverse-turn-forming modules often serve as a 
recognition site for phosphotyrosine-binding (PTB) domains that constitute most 
signaling and cytoskeletal molecules (Trub, Choi et al. 1995). Indeed, most 
integrin interactions with cytoplasmic proteins have been proposed to be 
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mediated by the NPXY-PTB affinity. For example, NPXY motif of the β1 integrin 
is critical for PTB-mediated binding to integrin cytoplasmic domain-associated 
protein (ICAP)1-α (Chang, Hoang et al. 2002). Also β3 integrin binding to the PTB 
domain of talin requires the presence of the NPXY fold in the cytoplasmic tail of 
the integrin (Calderwood, Yan et al. 2002). Furthermore, a number of other PTB 
domain-containing proteins, such as Numb, Dok-1, Dab1, EPS8, and tensin, have 
been shown to interact with β integrin cytoplasmic tails via this mechanism, 
which supports the generality of this type of association (Calderwood, Fujioka et 
al. 2003). 
Phosphorylation of the tyrosine (Y) within the NPXY module of the β integrin 
cytoplasmic tail, which is mediated by Src family kinases, is thought to be key to 
processes such as cell adhesion and migration (Sakai, Jove et al. 2001). The 
addition of phosphate group is thought to modulate the binding of integrin to 
distinct PTB-containing effectors. Indeed, whilst the binding of ICAP1-α is 
phosphorylation independent (Chang, Hoang et al. 2002), the association with 
Shc is facilitated by this event (Cowan, Law et al. 2000). On the other hand, 
phosphorylation of the NPXY motif decreases the affinity of talin binding (Oxley, 
Anthis et al. 2008). 
The cytoplasmic portions of α integrins are also capable of forming associations 
with cytoplasmic proteins, and although these interactions are more elusive than 
those formed by β subunits, they also seem to modulate integrin affinity and 
function. Mammary-derived growth inhibitor (MDGI) has been recently shown to 
bind to the tail of several α integrin cytodomains, such as α1, α2, α10 and α11, 
and this is thought to suppress integrin function (Nevo, Mai et al.). α5 integrin 
cytoplasmic tail has been shown to form complexes with zonula occludens-1 (ZO-
1) at the leading edge of migrating cells, in a process that requires PKCε 
activation (Tuomi, Mai et al. 2009). Also, Rab21 has been demonstrated to 
associate with the cytoplasmic tails of α integrin subunits through their 
membrane proximal conserved segment GFFKR, in which residue R1161 appears 
to be particularly important (Pellinen, Arjonen et al. 2006). Integrin α1 
cytodomain can interact with T-cell protein tyrosine phosphatase (TCPTP) and 
this interaction activates the phosphatase, which in turn exerts negative 
regulation on EGFR phosphorylation (Mattila, Pellinen et al. 2005). Paxillin, a 
signalling adaptor protein, has been shown to bind to a 9 amino acid region (983-
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991) in the α4 integrin cytodomain and this interaction is implicated in α4 
integrin signalling (Liu and Ginsberg 2000). Interactions between the α2 as well 
as αIIb cytotail and cytoplasmic molecules have also been described. CIB 
associates with a hydrophobic 15 amino acid membrane-proximal region of αIIb 
cytotail (Barry, Boudignon-Proudhon et al. 2002), whilst α2 cytodomain directly 
associates with F actin (Kieffer, Plopper et al. 1995). 
1.2.4 Integrin signalling 
Integrin adhesion to their extracellular substrates exerts effects on a number of 
signal transduction pathways, which modulate a variety of cellular processes and 
behaviours, such as gene expression, proliferation, growth, apoptosis, cell 
shape, polarity and motility. Signalling downstream of integrins is similar to and 
intimately linked with signal transduction events originating from receptors for 
soluble ligands, such as G protein-coupled receptors (GPCRs) or receptor kinases. 
Importantly, activation of signalling pathways originating from ligation of soluble 
molecules; such as EGF, PDGF or thrombin; to their corresponding receptors, 
frequently requires adhesion of cells to the matrix via integrin receptors, in a 
way that determines anchorage dependence of cell survival and proliferation 
(Assoian 1997). An interesting feature of integrins, is their ability to signal 
bidirectionally. In other words, they can not only transduce information from 
extracellular stimuli (outside-in), but intracellular cues can also be translated 
into changes in the extracellular portions of the receptor (inside-out). 
1.2.4.1 Importance of integrin activation 
The majority of integrins can exist both in an inactive state, when they are not 
ligand-bound and do not transduce signals, or in an active form, that allows 
them to bind to extracellular ligands and signal to pathways within the cell. The 
ability to switch between these two activation states is crucial to their function.  
A prime example of the importance of integrin activation is the regulation of the 
platelet integrin αIIbβ3, which on circulating platelets exists in an inactive form. 
On platelet activation, a process triggered by thrombin, ADP, epinephrine 
(acting through appropriate GPCRs), von Willebrand factor (acting via GPIb/V/IX) 
or by collagen signalling through α2β1 integrin, αIIbβ3 is activated from within 
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the cell and can bind to fibrinogen, fibronectin and von Willebrand factor. This 
then allows their adhesion to blood vessel walls and aggregation with other 
platelets, leading to clot formation. Tight regulation of activation and 
inactivation prevents inactive platelet binding to fibrinogen, which could result 
in thrombosis, whilst allowing activated platelets to drive blood clotting, thus 
preventing hemorrhages (Kato 1997). Similarly, rapid activation of β2 integrins 
on white blood cells allows their recruitment to infection sites and their immune 
function (Hogg, Henderson et al. 2002). The importance of integrin activation in 
human physiology and disease is further evidenced by two genetic disorders: 
Glanzmann thrombasthenia and leukocyte adhesion deficiency-3 (LAD-III). 
Glanzmann thrombasthenia is an inherited bleeding disorder, which can be 
caused by either deficiency or defects in the αIIbβ3 integrin. Isolation of 
mutagen-induced thrombasthenia variants incapable of ligand binding, has 
identified mutations in the extracellular sites responsible for ligand binding, as 
well as in the sites of the cytoplasmic domain that mediate activation of the 
integrin. Interestingly, variants that have displayed defective integrin activation, 
but have shown no alterations in integrin sequence were also detected and this 
has indicated that mutated molecules responsible for integrin activation could 
be implicated in the generation of this thrombastenia variant (Baker, Tozer et 
al. 1997). LAD-III is a condition manifested by immune defects and bleeding 
disorders, and is caused by mutations in KINDLIN-3 gene, which result in the loss 
of kindlin-3 protein expression, and this in turn negatively affects integrin 
activation (Svensson, Howarth et al. 2009). Finally, even though rapid changes in 
the activation state have not been demonstrated for all integrins, it is believed 
that these processes are utilised by most, if not all, heterodimers to regulate 
cell adhesion in a spatio-temporal manner during dynamic processes such as cell 
invasion and metastasis (Hynes 2002).  
1.2.4.2 Insights into integrin activation mechanism 
Integrin activation is a shift from a low to a high affinity conformation for ligand 
binding and can be triggered from two directions. Firstly, the reorganisation of 
the extracellular domain of the receptor can be triggered by extracellular 
stimuli and ligand binding (outside-in). Secondly, high affinity cues can originate 
from within the cell, a process referred to as inside-out signalling.  
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It is believed that integrins are in the low affinity conformation for ligand 
binding when their extracellular domains are bent, and are in the high affinity 
state when these extend (Fig. 1.6A). Two models for integrin activation have 
been proposed, and they suggest different sequences of ligand binding and 
extension events. The switchblade model argues that only integrins with 
extended extracellular domains will bind the ligand (Luo, Carman et al. 2007), 
whereas the deadbolt model proposes that the extension can only occur 
following ligand binding (Xiong, Stehle et al. 2003). Both these models agree 
that ligand binding is facilitated by conformational changes within the 
extracellular head domain of the integrin. Indeed, the I/A domain of a collagen 
binding α2β1 integrin, has been shown to cooperate with the metal ion and the 
glutamate residue within the collagen recognition site, in the reorganisation and 
opening of the upper surface of the I/A domain, thus making it available for 
collagen binding. The conformational changes in the upper surface of the 
domain are then propagated to the lower part of the motif and could also extend 
to the rest of the molecule thus allowing the initiation of signalling cascades 
(Emsley, Knight et al. 2000). Subsequent studies have confirmed that the open 
conformation of the I/A domain is active and shows affinity for ligand binding, 
whilst the closed form is inactive and ligand-unbound. The transition from an 
inactive to active state occurs due to activating stimuli such as ligand binding or 
metal ion (such as Mn2+) occupancy (Xiong, Li et al. 2000). Furthermore, a 
disulphide bond engineered in the C-terminus of the I/A domain, locks the 
integrin in an inactive conformation, whilst its disruption opens it and makes it 
available for ligand binding (Lu, Takagi et al. 2001; Shimaoka, Lu et al. 2001).  
The transmembrane domains of both subunits of the heterodimer are also crucial 
for integrin activation, and in an inactive state are thought to associate with one 
another through GxxxG dimerisation motifs to form a coiled-coil association. 
Separation of the transmembrane domains is required for the transition from low 
affinity to high affinity mode (Gottschalk 2005). 
The cytoplasmic tails of α and β integrins can interact with one another and this 
association is key to modulating integrin affinity and activation from within the 
cell. It has been shown for the platelet αIIbβ3 integrin, that deletion of the 
entire cytoplasmic domain of the α subunit, or disruption of the conserved 
GFFKR sequence, generates a constitutively active integrin, thus suggesting that 
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this region acts as a negative regulator of activation and maintains low affinity 
state of the integrin (O'Toole, Mandelman et al. 1991; O'Toole, Katagiri et al. 
1994). Similarly, 7 amino acids within the conserved membrane proximal region 
of the β3 subunit control the ligand binding activity of the extracellular domain 
and have been demonstrated to maintain a low affinity state of the receptor 
(Hughes, O'Toole et al. 1995). It has subsequently been proposed, that these 
cytoplasmic regions of both α and β subunits, can maintain the low affinity 
states through the formation of a salt bridge between R995 in αIIb and D723 in 
β3, which stabilises the association of α and β transmembrane domains and this 
locks the integrin in a closed, inactive conformation (Hughes, Diaz-Gonzalez et 
al. 1996). Indeed, an NMR study confirmed that this salt bridge maintains a low 
affinity constraint and forms a part of an interface between membrane proximal 
regions of α and β cytoplasmic tail (Vinogradova, Velyvis et al. 2002). 
Vinogradova also observed that talin binding to the cytoplasmic portion of 
integrin displaces cytoplasmic tail association. It has therefore been proposed 
that integrin activation necessitates separation of the α and β transmembrane 
and cytoplasmic domains. Indeed, FRET studies performed on cytoplasmic tails 
of αLβ2 integrin confirmed the requirement for unclasping of cytoplasmic 
domains in integrin activation and bidirectional signalling (Kim, Carman et al. 
2003). Also, the separation of transmembrane domains has been demonstrated 
to be necessary for integrin activation (Partridge, Liu et al. 2005). By contrast, 
introduction of disulfide bridges that oppose α and β tail dissociation locks the 
receptor in an inactive state (Luo, Springer et al. 2004), thus further 
substantiating the need for cytoplasmic domain unclasping in integrin activation. 
1.2.4.3 Integrin activation by talin and kindlin as an example of inside-out 
signalling 
As mentioned in the previous section, the affinity of an integrin for its ligand is 
tightly regulated by the structure of the receptor, and can be controlled from 
within the cell through the binding of activation mediators, such as talins and 
kindlins to the cytoplasmic portion of the integrin.  
Talins are represented in mammals by two isoforms, talin1 and talin2 (Monkley, 
Pritchard et al. 2001) and both of these comprise an N-terminal head domain 
and a C-terminal actin-binding domain connected by a flexible rod region. The 
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head domain consists of FERM (4.1, ezrin, radixin, moesin) domain, with 3 main 
subdomains (F1, F2 and F3) and the F3 motif resembles a PTB domain and binds 
the NPXY motif on the integrin cytoplasmic tail (Garcia-Alvarez, de Pereda et al. 
2003). The helical rod contains numerous vinculin binding sites as well as an 
additional integrin recognition site. Furthermore, it is believed that talin owes 
its ability to increase integrin affinity to the presence of an additional integrin 
binding site within the head domain. Upon PTB domain binding to the membrane 
distal NPXY motif within the β-cytotail, an additional loop contained within the 
F3 domain binds to the membrane proximal region of the cytoplasmic β-tail, 
which mediates the interaction between the two subunits of the heterodimer. 
This in turn displaces the α tail, thus opening up their extracellular domain and 
yielding a high affinity conformation of the receptor (Fig. 1.6B) (Wegener, 
Partridge et al. 2007). Interestingly, the capacity for integrin-binding is tightly 
controlled by conformational constraints within the talin molecule, which are 
imposed by the binding of the C-terminus of the rod domain to the PTB fold 
within the head domain. It is not entirely clear how this control is achieved and 
how the intramolecular autoinhibitory interaction is abrogated to facilitate 
integrin binding. It is thought that binding of phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2) to talin, promotes its activation by liberating the 
integrin recognition sites and thus increases its association with the 
heterodimeric receptor (Martel, Racaud-Sultan et al. 2001). There is also 
evidence for GTPase-mediated talin activation routes in hematopoetic cells, 
where the activity of a GTPase, Rap1, is required for talin-driven integrin β1 and 
β3 integrin activation (Sebzda, Bracke et al. 2002). This is thought to depend on 
formation of a talin/Rap1/RIAM (Rap1 interacting molecule) complex on the β-
integrin tail (Watanabe, Bodin et al. 2008). Furthermore, phosphorylation of the 
tyrosine residue contained within the NPXY motif of the β-integrin cytoplasmic 
tail adds an extra level of complexity to the tight regulation of talin/integrin 
association. Indeed, addition of a phosphate group to the NPXY motif, has been 
shown to decrease the affinity with which it can bind the F3 domain on talin 
(Oxley, Anthis et al. 2008).  
Talin is not the only regulator of integrin inside-out activation. A family of FERM-
domain containing proteins called kindlins, has recently emerged as capable of 
binding to a region in β1, β2 and β3 integrin tails, which is located C-terminally 
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with respect to the talin-binding motif. Mammals express three distinct kindlin 
isoforms: kindlin1, kindlin2 and kindlin3, and all three localise to integrin-
dependent adhesion sites. Kindlins are thought to be necessary modulators of 
integrin function and to be required for integrin to switch from a low affinity to 
a high affinity state, and ultimately for integrin activation (Montanez, Ussar et 
al. 2008). Kindlin-driven integrin activation depends on a direct interaction 
between kindlin and the β-integrin cytoplasmic tail. The kindlin FERM domain 
resembles that of talin, but is distinct in that it is split into two halves by a 
pleckstrin homology (PH) domain inserted into the F2 fold. It is believed that the 
F3 subdomain, which is similar to a PTB fold, mediates direct interaction with β-
integrin tails and drives the integrin affinity switch (Kloeker, Major et al. 2004). 
In contrast to talin, which binds to the membrane proximal NPXY motif in the β-
integrin cytoplasmic tail, kindlin has affinity primarily for the distal NXXY 
domain in the β1, β2 and β3 cytoplasmic tails. In light of the fact that talin and 
kindlin bind to two distinct regions of the cytoplasmic domain of β integrins, and 
given the requirement for kindlin in talin-mediated integrin affinity modulation 
and the insufficiency of kindlins for integrin activation, it is highly probable that 
they cooperate to promote integrin activation. As a consequence, two different 
mechanisms have been suggested to explain the sequence of events during 
integrin inside-out activation. According to the sequential model of binding, 
kindlin association with the membrane distal NXXY motif facilitates talin binding 
to the membrane proximal NPXY motif, which in turn displaces kindlin from the 
β-integrin tail and leads to integrin activation. However, due to distinct binding 
sites for both activators in the cytoplasmic tail of the integrin, simultaneous and 
cooperative interaction is also possible, but the order of events is thus far 
unclear (Fig. 1.6C) (Moser, Legate et al. 2009). 
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Figure 1-6 Mechanism of integrin activation.  
A. Integrin heterodimers can switch from a bent inactive conformation to an active extended state. 
B. Integrin activation is mediated by talin binding to the NPXY motif in the β tail. Pulling forces on 
the β tail reorient the transmembrane domains of the heterodimer thus enabling transduction of 
conformational changes across the receptor. C. Proposed mechanisms for kindlin- and talin-driven 
activation of integrins. Kindlin binding to the β tail facilitates subsequent talin binding, which in turn 
displaces kindlin. Alternative model suggests simultaneous binding of kindlin and talin. Adapted 
from (Moser, Legate et al. 2009).  
Chapter 1  40 
1.2.4.4 Outside-in signalling and regulation of the cytoskeleton 
Upon ligand binding, conformational changes occur in the head and leg domains 
of the heterodimer, which result in the separation of the cytoplasmic tails thus 
making them available for interactions with cytoplasmic effector molecules. This 
in turn leads to the assembly of multimolecular complexes centred around the 
heterodimer, which organise the actin cytoskeleton and activate signalling 
pathways that lead to alterations in gene expression. Integrin receptors are 
devoid of catalytic activity and instead serve as scaffolds for the assembly of 
enzymatic and cytoskeleton-remodelling platforms. Over 150 adaptor, structural 
and signalling molecules have to date been associated with integrin-mediated 
adhesions (Zaidel-Bar, Itzkovitz et al. 2007).  
Integrins are known to control the activity of cyclin D1, both at the level of 
transcription and protein accumulation, and this is thought to be the major hub 
through which integrins affect cell cycle progression and proliferation (Walker 
and Assoian 2005). This has been proposed to be mediated by extracellular 
signal-regulated kinase (ERK), whose activity can be promoted by integrin-driven 
adhesion in a number of ways. Firstly, as a result of integrin activation, focal 
adhesion kinase (FAK)/Src signalling complexes are formed. This is initiated by 
autophosphorylation of FAK at tyrosine 397, which in turn creates a binding site 
for the Src homology 2 (SH2) domain of Src (Schaller, Hildebrand et al. 1994). 
Upon association of Src with FAK, Src can catalyse phosphorylation of other 
tyrosine residues on FAK, which in turn opens new binding sites for downstream 
effectors, such as growth factor receptor binding protein-2 (Grb-2) or Shc, and 
stimulates Ras-Raf-MEK-ERK pathway (Schlaepfer, Hanks et al. 1994). Src can 
also phosphorylate a FAK-associated protein, Crk associated substrate (p130Cas), 
and therefore form a binding pocket for the adaptor protein Crk (Cary, Han et 
al. 1998; Klemke, Leng et al. 1998), which in turn can activate ERKs. 
Additionally, active FAK can associate with phosphatidylinositol-3-kinase (PI3K), 
which leads to the activation of the latter (Chen and Guan 1994), and this in 
turn can potentiate ERK signalling. Secondly, selected α-integrin subunits can 
associate with the Src family kinase Fyn, through an adaptor protein caveolin-1. 
Activation of Fyn drives the recruitment and activation of Shc, which switches on 
the Ras-Raf-MEK-ERK signalling pathway (Wary, Mariotti et al. 1998). Finally, 
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active integrins can activate Raf by recruiting protein kinase C (PKC) (Miranti, 
Ohno et al. 1999). 
Integrin-mediated adhesion also affects cell survival and this occurs through the 
PI3K-driven stimulation of protein kinase B (PKB/Akt) activity and Bcl-2 
expression. Additionally, integrin binding to its ligand, activates c-Jun N-
terminal kinase (JNK) (Almeida, Ilic et al. 2000) and nuclear factor κB (NFκB) 
(Weaver, Lelievre et al. 2002), thus also enhancing survival signals. 
Not only do integrins affect signalling pathways that modulate survival, growth 
and proliferation, they also link physically to the actin cytoskeleton, thus 
controlling cell shape and motility. Proteins such as talin, filamin and α-actinin 
can directly connect integrins to F-actin. Kindlin, FAK, paxillin and integrin-
linked kinase (ILK) directly associate with integrins, but indirectly regulate the 
actin cytoskeleton. Vinculin, on the other hand, does not directly interact with 
integrins but does so with actin (Legate, Wickstrom et al. 2009). Upon integrin-
mediated adhesion, the primary link between the ligand-bound integrin and the 
cytoskeleton is established through direct talin binding to the integrin and talin’s 
actin-binding capacity (Zhang, Jiang et al. 2008), which is immediately followed 
by the recruitment of vinculin. Vinculin can associate with both talin and actin, 
thus acting as a crosslinker and stabilising the interaction (Humphries, Wang et 
al. 2007). α-actinin, is then also recruited to strengthen the adhesion that is 
further regulated by ILK, which forms a link between integrin and paxillin, which 
then binds to parvin and vinculin (Legate, Montanez et al. 2006). The affinity of 
α-actinin to actin can be modulated by its phosphoryaltion by FAK (Izaguirre, 
Aguirre et al. 2001). The above-described attachment of integrins to F-actin is 
necessary for cell protrusion and retraction during cell migration. This is 
achieved by tightly regulated F-actin polymerisation at the edge of the 
lamellipodium and requires the actin nucleation function of Arp2/3 complex, 
which mediates the assembly of branched actin filaments (Serrels, Serrels et al. 
2007). Arp2/3 is recruited to the adhesion sites through its interactions with FAK 
and vinculin (DeMali, Barlow et al. 2002). The activity of Arp2/3 requires the 
binding of Wiskott-Aldrich Syndrome protein (WASP), which induces 
conformational changes in Arp2/3 thus allowing it to serve as actin filament 
elongation template (Pollard 2007). Subsequently, actin polymerisation 
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generates protrusive force at the leading edge of the lamellipodium, hence 
driving forward cell movement. 
1.3 Integrin trafficking 
It is now well-established that integrin receptors undergo endocytic-exocytic 
transport, a process that encompasses continual receptor internalisation from 
the plasma membrane into internal membraneous compartments, and 
subsequent sorting to different cellular locations followed by return of the 
internalised receptors to the plasma membrane (Bretscher 1989; Pellinen and 
Ivaska 2006; Caswell, Vadrevu et al. 2009). This cascade of events is frequently 
referred to as receptor trafficking and is recognised to affect their function. 
Integrin trafficking events are thought to facilitate the establishment and 
maintenance of cell polarity, to contribute to cell migration and to modulate 
Rho GTPase-mediated signalling (Pellinen and Ivaska 2006; Caswell, Vadrevu et 
al. 2009). 
1.3.1 Different routes to endocytosis 
The first stage in the trafficking of integrins is their internalisation from the 
plasma membrane, and this can occur through two main endocytic routes: 
clathrin-mediated endocytosis (CME) and clathrin-independent endocytosis (Fig. 
1.7). During CME, cytoplasmic clathrin molecules assemble at the receptor-
containing sites of the plasma membrane and form clathrin-coated 
invaginations, which then detach from the membrane, in a process that requires 
dynamin GTPase, to form clathrin-coated vesicles (Conner and Schmid 2003). 
The formation of clathrin-coated pits and vesicles is orchestrated by endocytic 
adaptor proteins, such as adaptor protein-2 (AP-2) or epsin, which can 
selectively package specific receptors, into clathrin-vesicles (Hirst and Robinson 
1998). Following internalisation, clathrin-coated vesicles are deprived of their 
coating and fuse with early/sorting endosomes, where the fate of their cargo is 
decided. Clathrin-independent endocytosis (CIE) is thought to proceed via three 
distinct routes: dynamin-dependent caveolar endocytosis, frequently referred to 
as raft/caveolar endocytosis (RCE), dynamin-independent macropinocytosis 
(Nichols and Lippincott-Schwartz 2001), as well as through non-caveolar CIE 
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routes. RCE requires cholesterol-rich membrane rafts, which provide sites of 
enrichment for proteins that require endocytosis, and caveolae - minute 
uncoated plasma membrane pits that are frequently enriched in caveolin-1 
(Nichols 2003). This endocytosis route delivers plasma membrane receptors to 
endosomal-like structures called caveosomes, which are distinct from early or 
recycling endosomes - structures that originate from the CME pathway. On the 
other hand, non-caveolar CIE internalisation proceeds via a mechanism that is 
regulated by RhoA (Lamaze, Dujeancourt et al. 2001), ADP-ribosylation fator 6 
(Arf6) (Radhakrishna and Donaldson 1997) or Cdc42 (Sabharanjak, Sharma et al. 
2002). This pathway employs clathrin-independent carriers (CLICs), which are 
thought to be uncoated tubular or ring-shaped structures (Kirkham, Fujita et al. 
2005), contain glycosylphosphatidylinositol-anchored proteins (GPI-APs) and have 
recently been shown to be implicated in endocytic sorting at the leading edge of 
migrating cells (Howes, Kirkham et al.). CLICs originate directly from the plasma 
membrane, and whilst they acquire early endosomal antigen (EEA)-1 and Rab5, 
they mature into the GPI-enriched early endosomal compartment (GEEC). The 
GEEC then fuses with the early endosomal compartment (Kalia, Kumari et al. 
2006). Despite the different origin of the CME and CIE pathways, they do seem to 
intersect as receptors internalised through the CIE route appear to be sorted 
from caveosomes into early and recycling endosomes (Pelkmans, Burli et al. 
2004). 
Some receptors can only enter the cell through one internalisation route, for 
example the transferrin receptor is obliged to use clathrin-mediated 
endocytosis, while others, such as EGFR1 are more promiscuous with regard to 
their route into the cell (Sigismund, Argenzio et al. 2008). Similarly, particular 
integrin heterodimers can also enter the cell via more than one endocytosis 
pathway, as it is exemplified by the internalisation of α5β1 and αvβ3 integrins 
(Caswell, Vadrevu et al. 2009). In the next section, I will focus on the 
internalisation routes of the β1 integrins and particularly on what is known about 
the endocytosis of the major fibronectin-binding receptor, α5β1 integrin.  
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Figure 1-7 Main endocytosis routes. 
Transmembrane receptors can be internalized via two main routes: clathrin dependent and clathrin 
independent endocytosis. Clathrin-mediated internalization requires a coat protein - clathrin - and a 
number of adaptor proteins such as AP-2 or Numb. Caveolar endocytosis does not depend on coat 
proteins but also requires dynamin-1. Non-caveolar clathrin-independent endocytosis requires 
regulation fro RhoA, Arf6 and Cdc42. Receptors internalized through either of the pathways 
proceed to early endosomes for sorting. 
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1.3.1.1 Clathrin-mediated and clathrin-independent β1 integrin 
internalisation 
α5β1 integrin is constitutively internalised, and can undergo both clathrin-
mediated and caveolar endocytosis. As mentioned previously, the cytoplasmic 
portions of β subunits contain membrane proximal and membrane distal NXXY 
motifs, and these conserved sequences are known to recruit surface receptors, 
such as low density lipoprotein (LDL) (Chen, Goldstein et al. 1990) or insulin 
receptors (Rajagopalan, Neidigh et al. 1991), to clathrin coated structures, by 
allowing their interaction with adaptor proteins such as AP-2. Even though the 
initial studies, which utilised mutants either lacking the NXXY motifs or ones 
that contained mutated tyrosine residues, indicated no requirement for the 
conserved NXXY sequence in the internalisation of α5β1 integrin (Vignoud, Usson 
et al. 1994), more recent approaches contradict this observation. Indeed, 
expression of β1 integrin mutant β1YYFF - in which tyrosine residues of the NXXY 
motif were substituted with phenylalanines – in β1-null mouse embryonic 
fibroblasts (MEFs), clearly showed an endocytosis defect. Furthermore, integrin 
endocytosis was reduced in β1YYFF MEFs isolated from mice that harboured this 
mutation in the germline in comparison to wild type MEFs, and the endocytosis 
of the wild type β1 integrin was inhibited by a clathrin antagonist, thus further 
supporting the requirement for the conserved NXXY motif in clathrin mediated 
endocytosis of α5β1 integrin (Pellinen, Tuomi et al. 2008).  
Clathrin adaptors, other than the previously mentioned AP-2, have also been 
shown to recruit β1 integrin cargos to clathrin-coated pits. Both disabled-2 
(DAB2) and Numb, contain PTB domains, which can interact with NPXY motifs in 
the cytoplasmic tails of integrins, thus contributing to clathrin-mediated 
endocytosis of these receptors. Indeed, suppression of Numb by RNAi or 
interfering with its recruitment to clathrin coated structures (CCS) through its 
phosphorylation by atypical protein kinase C (aPKC), inhibits α5β1 internalisation 
(Nishimura and Kaibuchi 2007). Although DAB2 has been shown to mediate 
clathrin-dependent endocytosis of β1 integrins, binding of DAB2 to the NPXY 
motif of the β integrin tail is controversial. Even though DAB2 and β1 integrin 
are known to bind to each other in vitro (Calderwood, Fujioka et al. 2003) and 
have been shown to coimmunoprecipitate from murine mammary epithelial cells 
(Prunier and Howe 2005), two research groups have been unable to reproduce 
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this interaction in HeLa cells (Chetrit, Ziv et al. 2009; Teckchandani, Toida et al. 
2009), which argues against their direct association.  
Not only is it still a subject of debate whether DAB2 can recruit integrins to 
clathrin-coated pits by a direct association with their β1 cytotails, a consensus 
view on the location of this process and the activation status of the integrin that 
follows this route into the cell is still missing. One study has shown that DAB2 
can recruit β1 integrins to clathrin coated pits, when the integrins are dispersed 
along the cell surface, suggesting that it can control the bulk endocytosis of 
inactive integrins (Teckchandani, Toida et al. 2009). In contrast, another report 
implicates DAB-2 in the endocytosis of only active conformation integrins during 
focal adhesion turnover (Chao and Kunz 2009). In line with the view that certain 
endocytic machineries can select for integrin receptors in particular 
conformations is a study by Valdembri and colleagues, which identifies 
neuropilin 1 (NRP1) as a component of the integrin endocytic route in 
endothelial cells. This transmembrane glycoprotein supports the efficient 
endocytosis of active α5β1 integrin at adhesion sites, whilst being dispensable 
for internalisation of inactive α5β1 heterodimers. NRP1 supports α5β1 
internalisation by providing a physical link between the integrin and the 
endocytic adaptor GAIP interacting protein C1 (GIPC1) (Valdembri, Caswell et al. 
2009), thus linking the heterodimer to motor myosin VI (Myo6) which has also 
been proposed to be implicated in vesicular transport of protein cargos (Frank, 
Noguchi et al. 2004).   
Whilst there is a growing body of evidence supporting clathrin-mediated 
endocytosis of β1 integrins and explaining its molecular basis, reports on 
clathrin-independent internalisation of this receptor are still scarce. 
Nonetheless, as it was mentioned briefly above, there is clear evidence that in 
the context of mutant β1 integrin (β1YYFF), which lacks the NXXY motif, 
expression of Rab21 can induce clathrin-independent endocytosis of this 
receptor (Pellinen, Tuomi et al. 2008). Also, in myofibroblasts endocytosis of 
α5β1 integrin and its ligand fibronectin have been shown to depend on the 
expression of caveolin-1 (Shi and Sottile 2008). The modes of β1 integrin 
recruitment to caveosomes and their entry into the cell via this route remain 
mostly unresolved and need further investigation. One possible molecular 
mechanism of clathrin-independent internalisation of integrins is provided by a 
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study, which identified protein kinase C alpha (PKCα), as necessary for caveolae-
mediated internalisation of α2β1 (Upla, Marjomaki et al. 2004). It is therefore 
possible that binding of PKCα to cytoplasmic domains of β1 integrin (Ng, Shima 
et al. 1999) can drive integrin endocytosis via this route.  
1.3.2 Integrin recycling 
Integrin recycling is defined as the return of these heterodimeric receptors to 
the plasma membrane, where they can re-engage with the extracellular matrix 
components or with counter-receptors on neighbouring cells, and most reports 
indicate that after internalisation the majority of the integrin is indeed returned 
to the cell surface, rather than undergoing lysosomal degradation (Bretscher 
1989; Roberts, Barry et al. 2001). After internalisation by one of the above 
discussed routes, integrins reach early endosomes, where sorting events occur 
(in a Rab5 family protein dependent manner), which destine these receptors 
either for travel to late endosomes and lysosomes or for recycling to the plasma 
membrane. Cargo progression from early endosomes to late endosomes is 
thought to occur through the replacement of early endosomal Rab5 with late 
endosomal Rab7, and this is mediated by a Rab7 GEF - the class C VPS/HOPS 
complex – that interacts with Rab5 thus mediating this conversion (Rink, Ghigo 
et al. 2005).  
Receptor return to the plasma membrane can occur through two distinct routes, 
in a direct and Rab4-dependent manner (short loop) or through a Rab11- and/or 
Arf6-dependent pathway (long loop) (Fig. 1.8). The latter requires the delivery 
of the recycling cargo from sorting endosomes to the perinuclear recycling 
compartment (PNRC) - which is located near to the microtubule organising 
centre and is often enriched in the Rab11 family GTPases - prior to its trafficking 
to the plasma membrane (Caswell, Vadrevu et al. 2009). These two recycling 
pathways differ with respect to the integrins, whose trafficking they supervise, 
and the signalling cascades that modulate them, but are similar in that both are 
tightly controlled. Indeed, PDGF-driven recycling of αvβ3 integrin through the 
short-loop endocytic pathway (Roberts, Barry et al. 2001) relies on a direct 
interaction between the C-terminal domain of the β3 cytoplasmic tail and 
protein kinase D1 (PKD1) (Woods, White et al. 2004).  
Chapter 1  48 
On the other hand, recycling of β1 heterodimers proceeds through the PNRC and 
is controlled by Rab11, in a way that is promoted by kinases such as protein 
kinase B (PKB/Akt) (Roberts, Woods et al. 2004) or protein kinase C epsilon 
(PKCε) (Ivaska, Whelan et al. 2002). Roberts and colleagues have shown that 
whilst α5β1 integrin internalisation and delivery to the recycling compartment 
was independent of PKB/Akt, its return to the plasma membrane was regulated 
by the activity of PIP-3 kinase and PKB/Akt. Furthermore blockade of integrin 
recycling, which was implemented by inhibition of PKB/Akt, can be reversed by 
expression of inactive mutant of glycogen synthase kinase 3 (GSK-3), thus 
suggesting that PKB/Akt acts via GSK-3 inactivation to promote integrin 
recycling. This was further substantiated when integrin recycling was suppressed 
by the expression of active GSK-3 mutant, which is insensitive to 
phosphorylation-mediated inactivation by PKB/Akt. PKB is also thought to 
mediate the recycling of integrins by phosphorylating ACAP1 (Arf6 GTPase 
activating protein with coiled-coil, ANK repeat and PH domain protein 1), which 
when phosphorylated binds directly to internalised β1 integrin and promotes its 
recycling (Li, Ballif et al. 2005). By contrast, PKCε is thought to contribute to 
the recycling of internalised β1 integrins by phosphorylating an intermediate 
filament protein, vimentin, which may facilitate integrin recycling by releasing 
mechanical constraints on integrin recycling vesicles. Indeed, upon inhibition of 
PKCε and vimentin phosphorylation integrins become trapped in intracellular 
vesicles and fail to return to the plasma membrane (Ivaska, Vuoriluoto et al. 
2005). 
It is not only Rab11, but also Arf6, that contributes to the recycling of β1 
integrin from the PNRC to the plasma membrane upon serum stimulation and 
this process requires the actin cytoskeleton in an Arf6-dependent manner 
(Powelka, Sun et al. 2004). Furthermore, a key contribution to the recycling of 
β1 integrin heterodimers is made by GTPases of the Rab5 family, as shown by 
studies focused on Rab21 and Rab5. Rab21 has been demonstrated to associate 
with several integrin α subunit cytoplasmic tails to facilitate the trafficking of 
these receptors, and this is dependent on Rab21 being in its active 
conformation. Indeed, expression of a Rab21-GDP-locked mutant leads to the 
accumulation of active integrin in large focal adhesion sites, whilst nucleotide 
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exchange and the presence of Rab21-GTP allows for the initiation of the β1-
endocytic pathway (Pellinen, Arjonen et al. 2006).  
Chapter 1  50 
 
Figure 1-8 Schematic summary of integrin trafficking pathways. 
Internalised heterodimers are trafficked to early endosomes from which they can directly and 
rapidly recycle back to the plasma membrane in a Rab4-dependent manner (short loop). 
Alternatively they can be transported to the perinuclear recycling compartment, from which they 
return to the cell surface in a Arf6/Rab11-dependent pathway (long loop).  
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1.3.3 Signalling endosomes 
It is well established that endosomes can function to terminate signalling 
processes through receptor internalisation and degradation, but they are also 
recognised to act as platforms for the assembly of signallosomes downstream of 
signalling receptors (Miaczynska, Pelkmans et al. 2004; Gould and Lippincott-
Schwartz 2009). It is also known that internalisation and recycling of receptors 
influence which of the downstream effectors are activated and also determine 
whether the nature of this activation is transient or sustained. Signalling 
downstream of Epidermal growth factor receptor (EGFR) is a good example of 
endocytosis-mediated modulation of receptor-activated pathways. Upon EGFR 
internalisation, Grb2 (growth factor receptor-bound protein 2), Shc (Src-
homology containing protein) and SOS (son of sevenless) remain in association 
with EGFRs and this allows persistent signalling through the Ras-MAPK pathway 
on the endosomes (Di Guglielmo, Baass et al. 1994). In contrast, endocytosis of 
EGF receptors diminishes their signalling to PI3-kinase, due to the limited access 
of the receptor to PtdIns(3,4)P2 in the vesicles (Haugh and Meyer 2002). 
Furthermore, distinct EGFR internalisation modes exert different effects on the 
longevity of signalling downstream of this receptor. EGFR can be endocytosed 
via clathrin-independent pathways, but it is CME that is mostly employed for the 
delivery of that receptor to intracellular vesicles. CME of EGFR has been shown 
to favour the recycling of the internalised receptor to the plasma membrane, 
thus prolonging the duration of EGFR-activated signalling (Sigismund, Argenzio et 
al. 2008). By contrast, clathrin-independent and lipid raft-dependent 
internalisation of EGFR predominates when this receptor becomes ubiquitinated 
following activation with high doses of EGF (Sigismund, Woelk et al. 2005), and 
this endocytosis route attenuates EGFR-signalling by targetting it for degradation 
(Sigismund, Argenzio et al. 2008). 
Also other receptor tyrosine kinases have been shown to be capable of signalling 
from endosomes. The endosomal fraction of the platelet-derived growth factor 
receptor (PDGFR) has been shown to be specifically activated without the 
activation of the plasma-membrane pool of PDGFR. This in turn recruited 
signalling molecules such as Grb2, Shc, phospholipase C-gamma1 (PLC-γ1) and 
p85alpha subunit of PI3-K to PDGFR-positive endosomes and led to the activation 
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of signaling pathways involved in cell proliferation and survival (Wang, Pennock 
et al. 2004). Moreover, the nerve growth factor (NGF) has been proposed to 
induce the formation of signalling endosomes following the observation that is 
was bound to its activated receptor TrkA on endosomal structures. Under these 
conditions, TrkA was tyrosine-phosphorylated and bound to PLC-γ1, which points 
to its competency for the initiation of signal transduction from endosome 
(Grimes, Zhou et al. 1996). Furthermore, internalization of β2-adrenergic 
receptor (β2-AR) into endosomal compartments is crucial for the full activation 
of MAPK pathway, as evidenced by the attenuation of Raf-mediated activation of 
MEK following endocytosis inhibition. This suggests that signalling cascades 
downstream of some GPCRs are preferentially activated after receptor 
internalisation into the endocytic pathway (Daaka, Luttrell et al. 1998).  
Signalling endosomes have been implicated in regulation of signal transduction 
events within the osteoblastic niche and this occurs through intercellular 
transfer to signalling endosomes. Haematopoietic stem-progenitor cells (HSPCs) 
have been shown to make contacts with osteoblasts through membrane domains 
containing prominin 1, CD63 and rhodamine-phosphatidylethanolamine. At the 
contact sites, portions of these membrane domains were taken up by osteoblasts 
and internalised into SARA (SMAD anchor for receptor activation)-positive 
signalling endosomes. This in turn led to attenuated Smad signalling and 
increased synthesis of Stromal-Derived Factor-1 (SDF-1, also known as CXCL12), 
which mediates homing of HSPC to bone marrow (Gillette, Larochelle et al. 
2009). Another physiologically relevant example of the importance of endosomal 
signalling is the diversification of signalling pathways downstream of tumour-
necrosis factor receptor-1 (TNRF1). CME of TNFR1 and CD95 is necessary for the 
recruitment of DISC proteins and the initiation of apoptotic cascade from the 
endosomal signalling complex. On the other hand, anti-apoptotic signals are 
generated independently of receptor endocytosis and this occurs through the 
binding of TNFR1 to RIP and TRAF2, which then activates NF-κB and MAPK 
(Schutze, Tchikov et al. 2008). 
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1.3.4 Integrin trafficking in cell migration 
The initial demonstrations of integrin internalisation and recycling have 
encouraged a proposal that these processes contribute to focal adhesion 
turnover and cell migration on 2D substrates. For a number of years, this 
contribution has been thought to be driven by integrin internalisation at the rear 
of a migrating cell, a process which enables detachment of the trailing edge. 
Upon integrin endocytosis, heterodimer-containing vesicles would be transported 
to the leading edge of the cell, where they could be returned to the cell surface 
to further facilitate attachment and forward cell movement (Fig. 1.9A) 
(Bretscher 1996). This concept of long-range transport of endosomal integrins 
during cell migration has thus far not been substantiated. Nonetheless, there is 
experimental data demonstrates specific trafficking of internalised integrins 
from one end of the cell to the other during processes other than cell migration, 
i.e. to and from the cleavage furrow, during and after cytokinesis (Pellinen, 
Tuomi et al. 2008). In contrast to the above proposed long-range movement of 
integrins during cell migration, the more generally accepted view is that integrin 
heterodimers are both endocytosed and returned to the plasma membrane 
toward the cell front (Fig. 1.9B) (Caswell, Vadrevu et al. 2009). Consistent with 
this are observations that clathrin dependent endocytosis is largely polarised to 
the front proportion of the cell (Rappoport and Simon 2003) and the recycling 
compartment is normally also positioned near to the leading edge of migrating 
cells (Pierini, Lawson et al. 2000). Further support to this view, is lent by the 
recent investigations, which have indicated that integrin trafficking is spatially 
restricted to the leading edge during migration of cancer cells on a 3D matrix. 
Indeed, this study reported that both integrin internalisation and recycling takes 
place at the cell front, thus retaining a cycling pool of integrin at the leading 
edge of migrating cells (Caswell, Spence et al. 2007). These workers have 
proposed that such spatially-restricted cycling of adhesion receptors may act to 
localise downstream signalling and also promote focal adhesion turnover and 
actin dynamics at the cell front so as to drive membrane protrusion and cell 
movement.  
It is thought that integrin trafficking exerts effects on cell migration by 
regulating recycling of other cell surface receptors, such as EGFR (Caswell, Chan 
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et al. 2008) and by controlling the balance of downstream signalling to different 
Rho GTPases, such as Rac1 and RhoA. Epithelial cells move on 2D substrates with 
high persistence whilst maintaining a fan-like morphology. This is supported by 
the activity of Rac1, which encourages the formation of a flat lamellipodium at 
the front of the migrating cell and RhoA which limits the lamellipodial activity to 
the leading edge thus aiding in lagging end retraction. When the balance 
between the activities of these two GTPases is disturbed, the persistence of 
migration changes. Increased Rac1 activity leads to the extension of multiple 
processes at the cell front and results in directionality loss. The same phenotype 
occurs when signalling to RhoA is enhanced, as this weakens adhesion sites not 
only at the rear, but also at the front of the cell, thus collapsing lamellipodial 
extensions (Pankov, Endo et al. 2005). The disturbance in the Rac1/RhoA 
balance and switch from persistent to random migration can occur following a 
change in the expression levels of αvβ3 with respect to α5β1 integrin (Danen, 
van Rheenen et al. 2005), but can also be affected by the trafficking of these 
two heterodimers (Caswell, Chan et al. 2008). When αvβ3 integrin is expressed, 
Rac1 signalling is promoted, whilst α5β1 expression drives RhoA activation 
(Danen, van Rheenen et al. 2005). Furthermore, when αvβ3 integrin is 
competent to bind to its ECM ligands, it is actively recycled through the Rab4 
route in a PKD1 dependent manner (Woods, White et al. 2004) and this renders 
α5β1 recycling slow. Under these circumstances Rho activity is low and cells 
migrate persistently. Upon blockade of αvβ3 integrin with ligand mimetics, such 
as Cilengitide, the recycling of α5β1 through a Rab11- and RCP-dependent 
pathway is favoured. This mediates the activity of Rho, which in turn signals to 
ROCK and results in directionality loss and drives random and fast cell migration 
on 2D. Additionally, increased α5β1 cycling enhances the recycling of EGFR1 in a 
way that potentiates its autophosphorylation and activates pro-invasive PKB/Akt 
signalling (Caswell, Chan et al. 2008). 
The PKCε-dependent recycling of β1 integrin has also been shown to promote 
directional cell movement towards β1 integrin substrates and this requires the 
catalytic activity of this kinase. When the activity of PKCε is inhibited, it 
becomes trapped together with β1 integrin in a CD81-positive compartment and 
this results in decreased directional motility (Ivaska, Whelan et al. 2002). This is 
thought to occur through PKCε-driven phosphorylation of an intermediate 
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filament protein, vimentin, which has been proposed to facilitate integrin 
recycling possibly through a release of a mechanical constraint. On inhibition of 
PKCε and vimentin phosphorylation, integrins become trapped in intracellular 
vesicles, fail to return to plasma membrane and haptotaxis is severely 
attenuated. On the other hand, ectopic expression of vimentin promotes cell 
motility in a way that requires PKCε, as evidenced by mutagenesis of PKC sites 
on vimentin  (Ivaska, Vuoriluoto et al. 2005). Also, Rab21-mediated trafficking of 
integrin heterodimers has been shown to affect breast and prostate cancer cell 
adhesion and motility. This GTPase associates with α subunit cytoplasmic 
domains of integrin heterodimers following integrin internalisation and it 
facilitates integrin endo/exocytic cycling. Suppression of Rab21 results in the 
inhibition integrin-mediated cell adhesion and migration, whilst its 
overexpression promotes cell adhesion and motility (Pellinen, Arjonen et al. 
2006) 
An interesting insight into the contribution of integrin trafficking and 
degradation to cell migration has been provided by recent findings, which 
demonstrate that in migrating fibroblasts a proportion of internalised α5β1 
integrin is sorted to multivesicular endosomes (MVEs) together with its ligand, 
fibronectin. These can be then routed from MVEs to lysosomes for degradation. 
This process requires fibronectin-mediated ubiquitination of the α5 subunit as 
well as the interaction of α5β1 with endosomal sorting complex required for 
transport (ESCRT) and is thought to control cell migration by preventing the 
accumulation of ligand-bound integrin on the endosomal pathway (Lobert, Brech 
et al.).  
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Figure 1-9 Integrin trafficking in cell migration. 
A. According to the initial model of integrin trafficking in cell migration, hetrodimers are 
endocytosed at the rear of the cell and transported to the cell front for reinsertion into the 
membrane. B. Another model suggests that in invasive cells, both integrin internalization and 
recycling occur at the cell front.  
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1.3.5  Integrin recycling in cancer 
It has in recent years become apparent that the trafficking of integrins can 
affect their function, and that dysfunctional integrin signalling caused by altered 
integrin internalisation and recycling can mediate tumour cell dissemination and 
cancer metastasis. Most of the investigations aimed at understanding the 
molecular machineries underpinning integrin internalisation and recycling and 
their contribution to cell adhesion and migration have been carried out in two-
dimensional environments, with cells seeded onto inflexible plastic or glass 
substrates. When cells migrate in vivo during tumour invasion and metastasis, 
they have to migrate through a meshwork of extracellular matrix components, 
rather than simply moving on a flat substratum. Integrin trafficking should 
therefore be studied in a more physiologically-relevant environment if its 
contribution to cancer progression in vivo is to be understood. One of the first 
direct links between integrin trafficking and invasive migration of tumour cells 
within a physiologically relevant environments was provided in a study on αvβ6 
integrin trafficking performed by Ramsay and colleagues (Ramsay, Keppler et al. 
2007). αvβ6 integrin is not constitutively expressed in normal epithelia and its 
expression has long been associated with poorer clinical outcome in a range of 
cancer types. Expression of this heterodimer has also been linked to enhanced 
tumour cell invasion (Thomas, Nystrom et al. 2006). A HS-1 associated protein X1 
(HAX-1) has been shown to bind directly to the cytoplasmic tail of β6 integrin. 
This association drives invasive migration of oral squamous carcinoma cells 
through matrigel and in organotypic invasion assays, by facilitating clathrin-
mediated endocytosis of αvβ6 integrin. These observations thus form a link 
between integrin trafficking and tumour cell invasion (Ramsay, Keppler et al. 
2007). Also, Rab11-dependent endocytic pathways have been implicated in 
hypoxia-induced breast carcinoma cell invasion through matrigel plugs in a 
process that requires efficient trafficking of αvβ6 integrin (Yoon, Shin et al. 
2005). Furthermore, a member of the Rab11 family, Rab25 has been shown to 
mediate the trafficking of α5β1 integrin and this contributes to invasive 
migration of ovarian carcinoma cells through three-dimensional matrices. 
Interestingly, Rab25 exerts no effects on directional migration of cancer cells 
across two dimensional surfaces, but it promotes tumour cell invasion into 
fibronectin-containing matrigel in a way that requires direct association of this 
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GTPase with the cytodomain of the β integrin subunit. Moreover, when cells are 
plated onto cell-derived matrices, Rab25 drives the extension of long 
pseudopods, at the tips of which this GTPase and its integrin cargo colocalise. 
This study also indicates that spatial restriction of the cycling integrin to the tip 
of a pseudopod may contribute to invasive migration of cancer cells (Caswell, 
Spence et al. 2007).  
In addition to allowing membrane protrusion and focal adhesion turnover, 
integrin signalling and recycling can affect cancer progression in vivo and 
invasive tumour cell migration into three dimensional environments, by 
modulating the recycling of receptor tyrosine kinases (RTKs). Indeed, as 
mentioned previously, blocking αvβ3 integrin function allows the binding of RCP 
to β1 integrin tail, but also recruits EGFR1 to RCP-containing vesicles and 
promotes the coordinate recycling of α5β1 integrin and EGFR1. This in turn 
potentiates EGFR1 autophosphorylation and affects its signalling, in a way that 
favours PKB/Akt activation (Caswell, Chan et al. 2008). Given that PKB/Akt has 
been shown to promote tumour cell migration, it is possible that in the above 
context, decreased recycling of αvβ3 contributes to increased tumour cell 
invasion by potentiating PKB/Akt signalling (Caswell, Vadrevu et al. 2009). In 
line with the loss of αvβ3 integrin function and recycling acting to promote 
invasion, is a recent report of Kaur and colleagues. αvβ3 integrin expression has 
been shown to decrease invasion of ovarian cancer cells, attenuate metastatic 
spread in xenograft models and to slow down tumour progression and therefore 
increase disease-free and overall survival in ovarian cancer. Importantly, this 
correlation between high αvβ3 expression and favourable prognosis in ovarian 
cancer patients could explain why this integrin might not be a good therapeutic 
target in that type of tumours (Kaur, Kenny et al. 2009). Interestingly, mutant 
p53 expression - which is know to be involved in malignant transformation and 
metastasis (Petitjean, Achatz et al. 2007) - has been recently shown to promote 
loss of migrational directionality and to drive β1-integrin-dependent tumour 
invasion by enhancing recycling of α5β1 integrin and EGFR1. This occurs in a way 
that requires Rab-coupling protein (RCP) function and p63 inhibition, and results 
in constitutive activation of EGFR and integrin signalling (Muller, Caswell et al. 
2009). 
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Integrin recycling is also thought to exert effects on tumour development and 
progression by altering the recycling of vascular endothelial growth factor 
receptors (VEGFRs) to affect angiogenesis. Tumour angiogenesis is a process that 
involves generation of new vasculature, which penetrates the cancerous growth 
and allows for the delivery of nutrients and oxygen to cancer cells. It is thought 
to be initiated through hypoxia-induced secretion of VEGF by tumour cells, 
which then binds to VEGFR2 on adjacent epithelial cells to activate signalling 
cascades leading to endothelial cell proliferation, tubulation and generation of 
new vessels (Olsson, Dimberg et al. 2006). Angiogenesis is also thought to be 
regulated by αvβ3 integrin (Brooks, Clark et al. 1994). Indeed, it has been 
recently found that in the absence of agents that block αvβ3 function (such as 
Cilengitide) VEGFR2 recycling is slow and its stimulation with VEGF drives 
internalisation and degradation of this receptor. However, low concentrations of 
Cilengitide activate the Rab4 recycling pathway and promote αvβ3 and VEGFR2 
trafficking, which protects VEGFR2 from degradation. This in turn increases 
surface levels of VEGFR2 and prolongs VEGFR2-mediated signalling, thus 
promoting endothelial cell migration and tubulation, which drive angiogenesis 
(Reynolds, Hart et al. 2009). This is consistent with observations that β3-null 
mice display enhanced tumour angiogenesis (Reynolds, Reynolds et al. 2004) and 
could explain why αvβ3 inhibitors that have entered clinical trials have had 
limited success as anti-angiogenic agents.  
Recently, a link between integrin trafficking, cell division and human cancer has 
been established through the demonstration that Rab21-mediated integrin 
trafficking from the cell surface to the cytosolic compartment is required during 
cytokinesis. Successful cell division has been shown to require Rab21 activity, its 
association with α integrin subunits and efficient integrin-mediated cell/matrix 
adhesion at the cleavage furrow. More importantly, loss of Rab21 has been 
detected in ovarian human cancer cells and this is correlated with genetic 
instability and accumulation of multinucleate cells, and this phenotype can be 
rescued by introduction of Rab21. This suggests that dysregualtion of integrin 
trafficking through Rab21 loss or inactivation can drive genetic instability and 
tumour progression (Pellinen, Tuomi et al. 2008). 
Even though in the recent years multiple indications of the importance of 
integrin trafficking in tumour progression have emerged, some of the above 
Chapter 1  60 
observations indicate that simply blocking integrin engagement with the matrix 
or its trafficking, might not be an efficacious way of designing anti-cancer 
therapies. This is mainly due to the implications of crosstalk between the 
pathways that traffic different integrin heterodimers and RTKs on the 
effectiveness, or rather ineffectiveness of integrin blocking-therapies, 
particularly in the context of αvβ3 integrin blockade and EGFR1/VEGFR2 
recycling. Taken together these descriptions highlight the need for more 
detailed understanding of integrin trafficking events occurring during tumour 
progression, as well as of the background in which they happen, if effective 
therapies that interfere with pro-invasive integrin function are to reach the 
clinic.  
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1.4 Rab25 and its disputed role in cancer progression 
1.4.1 Rab25 is a member of the RAS-superfamily 
Rab25 belongs to the superfamily of RAS-related proteins, of which the 
oncoproteins H-RAS, K-RAS and N-RAS, are prominent members. There are over 
170 members of the RAS-superfamily of GTPases, and they all share a common 
ability to bind and hydrolyse GTP (guanosine triphosphate) to GDP (guanosine 
diphosphate) (Colicelli 2004). The binding of GTP to the GTPase induces 
conformational changes in the latter, which in turn affects its affinity for binding 
effector molecules. These small GTPases continuously cycle between active and 
inactive forms, and their activity depends on the ratio of active (GTP-bound) 
versus inactive (GDP-bound) complexes. The GDP/GTP exchange rate and thus 
the activity of the GTPase are controlled by guanine nucleotide exchange factors 
(GEFs), which allow disassociation of GDP and promote the formation of an 
active complex (Rossman, Der et al. 2005), and by GTPase activating proteins 
(GAPs), which enhance the GTPase activity of the enzyme thus accelerating the 
formation of inactive forms (Bernards and Settleman 2004).  
RAS-superfamily of proteins can be divided into five main families: RAS, RHO, 
RAB, ARF and Gα-family (Colicelli 2004). Rab proteins were first identified as 
Ras-related genes in a rat brain cDNA library, and were denoted as Rab1, Rab2, 
Rab3 and Rab4 (Touchot, Chardin et al. 1987). The human Rab family of small 
GTPases encompasses 70 members, whose roles in multiple stages of vesiculo-
tubular transport have been studied in detail (Zerial and McBride 2001). Rab11A 
and Rab11B are the closest homologues of Rab25 and together they form the 
Rab11 subfamily. The crystal structure of Rab25 has been solved at 2.3Å (PDB: 
2OIL) and it is largely similar to that of other Rabs with only subtle variations. Its 
core is formed by a six-stranded β-sheet, which is surrounded by five α-helices. 
The 72% sequence identity between Rab25 and Rab11 is reflected in the 
similarity between GDP-bound structure of Rab25 and that of Rab11 (PDB: 1OIX), 
with the exception of two loop regions spanning the residues 39–47 and 67–77. 
Also, some of the exposed surfaces are divergent due to the varying orientations 
of side chains, and these may also be responsible for distinct roles of Rab11 
family members (www.thesgc.org/structures/structure_description/2OIL/). 
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Rab25 was first identified in rabbit gastric tissue and its expression shown to be 
restricted to gastrointestinal mucosa, lung and kidney, thus suggesting its 
epithelial distribution (Goldenring, Shen et al. 1993). It was then detected on 
immunoisolated tubulovesicles from gastric parietal cells, along with secretory 
carrier membrane proteins (SCAMPs), and this suggested a role for Rab25 in 
gastric cell secretion, which requires fusion of intracellular tubulovesicles with 
the apical plasma membrane (Calhoun and Goldenring 1997). Rab25, together 
with Rab11A, has been shown to associate with the apical pericentriolar 
endosomal compartment of epithelial Madin-Darby Canine Kidney (MDCK) cells. 
The apical pericentriolar endosomal compartment, also known as the apical 
recycling compartment, is a site where apical and basolateral endocytic 
pathways in epithelia converge, and where sorting of apically and basolaterally 
internalised cargo occurs before its return to the site of origin or for transcytosis 
to the opposite pole of the membrane. Rab25 expression has been shown to 
decrease the rate of transcytosis and apical (but not basolateral) recycling of 
internalised ligand, whilst expression of its dominant-negative mutant did not 
alter either of these processes, thus suggesting that Rab25 may selectively 
modulate apical recycling and transcytosis (Casanova, Wang et al. 1999).  
1.4.2 Rab25 as tumour promoter 
There have recently been a number of reports implicating Rab25 in different 
facets of tumorigenesis. Rab25 was first implicated in tumour progression and 
invasion in a study performed by Wang and colleagues, where it was shown to be 
upregulated in tumours established from highly metastatic rat mammary 
carcinoma cells (MTLn3), by comparison to those generated using their non-
metastatic counterparts (MTC tumour cell line) (Wang, Wyckoff et al. 2002). 
Rab25 was subsequently identified as a prominent component of the gene 
signature, which was associated with a subpopulation of mammary tumour cells 
that invaded from the primary subcutaneous tumour, into a matrigel-containing 
microneedle (Wang, Goswami et al. 2004). Not only has Rab25 been implicated 
in the invasiveness of breast tumours, it has also been reported to drive the 
progression of ovarian carcinomas. Cheng and colleagues reported this GTPase to 
be the driver of the 1q22 amplification in breast and serous ovarian cancers and 
demonstrated a correlation between enhanced Rab25 gene copy number (as well 
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as RNA levels) and poor prognosis, thus implicating it in progression and 
aggressiveness of these tumour types (Cheng, Lahad et al. 2004). Rab25 can also 
promote ovarian cancer cell proliferation, survival and colony formation in vitro, 
as well as subcutaneous and intraperitoneal growth of xenografts in nude mice 
(Cheng, Lahad et al. 2004; Fan, Xin et al. 2006). Other workers have shown that 
Rab25 is associated with a subpopulation of highly aggressive serous ovarian 
cancers (Davidson, Zhang et al. 2006) and the aforementioned work from our 
laboratory is consistent with a role for Rab25 in enhancing the invasive potential 
of human ovarian cancer cells (Caswell, Spence et al. 2007). 
1.4.3 Rab25 can function as tumour suppressor 
By contrast with its role as a tumour promoter, recent results indicate that 
Rab25 can suppress colorectal cancer initiation and progression. Loss of Rab25 
has been associated with poor patient survival in human colorectal 
adenocarcinomas, and has been suggested to promote the development of this 
type of neoplasia. Similar results supporting the function of Rab25 as tumour 
suppressor in the intestinal epithelium were obtained from mouse models. 
Colorectal adenocarcinoma is thought to progress through a series of genetic 
aberrations and patients with hereditary colon cancer predisposition, such as 
those suffering from familial adenomatous polyposis (FAP), have been shown to 
develop a multitude of benign polyps due to mutations in the adenomatous 
polyposis coli (APC) gene. The mouse homologue of APC, which harbours a 
mutation designated multiple intestinal neoplasia (Min) contains a stop mutation 
codon at residue 850, which results in these mice (APC/Min+) presenting with 
adenomatous polyps in the small intestine and colon, but these lesions rarely 
develop into adenocarcinomas. Crossing Apc/Min+ mice onto Rab25-deficient 
mice has resulted in a four fold increase in the number of intestinal polyps and a 
two fold increase in intestinal tumours when compared to Apc/Min+ mice on a 
Rab25 wild type background, indicating that Rab25 loss can drive tumour 
progression (Nam, Lee et al.). In a report that focuses on breast cancer, Cheng 
and colleagues report loss of Rab25 expression in 33% of breast cancers when 
compared to matched normal breast tissue. Additionally, these authors found 
that overexpression of Rab25 in breast cancer cells impaired proliferation and 
anchorage-independent growth (Cheng, Ding et al. 2006). Interestingly, in a 
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subsequent study, they detected Rab25 loss in 75% of hormone receptor (HR)-
negative breast cancer patients, whilst this GTPase was highly expressed in most 
(78.6%) HR-postive tumours and normal breast tissue, when measured by RT-
PCR. Furthermore, immunohistochemical analysis of 32 samples revealed that 
the average Rab25 protein expression in ER-negative tumours was significantly 
lower when compared to ER-positive cancers, further indicating that Rab25’s 
role in tumorigenesis is likely to be very context dependent (Cheng, Volk et al.). 
Indeed, in our laboratory we have seen a significant correlation between 
reduced levels of Rab25 and poor patient survival in ER-negative breast cancer 
patients (Claire Kelly, unpublished data).  
Taken together, the above reports implicate Rab25 in various facets of tumour 
aggressiveness and progression, but the exact role played by Rab25 in these 
processes appears to be context specific. It is therefore imperative to determine 
the potential roles that Rab25 effector and interacting proteins can play in 
switching its function from tumour promoter to tumour suppressor, to resolve 
the conundrum surrounding Rab25’s role in tumour progression. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents and Solutions 
Solution Details Source 
2% gelatine  Sigma 
Ampicillin  Sigma 
Ascorbic acid  Sigma 
DNA ladders 100bp and 1kb Invitrogen 
DNA loading dye  
 
30% (w/v) sucrose, 0.35% 
Orange G (Sigma) 
 
DNaseI (10µg/ml)  Roche 
Dulbecco’s Modified Eagle 
Medium (DMEM) 
 Gibco 
EGF  Peprotech 
Ethidium bromide  Invitrogen 
Foetal Bovine Serum (FBS)  Autogen Bioclear 
Hybond-P PVDF membrane  GE Healthcare 
IPTG  Isopropyl β-D-1-
thiogalactopyranoside 
Roche 
Kanamycin  Sigma 
LB Agar LB + 1.5% agar  
L-Broth (LB) 1% w/v bacto-tryptone, 86nM 
NaCl, 0.5% yeast extract 
Beatson Institute 
Central Services 
L-Glutamine (200mM)  Gibco 
Lyophilised fibronectin 1mg Tebu-Bio 
Matrigel  BD Biosciences 
NDLB cell lysis buffer 150mM NaCl, 50mM Tris, 10mM 
NaF, 1mM Na3VO3, 5mM EDTA, 
5mM EGTA, 1% Triton X-100, 
0.5% Igepal CA-630 
 
NuPAGE MES SDS Running 
Buffer (20X) 
 Invitrogen 
NuPAGE pre-cast gels  Invitrogen 
NuPAGE Sample Buffer (4X)  Invitrogen 
NuPAGE Sample Reducing 
Agent (10X) 
 Invitrogen 
PBS/EDTA (PE) PBS + 1mM EDTA Beatson Institute 
Central Services 
PBS-T PBS + 0.1% Triton X-100  
Penicillin-Streptomycin  Gibco 
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Phosphate Buffered Saline 
(PBS) 
170mM NaCl, 3.3mM KCl, 
1.8mM Na2HPO4, 10.6mM H2PO4 
Beatson Institute 
Central Services 
RNA loading buffer 
 
6µl dye, 10.5µl formaldehyde, 
30µl formamide, 3µl 10xMOPS, 
3µl H2O 
 
RPMI-1640 Medium  Gibco 
Soluble fibronectin 1mg/ml  Sigma 
TBS Tween (TBST) TBS + 0.1% Tween-20  
Transfer Buffer 50mM Tris, 40mM glycine, 
0.04% SDS, 20% methanol 
Beatson Institute 
Central Services 
Tris Buffered Saline (TBS) 10mM Tris-HCl, pH 7.4, 150mM 
NaCl 
Beatson Institute 
Central Services 
Tris-acetate-EDTA (TAE) 40mM Tris, 0.1% glacial acetic 
acid, 1mM EDTA 
Beatson Institute 
Central Services 
Tris-EDTA (TE) 10mM Tris-HCl, pH 8.0, 1mM 
EDTA 
 
Trypsin  Gibco 
X-gal 5’-bromo-4-chloro-3-indolyl-D-
galactopyranoside 
Roche 
Table 2-1 Reagents and solutions 
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2.1.2 Antibodies and dyes 
Antigen Details Dilution for WB Source 
Active α5 
integrin 9EG7 
  BD-Pharmingen (553715) 
Alexa-647 
succinimidyl 
ester 
  Molecular Probes 
Calcein AM   Molecular Probes 
CLIC3 Chicken 1:1000 Abcam (ab16050) 
CLIC3 Rabbit 1:5000 (1:500 IHC) In-house 
dsRed Rabbit 1:1000 Clontech (632496) 
Flag Mouse 1:1000 Sigma (F-3165) 
GFP Mouse 1:5000 Abcam (AB1218) 
GST Rabbit 1:5000 Santa Cruz (sc-459) 
Phalloidin TRITC/FITC-
conjugated 
1:500 Sigma 
Rab11 Mouse 1:1000 Transduction Labs 
(r56320) 
Rab25 Rabbit 1:5000 (1:1000 IHC) In-house 
Vinculin Mouse 1:5000 In-house 
α5 integrin Mouse  BD-Pharmingen (555651) 
β-actin Mouse 1:5000 Sigma (A-1978) 
Table 2-2 Antibodies and dyes 
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2.1.3 Enzymes and kits 
Kit Supplier 
Amaxa Nucleofection Kit Lonza 
Coomassie Plus (Bradford) Protein Assay Thermo Scientific 
DNA Polymerase Promega 
Glutathione sepharose beads GE Healthcare 
HyperFect Qiagen 
Improm II Reverse Transcription Kit Promega 
pGEM-T-Easy Cloning Kit Promega 
PreScission Protease GE Healthcare 
Qiaprep Spin Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QuantiTect Primer Assay Qiagen 
QuantiTect SYBR Green Master Mix Qiagen 
Rapid DNA Ligation kit Roche 
Restriction enzymes and reaction buffers New England Biolabs 
RNeasy Kit Qiagen 
SimplyBlue SafeStain  Invitrogen 
siRNA oligonucleotides Dharmacon 
Slide-A-Lyser Dialysis Cassettes Thermo Scientific 
SuperSignal West Pico Chemiluminescent 
Substrate 
Thermo Scientific 
T-PER Tissue Protein Extraction Reagent  Thermo Fisher 
Table 2-3 Enzymes and Kits 
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2.1.4 Tissue Culture plastic ware 
Supplier: BD Biosciences 
 Falcon tissue culture dishes (60mm and 90mm) 
 Falcon multi-well plates 
Supplier: TCS Biologicals 
 Nunc tissue culture flasks and dishes  
 Nunc cryotubes 
Supplier: Corning Incorporated 
 Transwell inserts (8µm pores) 
Supplier: Appleton Woods 
 IWAKI-3 cm glass bottom dishes 
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2.2 Methods 
2.2.1 Microarray screen and validation 
2.2.1.1 Total RNA extraction and quality control 
Total cellular RNA was isolated from A2780-DNA3 and A2780-Rab25 cells grown 
for 16 hours on either plastic or CDM using the RNeasy kit, according to the 
manufacturer’s instructions. Briefly, cells were grown to approximately 80% 
confluency in 10cm dishes, washed twice in ice-cold PBS (pH 7.4), residual PBS 
was allowed to drain and was aspirated. Cells were then lysed on ice, in 350µl of 
RLT buffer supplemented with β-mercaptoethanol (10µl per 1ml of the buffer). 
Cell lysates were homogenised by repeated suction through a sterile 25G needle.  
Samples were further homogenised using QIAshredder columns and RNA was 
extracted and purified as it is described in the handbook. Residual genomic DNA 
was removed by an on-column DNAseI digestion. RNA was eluted from the 
column in two sequential steps, each in 30µl of sterile water. RNA was then 
snap-frozen and stored at -80ºC. 
The integrity of the harvested RNA was verified on a 2% agarose gel. 1g of 
agarose was dissolved in 50ml of TAE buffer by heating in a microwave, cooling 
to approximately 50ºC and adding ethidium bromide at a final concentration of 
0.5g/ml. The gel was then cast, allowed to set and 5µl of the RNA sample, 
previously boiled at 70ºC for 5 minutes with 10µl of RNA loading buffer, was 
loaded into the pockets of the gel. Electrophoresis was performed in TAE buffer 
at 100V for one hour and the RNA was visualised by UV illumination. The 
concentration and purity of RNA samples was inspected using a NanoDrop 
spectrophotometer. Samples whose concentration was lower than 0.6µg/µl were 
concentrated by centrifugation in SpeedVac concentrator for approximately 1.5 
hours, whilst the ones whose A260/280 amounted to less than 1.9 were subjected 
to an additional clean-up step using the Qiagen RNeasy kit.  
2.2.1.2 Microarray data analysis 
Total RNA samples were generated in triplicate as described above. Biotinylated 
cRNA was hybridised to GeneChip® human genome U133 Plus 2.0 chip by Cancer 
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Research UK Paterson Institute Microarray Service. The cel files were normalized 
and analyzed in Partek® Genomics Suite Software, version 6.5beta Copyright © 
2009. Default GCRMA normalization and log2 transformation of the data was 
followed by the removal of technical batch effects.  Multiway ANOVA was used 
to identify significantly regulated genes from one of experimental groups and 
linear contrasts performed between all pairs of experimental conditions. 
Multiple test corrections were performed for all calculated p-values. The fold 
change values were used for selection and ordering of differentially expressed 
genes. Finally, unadjusted p-value was used for further reduction of the gene 
lists. Initial analyses were performed by Keith Vass, then under the guidance of 
Jo Thurlow and eventually by Gabriela Kalna.  
2.2.1.3 cDNA synthesis 
cDNA was synthesised from total RNA using ImpromII kit according to the 
manufacturers instructions and in the final reaction volume of 20µl. The 
template/oligo-dT primer thermal denaturation was performed in the first 
instance and the reaction was set up as follows: 
1µg RNA    x µl (as determined by RNA concentration) 
Oligo-dT primer (0.5 µg/µl) 1 µl 
H2O     make up to 10 µl. 
 
The mixture was heated to 70ºC for 5 minutes in the Biorad DNA Engine Peltier 
Thermal Cycler and then chilled on ice for two minutes. The following reverse 
transcription reaction mix was then assembled: 
H2O     0.5 µl 
5x Reaction buffer   4 µl 
MgCl2 (25mM)   3 µl 
dNTPs (10mM)   1 µl 
RNasin (40U/µl)   0.5 µl 
 
and added to the RNA containing tube. Subsequently, 1µl of Improm Reverse 
Transcriptase was added, the sample was then incubated at 25ºC for 5 minutes 
to allow for the initial annealing and the elongation then proceeded for one hour 
at 42ºC. Upon completion of the first strand synthesis, the reaction was 
terminated by incubation at 70ºC for 15 minutes and the sample was then cooled 
at 4ºC. 
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2.2.1.4 Primers for real time PCR 
All primers utilised for real time PCR were purchased from Qiagen as QuantiTect 
Primer Assay kits and had been verified by the supplier to be suitable for use in 
RT-PCR. Their sequences are not disclosed, therefore corresponding catalogue 
numbers are listed below: 
CLIC3  Hs_CLIC3_1_SG QuantiTect Primer Assay (200) (QT00011781) 
SLC16A6 Hs_SLC16A6_1_SG QuantiTect Primer Assay (200) (QT00009338) 
KCNJ2  Hs_KCNJ2_1_SG QuantiTect Primer Assay (200) (QT00001022) 
Β-actin Hs_ACTB_2_SG QuantiTect Primer Assay (200) (QT00095431) 
GAPDH Hs_GAPDH_2_SG QuantiTect Primer Assay (200) (QT01192646). 
2.2.1.5 qPCR 
QuantiTect SYBR Green PCR kit was utilised to perform quantitative PCR on a 
BioRAD DNA Engine thermal cycler fitted with a Chromo4 Engine (Bio-Rad) and 
coupled to Opticon Monitor 3 software. Prior to the assembly of qPCR reactions 
the cDNA template was diluted 1:8 in sterile water. The qPCR reactions were 
then assembled on a cooling block as follows: 
2x SYBR Green Mix   10 µl 
10x Primer Assay    2 µl 
cDNA template (1:8 diluted)  8 µl. 
 
The PCR reaction was performed according to the protocol outlined below: 
Initial Denaturation   95ºC 15 min 
40 cycles: 
Denaturation   95ºC 30 sec 
Annealing   60ºC 30 sec 
Elongation    72ºC 30 sec 
Plate Read 
Final Elongation   72ºC 5 min 
Dissociation Curve   70ºC - 90ºC in 0.3ºC steps. 
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Data was extracted from the Opticon Monitor 3 software and the ΔΔC(t) method 
(Livak and Schmittgen 2001) or one that also incorporates amplification 
efficiencies (Pfaffl 2001) was used to calculate changes in gene expression with 
β-actin and GAPDH serving as reference genes. Each experiment was performed 
in triplicate and each of the replicas incorporated three technical repeats. 
2.2.2 Cloning and DNA manipulation 
2.2.2.1 Bacterial strains 
All cloning procedures utilised competent E.coli DH5α, whilst recombinant 
protein production was performed in BL21(DE3)pLysS E.coli strain. Both were 
generated and supplied by the Central Services at the Beatson Institute. 
2.2.2.2 Bacterial transformation 
50µl of E.coli DH5α cells was thawed on ice and gently mixed with 10-20ng of 
plasmid DNA or ligation reaction mix and incubated on ice for 10 minutes. The 
cells were then subjected to heat shock at 42C for 45sec in a water bath, and 
then chilled on ice for further 2 minutes.  450L of SOC medium was then added 
and the cells were allowed to recover at 37C with shaking for approximately 
one hour.  200L of the transformation mix was spread onto pre-warmed LB agar 
plates containing either 50µg/ml ampicillin or kanamycin and incubated at 37C 
overnight. Individual colonies were then used to inoculate 5 ml of LB medium 
containing the appropriate antibiotic and the culture was grown overnight at 
37C with shaking. For long term storage 500µl of the bacterial culture was 
mixed with equal volume of sterile glycerol and stored at -80ºC. 
2.2.2.3 Plasmid preparation 
Overnight bacterial culture was pelleted by centrifugation at 3000rpm for 10 
minutes in a Beckman Coulter centrifuge. The pellet was processed using the 
QIAprep Spin Mini-Prep Kit by the Beatson Institute Central Services. If sequence 
verification was required, the samples were further processed by the Beatson 
Molecular Technology Services on an Applied Biosystems 3130xl sequencer and 
the sequences were mostly analysed using Vector NTI package (Invitrogen). For 
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large scale plasmid preparation bacterial transformants were cultivated 
overnight in 100ml of LB media containing the appropriate antibiotic, pelleted 
by centrifugation as described above but for 20 minutes. The pellets were 
processed by Central Services. Double stranded DNA was quantified using an 
Eppendorf Biophotometer and 260nm absorbance. 
2.2.2.4 Polymerase chain reaction (PCR) 
PCR was performed using GoTaq DNA Polymerase kit and the manufacturer’s 
specifications were followed. Approximately 100ng of plasmid DNA template, 
0.8mM of both forward and reverse primers, 0.2mM of each dNTP with 1.25 units 
of the polymerase were assembled in the provided reaction buffer and in the 
total volume of 50µl. Temperature cycling was performed in a DNA Engine 
Thermal Cycler (Biorad) under the following conditions: 
Initial Denaturation   95C   10 min 
25 cycles:     
Denaturation   95C  30 s 
Annealing   55-60C 30 s 
Extension   68C  1 min/1kb 
Final Extension   68 C  10 min. 
 
PCR products were then subjected to agarose gel electrophoresis and 
purification, before being later utilised in subsequent cloning procedures. 
Primers used in this project were synthesised by Invitrogen and are listed below: 
CLIC3 pGEX-6P-Fw BamHI  5’ ACTGGGATCCATGGCGGAGACCAAGCTC 3’ 
CLIC3 pGEX-6P-Rev NotI  5’ CAGTGCGGCCGCCTAGCGGGGGTGCACGG 3’ 
FLAG-CLIC3 pcDNA3-Fw BamHI 5’ GATCGGATCCATGGACTACAAAGACGATGA 
CGACAAGGCGGAGACCAAGCTCCAG 3’ 
FLAG-CLIC3 pcDNA3-Rev NotI  5’ GATCGCGGCCGCCTAGCGGGGGTGCACGG 3’ 
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2.2.2.5 Intermediate cloning into pGEM-T-Easy 
Purified PCR-generated DNA fragments were ligated into pGEM-T-Easy vector, 
which utilises the adenosines added to the 3’-ends of the PCR products. Ligation 
reactions were carried out using T4 DNA ligase in the provided ligation buffer 
and in the total volume of 10µl. 50ng of pGEM-T-Easy vector and a vector to 
insert ratio of 1:3 were used. Ligations were performed at 4C overnight. DH5α 
cells transformed with pGEM-T-Easy ligation mix were spread onto LB plates 
containing 40g/ml X-gal and 0.1mM IPTG in addition to 100 g/mL ampicillin.  
Following overnight incubation at 37ºC, individual white colonies were used to 
inoculate 5ml of antibiotic supplemented LB media for further screening. Blue 
colonies were ignored and considered not to be bearing an insert. 
2.2.2.6 Restriction enzyme digestion and ligation 
Double DNA restriction digests were performed using the appropriate restriction 
enzymes and their corresponding reaction buffers. Typically, 1µg of plasmid was 
incubated with 1 unit of two restriction enzymes in the total volume of 20µl, at 
the appropriate temperature (mostly 37ºC), usually for 2 hours. DNA from 
restriction digests was subjected to agarose gel electrophoresis to confirm the 
efficiency of the digest and to allow the subsequent DNA purification from the 
gel slice. The resultant fragment was then cloned into the recipient plasmid 
backbone using the same ligation conditions as those described in the previous 
section.  
2.2.2.7 Agarose gel electrophoresis 
DNA electrophoresis was carried out in 1% (w/v) electrophoresis grade agarose 
dissolved in 1xTAE buffer. Prior to gel solidification ethidium bromide was added 
at the final concentration of 0.5g/ml. DNA samples were diluted in 6x DNA 
loading dye before electrophoresis and loaded on to the gel alongside suitable 
DNA ladder (mostly 1kb ladder). Electrophoresis was conducted in 1xTAE buffer 
at 100 V for approximately one hour.  DNA samples were visualized using UV 
transillumination.  Following electrophoresis, agarose slices containing DNA were 
excised and DNA purified using QIAquick Gel Extraction Kit according to 
manufacturer’s instructions.   
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2.2.3 Recombinant protein production 
2.2.3.1 Protein expression 
500ml of sterile LB media, supplemented with 100ug/ml ampicillin, was 
inoculated with 10ml of an appropriate overnight culture and grown in an orbital 
shaker at 37ºC for a couple of hours. After that time 1ml samples of culture 
were removed at half an hour intervals and the optical density was measured at 
600nm (OD600) against an LB media control.  When OD600 reached 0.6-0.8, 
ensuring logarithmic growth phase of bacteria, expression of the recombinant 
protein was induced with 0.25mM IPTG. Expression of the target protein was 
undertaken for 3 hours in an orbital shaker, at 37ºC. 1ml of the culture was 
sampled prior to induction as well as one, two and three hours after induction 
and bacterial cells were pelleted at 3000rpm for 10 minutes. The whole culture 
was then harvested by centrifugation at 3000rpm for 25 minutes.  The cell pellet 
was then frozen overnight and defrosted the following day. It was subsequently 
re-suspended in 10ml of PBS containing 0.1% TX-100 and additional 10ml of the 
same solution was then introduced. Following the addition of Roche Diagnostic’s 
protease inhibitor cocktail tablet, lysosyme was added at a final concentration 
of 1mg/ml and the cell suspension subjected to 8-seconds-long sonication cycles 
until sufficient cell lysis was achieved. The cell debris was removed by 
centrifugation at 11000rpm for 45 min at 4ºC. The pellet was resuspended in 
20ml of PBS and 50µl were used to analyse the insoluble protein fraction.  The 
cleared lysate was used to recover soluble recombinant protein in subsequent 
purification steps.     
2.2.3.2 Protein purification 
Glutathione sepharose beads were prepared as per the manufacturer’s 
instruction. Approximately 20ml of the cell supernatant was recovered and 
applied to 0.5ml of pre-swollen 4% beads and incubated with gentle agitation for 
3 hours at 4oC to allow the binding of the expressed fusion protein to the resin.  
The beads were then collected by centrifugation at 1000rpm for 10 minutes at 
4oC and washed four times with 1ml PBS with 0.1% TX-100, followed by four 
washes in 1ml PBS.  The protein was eluted from the glutathione beads with 1ml 
of 100mM NaCl, 50mM Tris-HCl, and 3mg/ml glutathione (pH 8.0) by incubating 
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for 10min at 4oC with repeated inversion.  The beads were then collected by 
centrifugation at 7000rpm for 5 minutes at 4ºC and the eluate was collected in a 
separate tube. This was repeated three times and resulted in the generation of 
three elution fractions.  The eluted fractions were pooled and protein 
concentration was measured. Where necessary, PreScission cleavage was 
performed, which removed the GST tag from the recombinant protein. Typically, 
1 unit of the enzyme was used for every 100µg of recombinant protein in 1mM 
DTT and 1mM EDTA and the digestion was carried out for 4 hours at 4ºC. 
Following the removal of the GST-tag glutathione sepharose beads were applied 
and the sample was gently agitated for 2 hours at 4ºC to capture cleaved GST 
and GST-tagged PreScission protease. The beads were then collected by 
centrifugation at 7000rpm for 5 minutes and the supernatant containing pure 
recombinant protein was collected. Where necessary, the above process was 
repeated. The expression time-course, soluble and insoluble fractions, as well as 
protease cleavage and purification efficiency were analysed by SDS-PAGE and 
Coomassie staining. The purified protein was dialysed overnight using Slide-A-
Lyser dialysis cassette (10kDa MWCO) against 2L of PBS (pH 7.4), at 4oC. The 
purified protein was frozen on dry ice, and stored in aliquots, at –80oC.   
2.2.4 Mammalian cell culture techniques 
2.2.4.1 Cell origin 
Stable clones of A2780-DNA3 and A2780-Rab25 cells were a kind gift from Gordon 
Mills and were generated as described previously (Cheng, Lahad et al. 2004). A 
number of cell lines were obtained from other groups within the Beatson 
Institute for Cancer Research, including Telomerase-immortalised human 
foreskin fibroblasts (Tifs) from Brad Ozanne. Primary cultured Human dermal 
fibroblasts (HDFs) were purchased from the American Type Culture Collection 
cell bank. 
2.2.4.2 Cell maintenance   
A2780 adenocarcinoma cells were cultivated in RPMI-1640 supplemented with 
10% (v/v) serum, 2mM L-glutamine plus 10Units/ml penicillin and 10µg/ml 
streptomycin, at 37°C, in a humidified atmosphere containing 10% CO2.  HDF and 
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Tif fibroblasts were grown in DMEM media supplemented as it is described 
above. For sub-culturing, medium was removed by aspiration, the monolayer 
rinsed with PBS, then with 10% trypsin/PE solution.  Following detachment the 
cells were re-suspended in culture media and subsequently transferred into 
appropriate tissue culture flasks.    
For long term storage, cells were trypsinised and pelleted by centrifugation. 
They were then re-suspended in 10% DMSO in FCS, placed in cryotubes and 
frozen at -80ºC over night to then be transferred to liquid nitrogen vapour tanks 
where they were stored.  
2.2.4.3 Nucleofection 
Nucleofection provides a more efficient alternative to DNA transfection and was 
used for the introduction of DNA plasmids and siRNA into A2780 cells. The cells 
were passaged the day before nucleofection and were 75-80% confluent when 
nucleofected. Cells were trypsinised, re-suspended in growth media and 
centrifuged for 5 minutes at 1000rpm. The media was then aspirated and cells 
washed in PBS. Following centrifugation, the cell pellet was suspended in 100µl 
of pre-warmed Nucleofector Solution T, which was then mixed with the 
appropriate DNA or siRNA. Typically 3µg of plasmid DNA or 5µl of 20µM siRNA 
(1µM final siRNA concentration) were used for each transfection, with the 
exception of co-transfecting GFP-α5 and Cherry-CLIC3, when 4.8µg of the 
integrin and 1.2µg of the CLIC3 construct were used. The resultant suspension 
was then transferred to a nucleofection cuvette and inserted into the Amaxa 
Nucleofector. Nucleofection carried out using A-23 programme and the 
nucleofection mix was suspended in 500µl of warm media and added to pre-
prepared tissue culture dishes. Cells were allowed to recover and settle for at 
least 18 hours prior to life cell imaging, 4 or 12 hours prior to setting up invasion 
assays when siRNA or overexpression constructs were used, respectively.  
2.2.4.4 Inverse invasion assay 
Inverse invasion assays were performed as described previously (Hennigan, 
Hawker et al. 1994). An aliquot of complete matrigel was thawed slowly on ice 
and diluted in and equal volume of ice-cold PBS supplemented with 25µg/ml 
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soluble fibronectin. 100µl of the diluted matrigel mix was pipetted into each 
Transwell (8µm diameter pores), which had previously been inserted into a well 
of a 24-well tissue culture plate, and left to set at 37ºC. The transwells were 
then inverted and 4x104 cells, previously trypsinised and washed in PBS, were 
placed on the underside of the filter. The transwells were then covered with the 
base of the 24-well tissue culture plate so that they made contact with cell 
suspension droplets. Cell attachment was allowed to proceed for four hours, 
before the plate was inverted back and the non-adherent cells were washed off 
by three sequential washes in 1ml of serum-free medium. The transwells were 
left in the last 1ml of serum-free medium, which constituted the lower chamber 
of the assay, and 100µl of 10% FCS-RPMI supplemented with 25ng/ml EGF was 
pipetted on top of the transwell. The cells were then allowed to invade into the 
matrigel and towards the gradient of serum and EGF for 48 or 72 hours at 37ºC in 
the atmosphere of 5% CO2. To visualise cells that migrated into the matrigel 
plug, 4µM Calcein AM (acetoxymethyl ester of calcein) was used. This was done 
by placing the transwells in a new 24-well dish and pipetting 1ml of calcein 
solution in RPMI over the top of the transwell. After one hour at 37ºC the cells 
were imaged by confocal microscopy using a Leica SP2 confocal microscope and 
a 20x objective at an excitation wavelength of 488 nm and emission wavelength 
of 515nm. Optical sections were captured at 15µm intervals, starting from the 
underside of the transwell filter and moving upwards in the direction of cell 
invasion. The resulting images were quantified using Image J software. The 
threshold fluorescence intensity of the images was set to only register cells that 
lay within each individual optical slice, and the sum of the fluorescence in the 
sections from 45µm and above was divided by the total fluorescence of all the 
sections, thus giving and invasion index ‘beyond 45µm’. Data were generated 
from at least 3 individual experiments, in which each condition was represented 
by at least two transwells and optical sections were taken from at least 3 areas 
of each transwell.  
2.2.4.5 Generation of cell derived matrix  
Cell-derived matrix was generated as described previously (Cukierman, Pankov 
et al. 2001; Bass, Roach et al. 2007).  Briefly, tissue culture plates were coated 
with 0.2% sterile gelatin for one hour at 37ºC. Tissue culture dishes were then 
washed twice in PBS and cross-linked with 1% sterile glutaraldehyde for 30 
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minutes at 37ºC. Following two washes with PBS, the cross-linker was quenched 
with 1M sterile glycine in PBS (pH~7) for 20 minutes at room temperature. Upon 
two further PBS washes the dishes were equilibrated in DMEM containing 10% FCS 
for half an hour at 37ºC.  Primary cultured human dermal fibroblasts (HDFs) or 
telomerase immortalised fibroblasts (Tifs) were then seeded at near confluence 
(~2x104 cells/cm2) and grown for 10-14 days in DMEM containing 10% FCS and 
50µg/ml ascorbic acid. The media with ascorbic acid was changed every other 
day to ensure sufficient collagen production and the sticking of the matrix to the 
tissue culture plate. Matrices were denuded of living cells by incubation with 
PBS containing 20mM NH4OH and 0.5% TritonX-100 for approximately two 
minutes or until no intact cells were present, as examined by phase light 
microscopy. Extraction buffer was gently aspirated and the matrix washed twice 
with PBS containing calcium and magnesium. DNA residues were removed by 
incubation with 10ug/ml DNaseI in PBS containing calcium and magnesium at 
37ºC for 30 minutes. The matrices were then washed twice with PBS containing 
calcium and magnesium and stored at 4ºC in PBS with calcium and magnesium 
supplemented with pen/strep. The matrix was confirmed to be intact by phase 
microscopy prior to use. Matrices were blocked with 0.1% heat-denatured BSA 
prior to seeding of tumour cells. 
2.2.4.6 Labelling of fibronectin 
One mg of human lyophilised fibronectin (FN) was dissolved in one ml of filtered 
water and was allowed to stand at 4ºC for one hour. It was then dialysed into 
ice-cold PBS using a Slide-A-Lyser dialysis cassette with a 3.5KDa molecular 
weight cut off. After an overnight dialysis, the fibronectin solution was 
recovered and 1 volume of filtered 1M NaHCO3 (prepared directly prior to use) 
was added to 9 volumes of FN. 20µl of 10mg/ml Alexa-647 succinimidyl ester in 
DMSO was added to 1ml of FN and agitated for one hour at 37ºC. The Alexa-FN 
preparation was then dialysed into ice-cold PBS overnight. 
2.2.4.7 Live cell imaging, photoactivation and colocalisation quantification 
A2780 cells were seeded onto glass-bottomed 3-cm plates and imaged with a 64x 
objective of an inverted confocal microscope (Fluoview FV1000, Olympus) in an 
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atmosphere of 5% CO2 at 37°C. Different fluorescent channels within one sample 
were recorded sequentially to prevent bleed-through.  
Photoactivation was performed with a 405nm laser of the above mentioned 
microscope and Olympus SIM scanner. Images were then captured every 2 
seconds over a period of 120 seconds. Movies were generated from these time-
lapse images and stills corresponding to individual frames from the movies were 
analysed. The integrated fluorescence intensity of the photoactivated region and 
adjacent plasma membrane region were determined for each frame using the 
Fluoview FV1000 software. The loss of fluorescence in the activated region 
(vesicle) and its gain in the proximal plasma membrane region (membrane) was 
calculated relative to the fluorescence of the photoactivated region in the frame 
immediately after photoactivation. The obtained relative fluorescence values 
were then plotted against time.  
Colocalisation quantification was performed using Image J software, where the 
confocal images underwent two rounds of local contrast enhancement (image 
blurring, subtraction of the blurred image and subsequent contrast 
enhancement) and threshold adjustment. The number of pixels in the red 
channel was then expressed as a percentage of yellow pixels in the merged 
image. This was performed with the assistance from David Strachan. 
2.2.4.8 Fixing and staining cells for microscopy 
Cells were cultured on square cover slips placed in 8-well tissue culture dishes. 
Medium was aspirated and cells were washed in PBS and fixed in 4% 
formaldehyde for 15 minutes. Three PBS washes were performed and cells were 
then permeabilised with 0.2% Triton X-100 in PBS for 5 minutes. Following three 
more washes in PBS, non-specific binding sites were blocked with 1% BSA/PBS for 
1 hour. Subsequently primary antibodies diluted in the block solution were 
applied for 45 minutes. The actin cytoskeleton was counterstained with 
fluorophore-conjugated-phalloidin in PBS for 10 minutes. Coverslips were washed 
twice before being mounted onto glass slides using DAPI Vectashield anti-fade 
reagent. All the above steps were performed at room temperature. Glass slides 
were stored at 4ºC until viewed by confocal microscopy.  
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2.2.4.9 FLIM-FRET 
A2780 cells transiently expressing the appropriate fusion proteins were plated 
onto 3cm glass bottom dishes. Fluorescence resonance energy transfer was 
detected using a Lambert Instruments Fluorescence Attachment (LIFA) on a 
Nikon Eclipse TE 2000-U microscope equipped with a 100x oil immersion 
objective and a filter block consisting of a 470/40 excitation filter, a T495LP 
dichroic mirror, and a 525/50M emission filter. A modulated 490 nm LED was 
used as light source, which in combination with the modulated intensifier from 
the LIFA system, allowed measurement of fluorescence lifetimes using frequency 
domain. Donor (D) lifetime, τ, was analyzed using the FLIM software (version 
1.2.7; Lambert Instruments, The Netherlands). FRET efficiency was calculated 
from Donor lifetime with and without the presence of Acceptor using the given 
formula; Nfret = 1-(τfret/ τd), where τfret is the lifetime of donor in the presence of 
acceptor and τd is the life time of donor in the absence of acceptor. Experiments 
performed under the guidance of Kiran Vadrevu. 
2.2.4.10 Recycling assays 
Cells were serum-starved for 30-45 minutes, washed twice in ice-cold PBS and 
then surface labelled with 0.2mg/ml NHS-SS-biotin for 30 minutes at 4ºC. 
Labelled cells were washed twice in ice-cold PBS and transferred to media 
containing 10% FCS, which had previously been heated to approximately 15ºC. 
Cells were then transferred to an incubator and internalisation was allowed to 
proceed for 30 minutes in the presence or absence of 2.5µg/ml fibronectin at 
37ºC. Cells were then transferred to ice, washed twice with ice-cold PBS and 
biotin removed from proteins remaining at the cell surface by a 20 minute 
reduction with MesNa in PBS (pH 8.6). The internalised proteins were then 
chased from the cells by returning them to 37ºC in media containing 10%FCS. At 
the indicated times cells were returned to ice and biotin removed from the 
recycled proteins in a second reduction step. Residual MesNa (sodium 2-
mercaptoethanesulphonate) was quenched with 20mM IAA (iodoacetamide) for 
10 minutes and cells lysed. Levels of integrin recycled were determined by 
capture ELISA on 96-well plates pre-coated with 5µg/ml antibodies recognising 
either GFP, total α5β1 or active α5β1 integrin (9EG7 epitope) in 0.05M Na2CO3 
(pH9.6) at 4ºC. Non-specific binding sites were blocked with 5%BSA in PBS-T for 
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one hour at room temperature. 50µl of cell lysate was added to appropriate 
wells of the multititre plate and gently agitated overnight at 4ºC. Unbound 
proteins were removed by PBS-T washes and streptavidin-conjugated horseradish 
peroxidise in 1% BSA/PBS-T was then added for 1 hour. Following washes in PBS-
T and then PBS, biotinylated integrins were detected by chromogenic reaction 
with 0.56mg/ml ortho-phenylenediamine in a buffer containing 25.4mM 
Na2HPO4, 12.3mM citric acid (pH 5.4) with 0.003% H2O2, at room temperature for 
10 minutes. The reaction was terminated with 8M H2SO4 and absorbance was 
read at 490nm. The percentage of integrins recycled was inversely proportional 
to the proportion of biotinylated integrin remaining in the samples that 
recycled, versus the biotinylated integrin pool, which was not allowed to 
recycle. Assays performed with the assistance from Jim Norman. 
2.2.4.11  FACS 
Cells were stained with 1µM LysoTracker Red for 20 minutes at 37ºC and 
subsequently washed once with PBS. 0.5ml trypsin was used to detach cells from 
the culture dish and they were then re-suspended in 2ml of ice-cold media and 
immediately sorted using a Becton Dickinson Cellquest FACScan on basis of 
fluorescence resulting from excitation of cells with a 568 nm laser. The FacsScan 
was operated by, and data analysed with the help of Simon Wilkinson, Beatson 
Institute. 
2.2.5 Protein extraction and analysis 
2.2.5.1 Cell lysis for protein 
Protein extracts were prepared from cells when approximately 80% confluent.  
Cells were washed twice with ice cold PBS (pH 7.4) and lysed with 1.5x NDLB 
buffer containing protease inhibitors: 50µg/ml Aprotonin, 1mM AEBSF (4-[2-
Aminoethyl]benzynesulphonyl fluoride), and 50µg/ml Leupeptin. Cell lysates 
were scraped with a cell scraper, transferred to a 1.5 ml tube and centrifuged at 
13000rpm at 4°C for 10 minutes and cleared lysates were collected in new 
tubes. Samples were either processed immediately or stored at -20°C. 
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2.2.5.2 Protein extraction from mouse tissue 
Protein extracts were prepared immediately after tissue harvesting using T-PER 
Tissue Protein Extraction Reagent. 10ml of T-PER buffer was supplemented with 
protease inhibitors: 125µl of 100mM PMSF (phenylmethylsulfonyl fluoride), 20µl 
of 0.5M NaF, 20µl of 100mM Na3VO4, 30µl AEBSF, 30µl Aprotonin and 30µl 
Leupeptin. Tissue was then placed together with 500µl of the lysis buffer in 
homogenisation tubes containing ceramic beads (Precellys 24 Lysis and 
Homogenisation) and three cycles of homogenisation were performed at 
5000rpm, each consisting of two 20 seconds long steps with 10 second intervals. 
Following homogenisation lysates were clarified by centrifugation at 13000 rpm 
for 15 minutes at 4ºC. 
2.2.5.3 Protein quantification  
The protein concentration in cell lysates was determined using the Coomassie 
Plus (Bradford) Protein Assay and a 2mg/ml stock of BSA. 10µl 1.5x NDLB buffer 
blanks, 10µl of protein standards (0.2, 0.4, 0.6, 0.8 and 1mg/ml BSA) were 
added to the wells of a flat-bottomed 96-well plate, as were 10µl of lysates (all 
in triplicate).  200µl of the protein assay reagent was then added to each well 
and the absorbance was measured on a Dynatech MR7000 plate reader at 595 
nm. The absorbance values for the protein standards were used to generate a 
standard curve and the protein concentrations in the cell lysates were 
determined from the curve.  
2.2.5.4 SDS-PAGE and Coomassie staining 
SDS-poly-acrylamide gels were used to resolve protein samples. The required 
amount of lysate containing typically 40µg protein was mixed with 4x reducing 
sample buffer. Samples were then heated at 95°C for 10 minutes, briefly 
centrifuged to collect the whole sample, and resolved on gradient (4-12%), 
denaturing, pre-cast polyacrylamide gels. Electrophoresis was performed in gel 
tanks containing 1x MES running buffer, at 120V and for approximately 2 hours.  
Molecular weight markers were loaded on the gel adjacent to the lysate 
samples. After resolution by SDS-PAGE, the gel was either stained with 
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SimplyBlue SafeStain Coomassie reagent to visualise all proteins that were 
resolved, or Western Blotting was performed. 
2.2.5.5 Western Blotting 
Proteins previously separated by SDS-PAGE were transferred from the gel to 
PVDF membrane in blotting buffer for 75 minutes at 10V, using BioRad semi-dry 
transfer apparatus. Excess protein sites were blocked using 5% BSA in TBS-T at 
room temperature. The membranes were then incubated with primary 
antibodies at the appropriate dilutions, overnight at 4ºC. Membranes were then 
washed 3 times with TBS-T for 10-30 minutes and incubated with appropriate 
HRP-conjugated secondary antibodies at 1:3500 dilutions, followed by 3 
additional TBS-T washes. All incubation and wash steps were performed with 
gentle agitation. Proteins on the membranes were visualised by 
chemiluminescence using Pierce ECL Western Blotting Substrate. This was 
followed by autoradiography using Fuji Super RX medical X-ray film and a Kodak 
X-Omat 480 RA X-Ray processor.  
2.2.6 Protein expression analysis in tissue samples 
2.2.6.1 Immunohistochemistry 
Immunohistochemical staining was performed by Colin Nixon at the Histology 
Service (Beatson Institute). Briefly, formalin-fixed and paraffin embedded tissue 
sections were dewaxed in Xylene and passed through Ethanol (2x 100%, 1x 70%) 
for rehydration. Heat-induced epitope retrieval was carried out in either TRIS-
EDTA buffer (pH8) or citrate buffer (pH6). Enzymatic retrieval was attempted 
using proteinase K. Endogenous peroxidase was then blocked using 3% 
H2O2/methanol for 5 minutes before CLIC3 or Rab25-specific antibody was 
applied at 1:500 and 1:1000 dilution, respectively, for 45 minutes at room 
temperature. Tissue sections were then incubated in secondary antibody (Dako 
Envision rabbit kit, K4003) for 40 minutes and the staining was visualised with 
DAB and counterstained with Gills Heamatoxylin. Resulting whole sections were 
analyzed and images were captured digitally using a Zeiss Axioskop 50 
microscope and Axiovision software version 3.1. TMA slides were scanned at 20x 
magnification using NanoZoomer NDP scanner (Hamamatsu) and were then 
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stored on a dedicated server and were available for viewing using Slidepath 
Digital Image Hub. 
2.2.6.2 Pancreatic tumour TMA cohort and analysis 
The human pancreatico-biliary tissue microarray (TMA) was produced in the West 
of Scotland Pancreatic Unit, University Department of Surgery, Glasgow Royal 
Infirmary, and provided by Nigel Jamieson. The local Research ethics Committee 
approved tissue sample collection. All patients underwent 
pancreaticoduodenectomy and gave written and informed consent for sample 
collection. A total of 1500 cores from 224 patients with pancreatico-biliary 
cancer (including 118 cases with pancreatic ductal adenocarcinoma; PDAC) were 
arrayed on the TMA. Clinicopathological parameters and complete follow up 
data were available. From each patient at least 6 tumour cores (0.6mm 
diameter) and 2 cores of adjacent normal tissue were sampled. CLIC3 expression 
levels were assessed by two independent scorers and according to the intensity 
of immunohistochemical staining, as well as to the area of tumour cells that 
were CLIC3-positive. This was done using a histoscore, which serves as a semi-
quantitative assessment of staining intensity and is calculated from the formula: 
histoscore = (1 x % cells with weak staining) + (2 x % cells with moderate 
staining) + (3 x % cells with strong staining). Statistical analysis was performed 
by Nigel Jamieson with the SPSS version 15.0 package (SPSS Inc., Chicago, I11, 
USA). A histoscore of 100 was used as a cut off for low and high CLIC3 
expression. Kaplan-Meier survival analysis was used to assess the overall survival 
after surgery and patients alive at the time of follow up were censored. To 
compare the length of survival between the two expressor groups, a Log Rank 
analysis was performed. To adjust for competing risk factors, a Cox proportional 
hazards model and univariate analysis were used and hazard ratios (HR) with 95% 
confidence interval (CI) were reported as an estimate of the risk of disease 
specific death. Clinicopathological parameters that were identified as significant 
(p<0.10) in univariate analysis were incorporated into the Multivariate Cox 
Regression Analysis in a backwards stepwise fashion. Statistical significance for 
independent outcome predictors was set at p≤0.05. 
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2.2.6.3 Ovarian tumour TMA 
The ovarian tumour TMA containing 472 serous, mucinous, endometrioid and 
mesonephroid (clear cell) cancers was obtained from Charlie Gourley (Edinburgh 
Cancer Research UK). Ethical approval for the project was provided by the 
Lothian Research Ethics Committee. CLIC3 expression levels were assessed by 
two independent scorers and scoring system described earlier for the pancreatic 
TMA was followed. Statistical analysis of CLIC3 expression against the follow up 
data was performed by Charlie Gourley.  
2.2.7 Pull downs for mass spectrometry 
400µg of recombinant protein was mixed with 25µl of 50% slurry of glutathione 
sepharose beads and agitated for 1 hour at 4ºC. The beads were washed twice in 
0.1% BSA in PBS and were equilibrated in cell lysis buffer. Pre-cleared cell lysate 
was added to the beads coupled to recombinant protein and tumbled for 2 hours 
at 4ºC. Following the binding of cellular proteins to the GST-fusion protein, the 
unbound material was removed by 3 washes in lysis buffer, followed by 3min 
centrifugation at 6000rpm, at 4ºC. The protein complexes were eluted from the 
beads with 50µl of 1% SDS in lysis buffer. This was aided by inverting the tubes 
every couple of minutes for the total of approximately 10 minutes. The beads 
were collected by centrifugation for 8 minutes at 6000rpm at 4ºC and 16µl of 4x 
reducing sample buffer was added to the eluate. Beads were also resuspended in 
50µl of 1x sample buffer and samples were prepared for SDS-PAGE on a 10% pre-
cast polyacrylamide gel and Coomassie stained, as described earlier. Following 
protein visualisation, the gel was transferred to Dr Willy Bienvenut of the 
Beatson Institute Proteomics facility for in-gel trypsin digestion and mass 
spectrometry analysis. 
88 
3 Chloride intracellular channel 3 (CLIC3) is a 
component of Rab25 driven invasive phenotype 
3.1 Introduction 
The mechanistic and cell biological detail of cell migration on two dimensional 
surfaces (2D) has been extensively studied in the past. However, it has only in 
recent years become apparent that clear discrepancies exist between migration 
in 2D and in vivo.  
The forward movement of the cell is driven by the polymerisation of actin 
monomers into filamentous actin (F-actin), which generates contractile force 
capable of driving morphological rearrangements resulting in membrane 
protrusion that facilitates cell movement.  Actin polymerisation occurs in a 
plasma membrane proximal region and is controlled by forming homology (FH) 
proteins, Ena/VASP, Arp2/3 in association with WAVE and WASP as well as by 
cofilin (Krause, Dent et al. 2003; Pollard 2007). The complexity of the actin 
polymerisation mechanism allows the generation of a number of different F-
actin containing structures. On rigid 2D substrates, linear F-actin aggregates can 
laterally extended from the cell body to form filopodia or dorsally to establish 
microvilli, whereas arc-shaped F-actin sheets form lamellipodia. The formation 
of lamellipodia and filopodia depends on the Rac1- and Cdc42-driven 
organisation of cytoskeletal and adhesive structures (Ridley 2006). Small focal 
contacts are formed at the leading edge of these protrusions, which leads to 
integrin-mediated activation of RhoA and the recruitment of Rho activated 
kinase (ROCK) that facilitates the formation of actin-myosin bundles (Torka, 
Thuma et al. 2006). When cells move on thicker substrates, such as those 
composed of extracellular matrix proteins, they form ventral actin-rich 
protrusions called invadopodia, which mediate ECM proteolysis. On the other 
hand, cancer cells that disseminate and migrate away from the primary lesion to 
form metastases at distal sites of the body have to migrate through the 
extracellular matrix (ECM). The ECM is a three dimensional (3D) meshwork of 
extracellular proteins such as laminin, collagen and fibronectin and exists in 
three major forms; dense connective tissue, loose connective tissue and 
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basement membrane (Even-Ram and Yamada 2005). Cells migrating in 3D 
environments adopt different morphologies and modes of migration to those that 
move on 2D substrates, and this is particularly apparent both in that they can 
acquire epithelial polarity and in the type of contacts that they establish with 
the matrix components (Roskelley and Bissell 1995). When cells move in a truly 
3D matrix, the ventral and dorsal organisation present in 2D environments is lost 
and the existence of structures such as lamellopodia, stress fibres and 
invadopodia in vivo is debatable. Instead cancer cells moving in a 3D 
environment have been observed to acquire either an amoeboid morphology, 
which is characterised by high Rho/ROCK signalling pathway activity and the 
formation of bleb-like protrusions, or to migrate in an elongated fashion, which 
does not require Rho/ROCK-mediated actino-myosin contractility, but relies on 
matrix proteolysis.  When migrating in a mesenchymal fashion an actin-rich 
protrusion at the front of the cell called pseudopod is observed. It is also worth 
noting, that invading cells can switch from ameboid to mesenchymal mode of 
migration and vice versa (Olson and Sahai 2009).  
The differences in the nature of focal contracts established in 2D and 3D 
environments are worth noting. The ECM adhesion structures found in cells 
cultured on 2D surfaces are termed focal adhesions/contacts (which are rich in 
αvβ3 integrin, paxillin, vinculin and FAK) and fibrillar adhesions (that are 
composed mainly of α5β1 integrin and tensin (Zamir, Katz et al. 1999)), are 
replaced by their 3D counterparts; termed 3D matrix adhesions which are 
characterised by both paxillin and α5β1 integrin positivity (Cukierman, Pankov et 
al. 2001).  
On account of these shortcomings in studying cell adhesion and migration on 2D 
surfaces, it is necessary to use models that more closely mimic 3D ECM 
microenvironments in order to study tumour cell migration in the appropriate 
context. One way to achieve this is to use mono-component self-polymerising 
ECM constituents to coat 2D substrates. This approach however, oversimplifies 
the 3D model and doesn’t account for its structural complexity and varied 
composition. A better and more physiologically relevant model that offers many 
similarities to the ECM in vivo is cell derived matrix (CDM) (Cukierman, Pankov 
et al. 2001).  CDMs are generated by growing confluent monolayers of fibroblasts 
over 10-14 days, during which period they assemble extracellular matrix-like 
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fibrils around themselves. Following this, the pliable fibrillar, collagen- and 
fibronectin-rich matrix is denuded of cellular components using a non-ionic 
detergent and the remaining fibrillar ECM may then be used as a substrate on 
which to plate cancer cells to study their migratory and cytoskeletal 
characteristics (Fig. 3.1A&B). Indeed we have recently found that Rab25, which 
had previously been implicated in the aggressiveness of ovarian and breast 
tumours (Cheng, Lahad et al. 2004) and shown to be a component of an invasive 
gene signature of breast cancer cells (Wang, Goswami et al. 2004), alters the 
way in which A2780 ovarian adenocarcinoma cells migrate on CDMs but not on 2D 
plastic surfaces (Caswell, Spence et al. 2007).  When plated on 2D surfaces, 
A2780 migrate with the same speed, persistence and directionality regardless of 
the expression of Rab25. Conversely, when A2780 cells are plated onto CDMs 
Rab25 expression alters the way that they move, such that they migrate more 
persistently and do so by extending long pseudopods in the direction of 
migration (Fig. 3.2A), (Caswell, Spence et al. 2007).  Furthermore, Rab25 
increases the ability of A2780 cells to invade bona fide 3D matrices (such as 
matrigel or collagen plugs), and its ability to do so is potentiated when these 
plugs are supplemented with fibronectin, which is a ligand for α5β1 integrin. 
Further studies performed with integrin blocking antibodies and Rab25/Rab11 
mutants revealed that Rab25’s invasive capacity requires the binding of α5β1 
integrin to the RGD sites in fibronectin and that Rab25’s interaction with β1 
integrin cytoplasmic tail is indispensible for invasive tumour cell migration.  
It is also apparent from the studies of Rab25 function in A2780 cells that the 
ability of Rab25 to drive invasive migration is greater following stable expression 
of the GTPase than after its transient expression. This suggested that expression 
of Rab25 could in the longer-term be influencing the expression of other genes, 
which could collaborate with the GTPase to further promote tumour cell 
invasion. I therefore decided to determine whether Rab25 expression was able 
to alter the gene expression profile of A2780 cells in a way that was dependent 
on the cells being plated onto a 3D matrix, and whether any of these changes 
may collaborate with Rab25 to drive cancer cell invasion and tumour 
progression. To this end, I performed a mRNA microarray screen and searched 
for genes that were differentially expressed in a Rab25 and CDM-dependent 
manner (Fig. 3.2B).  
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Figure 3-1 Cell derived matrices (CDM) are three-dimensional and fibronectin rich 
substrates.  
Schematic diagram illustrating the protocol for generation of CDM (A). Confocal sections of CDM 
displaying either parallel (left) or intersecting (right) fibronectin fibres. Fibronectin was visualised by 
indirect immunofluorescence using a Cy2-conjugated secondary antibody (green). Scale bar, 10μm 
(B). 
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Figure 3-2 Experimental paradigm. 
A2780 cells lacking Rab25 expression (A2780-DNA3) and A2780 cells stably expressing Rab25 
(A2780-Rab25) were seeded onto plastic and CDM coated dishes for 16 hours and visualised 
using a bright field microscope. Blue boxes highlight the phenotypes exhibited by both cell lines on 
CDM. Scale bar, 50μm (A). Diagram illustrating the experimental approach for the identification of 
genes upregulated by Rab25 in a matrix dependent fashion. The green tick indicates an invasive 
phenotype, whose gene signature I set out to analyse (B). 
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3.2 Results 
3.2.1 Microarray analyses identified constituents of Rab25-driven 
invasive phenotype 
3.2.1.1 The quality and purity of RNA was sufficient to perform microarray 
hybridisation 
To identify alterations in gene expression profile that may be elicited by Rab25 
expression and/or the presence of a 3D matrix, I plated A2780 cells stably 
expressing Rab25 (A2780-Rab25) or an empty vector (A2780-DNA3) onto two 
dimensional (2D) plastic surfaces as well as onto CDMs. 16 hours following 
plating, RNA was harvested from the cells and traces of genomic DNA were 
removed by the application of mechanical shear and the addition of DNase.  
mRNA constitutes a very small proportion of total cellular RNA thus making its 
levels difficult to evaluate. Therefore it is the integrity of ribosomal RNA (rRNA), 
which is the most abundant cellular RNA component, that is commonly used to 
obtain an index of the condition of mRNA within the preparation of interest. 
Total RNA was resolved on a 2% agarose gel, which was then stained with 
ethidium bromide to visualise nucleic acids. This approach revealed the 
presence of intact 28S and 18S ribosomal RNAs (Fig. 3.3A) and showed no sign of 
RNA smear, indicating that RNAs had not been noticeably degraded during 
sample preparation. 
The concentration and purity of nucleic acids within the sample were verified 
spectrophotometrically and corrected so that the RNA concentration for each 
sample was greater than 0.6 μg/μl and the A260nm/A280nm absorbance ratio was at 
least 1.75 which gives an indication of RNA purity with respect to contamination 
with proteins (in accordance with the Paterson Cancer Research UK Microarray 
Facility guidelines). Having achieved these criteria for purity and content within 
our laboratory, the triplicate total RNA samples from A2780-DNA3 and A2780-
Rab25 cells plated onto both plastic and CDMs were sent to the Microarray 
Facility whereupon they were reassessed by gel electrophoresis (Fig. 3.3B) and 
an Agilent Bioanalyzer (Fig. 3.3C). These approaches employ capillary 
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electrophoresis and fluorescence to provide a more accurate determination of 
RNA purity, concentration and 28S/18S ribosomal RNA ratio. These samples were 
then further processed by the Microarray Facility in preparation for microarray 
hybridisation on the GeneChip Human genome U133 Plus2 Array, which provides 
expression analysis of over 47000 transcripts. 
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Figure 3-3 Confirmation of the purity and integrity of the RNA samples used for microarray 
analysis. 
A2780-DNA3 and A2780-Rab25 cells were seeded onto either plastic or cell derived matrices 
(CDM) for 16 hours, RNA was then harvested and purified using QIAGEN RNeasy kit. Its 
concentration and purity was verified spectrometrically, whilst the integrity was analysed by 
examination of 28S and 18S ribosomal RNA (rRNA) by electrophoresis on a 2% agarose gel (A). 
The same procedure was repeated using an Agilent Bioanalyser (B). In (C) shown are 
electropherogram scans from Agilent Bioanalyser. Peaks corresponding to high and low molecular 
weight rRNA are indicated. 
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3.2.1.2 GCRMA normalisation yields good clustering of experimental 
microarray replicas 
When analysing microarray data from multiple high density oligonucleotide chips 
it is imperative to remove non-biological variation between the arrays (such as 
differences in experimental procedures and differences in sample labelling 
intensities or technical divergences between replica arrays) as this may obscure 
any physiologically relevant alterations in gene expression. (Bolstad, Irizarry et 
al. 2003). Following hybridisation data acquisition, an automated normalisation 
step is performed on expression summary values, which relies on the proposal 
that intensities from each chip should be adjusted so that they have the same 
average value. This approach however isn’t sufficient for all experimental set 
ups and requires a supplementation with another normalisation method. The 
Robust Multiarray Average (RMA) is a method that encompasses three steps: 
background adjustment, quantile normalisation and summarisation of log 
transformed values (Irizarry, Hobbs et al. 2003).  
However, when applied to triplicate sets of four experimental samples (A2780-
DNA3 cells and A2780-Rab25 cells both plated onto plastic and CDM) RMA 
normalisation did not yield a good clustering of the samples as shown by the 
gene expression histogram and by the Principal Component Analysis (PCA) 
scatter plot, which visualises experimental replica clustering (Fig. 3.4A). Since 
the triplicate experimental samples were prepared in separate batches and the 
samples clustered according to the date when they were hybridised rather than 
according to their biological characteristics, the batch effect removal filter was 
applied. This approach uses mixed-model ANOVA to asses batch effects and it 
adjusts the data in such a way that the batches are equivalent to one another 
(Kozulin and Provis 2009). Nonetheless, this did not improve sample clustering 
(Fig. 3.4B). Therefore an improved form of RMA, GeneChip RMA (GCRMA) was 
used for normalisation and resulted in an enhanced gene expression clustering, 
but still failed to provide experimental replica clustering as depicted on the PCA 
scatter plot (Fig. 3.4C). This discrepancy was removed by the application of 
batch removal filter which led to near perfect clustering of experimental 
replicas as shown on the PCA plot (Fig. 3.4D).  
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Figure 3-4 GCRMA normalisation results in good clustering of experimental replicas.  
The Cel files were normalised and analysed in PARTEK ® Genomics Suite Software. Indicted are 
the clustering patterns obtained after RMA normalisation (A), RMA followed by batch effect removal 
(B), GCRMA normalisation (C) and GCRMA followed by batch effect removal (D). The panel on the 
left depicts histograms of gene expression, while the panel on the right represents Principal 
Component Analysis (PCA) scatter plots. Triangles, diamonds and rectangles correspond to 
different sample processing times. A2780-DNA3 cells on plastic (DNA3 plastic) in purple, A2780-
Rab25 on plastic (Rab25 plastic) in blue, A2780-DNA3 cells on CDM (DNA3 CDM) in green, 
A2780-Rab25 on CDM (Rab25 CDM) in red.  
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3.2.1.3 Microarray analyses identify genes whose differential expression is 
driven by Rab25 in two dimensional and in three dimensional–like 
environments 
Following normalisation, batch effect removal and log transformation, Multiway 
ANOVA was used to identify genes that were differentially expressed in A2780-
Rab25 versus A2780-DNA3 cells both plated onto CDM. Genes were primarily 
ranked according to fold change values (fold change ≥ 3) and subsequently p-
value was used for final filtering (p-value ≥ 0.01). These analyses returned 78 
and 22 genes that were up- and down-regulated, respectively, by Rab25 
expression when A2780 cells were grown on CDMs (Fig. 3.5, Appendix 3.1&3.2). 
The same method was used to identify 28 and 36 genes that were respectively 
up- and down-regulated by Rab25 expression, when A2780 cells were cultured on 
plastic surfaces (Fig. 3.6, Appendix 3.3&3.4). 
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Figure 3-5 Genes differentially expressed in Rab25-expressing cells when plated onto CDM. 
In the columns from left to right listed are: gene symbols, corresponding microarray probe 
numbers, p-values and fold changes. When identifying differentially regulated genes a fold change 
threshold of 3 was applied and maximum p-value was 1.00E-02 (Multiway ANOVA). Genes are 
ordered by decreasing fold change. The orange line separates the upregulated from the 
downregulated genes. 
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Figure 3-6 Genes differentially expressed in Rab25-expressing cells when plated onto 
plastic surfaces. 
The hits are ranked and ordered as for the previous figure. The panel on the left lists the genes 
upregulated by Rab25, whilst the one on the right the downregulated transcripts.  
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3.2.1.4 Eighteen genes (three of which are ion carriers) are upregulated by 
Rab25 in a matrix specific fashion 
Having identified genes whose expression was regulated by the presence of 
Rab25, I wished to refine my data set to highlight genes that were upregulated 
by Rab25 in a matrix specific fashion. Genes that were differentially expressed 
in A2780-Rab25 cells on CDM as compared to A2780-DNA3 cells on CDM, which 
also showed differential expression on plastic surfaces, of at least 1.5 fold, were 
removed from the primary list. This was done to prevent false positive 
discoveries and to exclude any genes that showed expression variation on 2D in 
the same direction as they did in 3D. This resulted in the identification of 18 
genes that were upregulated in a Rab25 and CDM specific manner and that could 
potentially be components of Rab25 driven invasive phenotype (Fig. 3.7).  
To identify the most promising target genes from the list of 18, I decided to 
apply two additional statistical filters. Firstly, I looked at the Bonferroni p-
value, which provides a conservative test of significance when comparing three 
or more groups of conditions and is derived from the unadjusted p-value by the 
multiplication of the later by the number of observations. Such a statistical 
analysis protects against ‘overdiscovery’ of significant events, but poses a big 
risk of false negatives. When Bonferroni correction is used changes in expression 
of only two genes appear statistically significant; CLIC3 (Bonferroni score of 
p=0.0012), and prostaglandin-endoperoxidase synthase 2 (PTGS2) (Bonferroni 
score of p=0.0197).  
When a less conservative step-up p-value that controls false discovery rates 
(Kwong and Wong 2002) was applied, a number of other genes appeared to be 
significantly upregulated, such as ADAM metallopeptidase with thrombospondin 
type 1 motif-5 (ADAMTS5)(step-up score of p=0.0106), acyl-CoA synthetase short-
chain family member 3 (ACSS3)(step-up score of p=0.0364), and tumour protein 
p53 inducible nuclear protein1 (TP53INP1) (step-up score of p=0.0425). 
Importantly, step-up adjustment also identified CLIC3 as the most significantly 
upregulated gene in that group (step-up score of p=0.0002). I, therefore, 
decided to determine whether CLIC3 may be a genuine downstream effector of 
Rab25.  
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In addition to pursuing CLIC3, I also wanted to explore the possibility that other 
Rab25 upregulated genes that are thought to encode for membrane transporters 
and/or channels may regulate invasive migration of tumour cells, so I also 
selected the genes for the monocarboxylic acid transporter 7 (SLC16A6) and the 
potassium inwardly-rectifying channel member-2 (KCNJ2) in my validation 
analyses.  Firstly, I looked at the fold changes in expression of CLIC3, SLC16A6 
and KCNJ2 as determined by the three individual microarray hybridisation 
experiments. As illustrated by both the heat map (Fig. 3.8A) (on which the 
colour of the box and the depth of the colour represent relative expression 
levels) and by numerical data presented as normalised, log transformed 
fluorescence values (Fig. 3.8B-D), the Rab25 and CDM driven upregulation was 
most reproducible for CLIC3 (Fig. 3.8B) and less so for SLC16A6, which showed 
very high induction in the second experimental replica, but less so in the first or 
third hybridisation (Fig. 3.8C). On the other hand, alteration in KCNJ2 mRNA 
levels was not observed in the first experiment, but occurred to a similar extent 
in the other two experimental repeats (Fig. 3.8D). 
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Figure 3-7 Eighteen genes are differentially expressed in a Rab25 and CDM-dependent 
fashion. 
This list contains genes that are regulated by Rab25, but only when cells are plated onto CDM. 
From left to right are: gene symbols, microarray probe numbers, p-values, Bonferroni p-values and 
step-up p-values for changes on CDM (in red and green very highly and highly significant  p-
values, respectively), fold changes on CDM and fold changes on plastic. Highlighted in yellow 
boxes are three genes whose upregulation I chose to validate; SLC16A6, CLIC3 and KCNJ2 and in 
the black box is CLIC3 – the main candidate gene (A). Gene names corresponding to gene 
symbols listed above (B). 
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Figure 3-8 Of the 18 genes that are upregulated in a Rab25 and CDM-dependent manner, 
three are transporters.  
The heat map shows 18 transcripts upregulated in A2780-Rab25 cells grown on CDM. The 
columns represent triplicate sets of samples, with the A2780-DNA3 (DNA3) and A2780-Rab25 
(Rab25) cells on CDM to the left and the same cell lines on plastic to the right. The 18 rows denote 
the 18 transcripts and the colour and intensity of the boxes allocated to each data point represent 
the log2 expression level: low expression (green), high expression (red) (A). Linear fluorescence 
values from each replica experiment (#1, #2 and #3) corresponding to probe sets recognising 
CLIC3 (B), SLC16A6 (C) and KCNJ2 (D) were extracted from the microarray data set. 
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3.2.2 Use of qPCR to validate CLIC3, SLCA16A6 and KCNJ2 
upregulation  
3.2.2.1 qPCR primer pairs amplify a single product and they do so in a linear 
manner over a range of cDNA concentrations 
Reverse transcription followed by quantitative polymerase chain reaction (qPCR) 
is a method of quantifying the initial amount of template DNA molecules for a 
gene of interest. The quantity of the template in an experimental sample is 
most commonly expressed relative to its amount in a control sample, and equal 
template loading for both samples is ensured by normalisation against a 
housekeeping gene. Unlike the conventional RT-PCR, qPCR allows ‘real time’ 
observation of amplicon accumulation, which is reflected by proportional 
fluorescence accretion as the amplification cycles proceed. The qPCR reaction 
consists of four stages characterised by different kinetics. Initially, in the lag 
phase the product is being amplified, but fluorescence generated in that process 
is beyond the detection threshold. Secondly, the exponential amplification 
phase occurs and the copy number of the template doubles with each 
amplification cycle. This stage is the most crucial for the quantification process 
as it allows the determination of the threshold cycle (CT), which is the point at 
which the amplification curve crosses the threshold and it is used for subsequent 
relative quantification. CT is inversely proportional to the log initial template 
quantity, which means that the more starting template there is the lower the CT 
value. Thirdly, in the retardation phase, the amplification inhibitory factors 
accumulate and the reaction constituents become limiting, which decreases the 
reaction rate. Finally, the process reaches a steady state and the amplification 
ceases (Schefe, Lehmann et al. 2006).  
One very important consideration for a successful and accurate template 
measurement in qPCR is the choice of suitable primers. I therefore confirmed 
that the primer pairs targeting CLIC3, SLC16A6, KCNJ2 and two 
housekeeping/reference genes – β-actin and GAPDH, respectively, were 
specifically amplifying a single product, as illustrated by the ethidium bromide 
stained agarose gel on which qPCR reaction mixes were resolved (Fig. 3.9A). The 
generation of a single product was also analysed by the inspection of the 
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dissociation (melting) curve of each amplification product, as generated by the 
Opticon Monitor Software. The melting curve analysis of the 5 amplicons of 
interest confirmed the presence of a single spike each (Fig. 3.9B), indicative of a 
single amplification product. Additionally, ‘-cDNA’ reaction (Fig. 3.9C), in which 
cDNA is replaced by water and ‘-RT’ reaction, for which a mock RT mix is used 
and no cDNA synthesis is possible (Fig. 3.9D), yield no template amplification 
confirming the purity of qPCR reaction components and the lack of amplification 
of possible genomic contaminants, respectively.  
Having confirmed that the qPCR reagents were suitable for validation of the 
candidate genes, I wanted to ensure that all the primer pairs were amplifying in 
a linear manner over a range of concentrations. This was achieved by performing 
qPCR reactions on serial dilutions of cDNA templates and plotting CT values 
against the logarithmic values of standard cDNA amounts, which were expressed 
as dilution factors of the cDNA preparation (i.e. 2x, 1x, 0.5, 0.25, 0.125. 0.0625, 
0.03215). The correlation coefficient (R2) values are 0.9955, 0.995, 0.992, 
0.9915 and 0.997 for CLIC3 (Fig. 3.10A), SLC16A6 (Fig. 3.10B), KCNJ2 (Fig. 
3.10C), β-actin (Fig. 3.10D) and GAPDH (Fig. 3.10E), respectively, indicating a 
near perfect linear relationship between the CT value and cDNA concentration 
and confirming that the amount of fluorescence measured is proportional to the 
amount of starting material. Additionally, the amplification efficiencies were 
calculated from the formula E=10^(-1/-a)-1, where ‘a’ represents the gradient 
of the linear fit (Arezi, Xing et al. 2003) and amounted to: 0.97, 0.87, 1.26, 1.07 
and 1.06 for CLIC3, SLC16A6, KCNJ2, β-actin and GAPDH, respectively.  
There are two ways of expressing changes in mRNA level following qPCR analysis. 
One is in absolute template concentrations and relies on the incorporation of 
previously generated standard curves for known concentrations of the template. 
However, the more commonly used method for qPCR data quantification 
describes changes in target gene expression in one sample relative to another, 
without measuring the absolute quantities of the template. A variation of such 
relative quantification method is the ΔΔCT model (Livak and Schmittgen 2001), 
which also takes into account the possible variation in initial mRNA content 
between the samples that may arise from unequal total RNA input by 
incorporating the relevant content of housekeeping genes for each of the 
analysed conditions and therefore allows for normalisation to an endogenous 
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reference gene. The ΔΔCT quantification requires near equal amplification 
efficiencies and was therefore suitable for the evaluation of changes in the 
levels of CLIC3 and SLC16A6, but not KCNJ2 mRNA levels with β-actin and GAPDH 
being used as reference genes. 
Given that the amplification efficiency for KCNJ2 primers differed significantly 
from the others, I decided to use a different mathematical model to calculate 
relative alterations in the expression of this gene; one that incorporates 
efficiencies of both the reference and target gene amplification in the 
calculation (Pfaffl 2001). Additionally, to confirm the suitability of the ΔΔCT 
method for the quantitative assessment of CLIC3 and SLC16A6 transcript levels, I 
have compared the results generated by the ΔΔCT method and by the model 
described by Pfaffl for 3 different data sets and observed no discrepancies in 
relative expression levels (not shown), confirming that ΔΔCT model is indeed 
suitable for analysing the expression of these two genes and that slight 
discrepancies in the amplification efficiencies are negligible and will not obscure 
the results. 
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Figure 3-9 Primers for quantitative PCR (qPCR) amplify a single product. 
Primer pairs targeting CLIC3 (red), SLC16A6 (green), KCNJ2 (pink) and two housekeeping genes; 
β-actin (blue) and GAPDH (orange) each amplify a single product as shown by electrophoretic 
separation on a 2% agarose gel (A) and by representative melting curves of each amplicon, which 
were generated using Opticon Monitor software (B). qPCR reactions run with the omission of cDNA 
(-cDNA control) or run on cDNA mix in which cDNA could not have been synthesised due to 
omission of reverse transcriptase (-RT control), yield no amplicon as shown on the plots derived 
from Opticon Monitor software (C).  
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Figure 3-10 Q-PCR primer pairs amplify a product in a linear manner over a range of cDNA 
concentrations. 
cDNA was synthesised from RNA isolated from A2780-Rab25 cells grown on cell derived matrices 
for 18 hours. Serial dilutions of cDNA were used in a series of triplicate q-PCR reactions to test the 
efficiency of the above primer-sets, in the presence of the SYBR Green dsDNA-specific fluorescent 
dye. Standard curves representing a plot of C(t) against the initial log quantity of the template and 
corresponding Rsq values are shown for CLIC3 (A), SLC16A6 (B), KCNJ2 (C) β-actin (D) and 
GAPDH (E). 
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3.2.2.2 CLIC3, SLC16A6 and KCNJ2 mRNA levels increase when A2780-
Rab25 cells are seeded onto CDM 
To validate the Rab25 and CDM driven upregulation of CLIC3, SLC16A6 and 
KCNJ2, I seeded A2780–DNA3 and A2780-Rab25 cells onto plastic or CDM for 16 
hours and subsequently harvested and purified total RNA. Furthermore, to assure 
that the contribution of the 3D-like matrix to the upregulation of the genes in 
question was not limited to one type of matrix, I employed two different types 
of CDM. Firstly, one that was prepared using primary cultured human dermal 
fibroblasts (HDF) (and previously utilised for the microarray samples) and 
secondly, one which was produced from telomerase immortalised human foetal 
foreskin fibroblasts (Tif).  
After having synthesised cDNA from the purified total RNA samples I performed 
qPCR analyses on triplicate sets of samples using two independent housekeeping 
genes; β-actin and GAPDH. When compared, the numerical data generated 
independently by normalisation to the two reference genes shows no or very 
little divergence regardless of which housekeeping gene was used (Fig. 3.11 & 
3.12). Preliminary visual inspections of the amplification curves indicated that 
the magnitude and specificity of Rab25 and CDM-driven upregulation was greater 
for CLIC3 than for SLC16A6 and KCNJ2. Indeed, CLIC3 mRNA levels increased 
approximately 5 fold following expression of Rab25 when cells were plated onto 
plastic surfaces, and about 22 fold when attached to HDF-derived CDM (Fig. 
3.11A). SLC16A6 and KCNJ2 expression displayed little or no response to Rab25 
expression on plastic, and approximately 5-6 fold increments when cells were 
plated onto CDM (Fig, 3.11B&C). Moreover, there was little noticeable 
difference in the mRNA levels of CLIC3 (Fig. 3.12A), SLC16A6 (Fig. 3.12B) or 
KCNJ2 (Fig. 3.12C) when cells were plated onto CDMs derived from either HDFs 
or Tif fibroblasts. 
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Figure 3-11 Validation of three microarray hits by q-PCR when cells are grown on HDF-
derived CDM.  
A2780-DNA3 (DNA3) and A2780-Rab25 (Rab25) cells were plated onto plastic surfaces and onto 
human dermal fibroblast (HDF) derived CDM substrates for 18 hours, RNA was then harvested and 
purified. cDNA was synthesised and used for quantitative PCR (q-PCR). Expression of CLIC3 (A), 
SLC16A6 (B) and KCNJ2 (C) was analyzed in the four experimental samples: DNA3 plastic (red), 
Rab25 plastic (green), DNA3 CDM (blue) and Rab25 CDM (orange). On the right shown are 
representative amplification plots for genes in question as well as housekeeping genes. The panel 
on the left shows relative abundance of the target genes, normalised to two independent 
housekeeping genes; β-actin and GAPDH. Data are mean ±SEM of three independent 
experiments, within which three technical replicas were performed. 
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Figure 3-12 Validation of three microarray hits by q-PCR when cells are grown on Tif-derived 
CDM.  
Q-PCR amplification plots and quantification of three independent experiments are shown as in the 
previous figure. The HDF-derived matrices were here replaced with telomerase immortalised 
fibroblast (Tif)-derived matrices.  
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3.2.3 The role of Rab25 in upregulation of CLIC3 expression  
3.2.3.1 Upregulation of CLIC3 mRNA but not SLC16A6 or KCNJ2 is opposed 
by RNAi of Rab25 
To determine whether the differences in levels of CLIC3, SLC16A6 and KCNJ2 
between A2780-DNA3 and A2780-Rab25 cells were owing primarily to expression 
of Rab25 and not to coincidental clonal variations between these two cell lines, I 
decided to use two approaches. Firstly, I transiently overexpressed Rab25 in 
A2780 cells plated on both plastic and CDMs and assessed levels of the 
transcripts in question. Secondly, I suppressed Rab25 levels in A2780-Rab25 cells 
with a short hairpin RNAi vector (shRNAi), seeded the cells onto plastic and CDMs 
and subsequently determined the levels of CLIC3, SLC16A6 and KCNJ2 mRNA. 
Additionally, in both cases I looked at possible effects of Rab25’s nearest 
homolog Rab11, on the expression levels of the three candidate genes.  
When transiently overexpressed (Fig. 3.13A&B), neither Rab11 nor Rab25 had 
any discernable and reproducible effects on the expression of CLIC3, SLC16A6 or 
KCNJ2, regardless of whether cells are seeded onto plastic or CDM (Fig. 3.13C). 
This inability of transiently expressed Rab25 to upregulate these three candidate 
genes is consistent with the observation that A2780 clones that stably express 
Rab25 are more invasive than cells transiently expressing the GTPase.   
I then suppressed levels of Rab11 GTPases and Rab25 with shRNAi (Fig. 3.14B) in 
A2780-Rab25 cells and plated them onto plastic or CDM (Fig. 3.14A). No 
reduction in SLC16A6 or KCNJ2 transcript levels was observed upon shRNAi of 
either Rab11A&B or Rab25, but suppression of Rab25 (but not Rab11s) 
substantially reduced levels of CLIC3 mRNA by about 40%, when cells were 
plated onto either substrate. These data indicate that continued expression of 
Rab25 (but not Rab11A&B) is necessary to maintain CLIC3 mRNA at high levels in 
A2780 cells, whereas the differences in expression of SLC16A6 and KCNJ2 
between A2780-DNA3 and A2780-Rab25 cells was likely owing to clonal variation 
between these two ovarian carcinoma lines. 
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Figure 3-13 CLIC3, SLC16A6 and KCNJ2 expression following transient overexpression of 
Rab25. 
A2780-DNA3 cells were transiently transfected with 3µg of GFP, GFP-Rab11 or GFP-Rab25 and 
were seeded onto either plastic surfaces or CDMs. After 16 hours overexpression was verified by 
fluorescence microscopy; scale bar, 50μm (A). Protein and RNA were then harvested and 
overexpression on CDM was also analysed by Western Blotting with GFP, Rab11 and Rab25 
specific antibodies (B). Changes in CLIC3, SLC16A6 and KCNJ2 transcript levels were analysed 
by qPCR. From left to right shown are relative expression levels of CLIC3, SLC16A6 and KCNJ2 
(C). Data are mean ±SEM of three independent experiments, within which three technical replicas 
were performed. 
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Figure 3-14 CLIC3, SLC16A6 and KCNJ2 expression following Rab25 suppression. 
A2780-Rab25 cells were transfected with 3µg of short hairpin vectors, containing non targeting 
control (mu6pro-NT) and targeting Rab11A&B (mu6pro-Rab11A&B) and Rab25 (mu6pro-Rab25), 
respectively. 24 hours after nucleofection cells were seeded onto either plastic or  CDM for 16 
hours and bright field images were taken; scale bar, 50μm (A). RNA and protein lysates were 
collected and the suppression of Rab11A&B and Rab25 was analysed by Western-blotting (B). 
Changes in CLIC3, SLC16A6 and KCNJ2 mRNA levels were investigated by q-PCR. From left to 
right shown are relative expression levels of CLIC3, SLC16A6 and KCNJ2 (C). Data are mean 
±SEM of three independent experiments, within which three technical replicas were performed. 
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3.2.3.2 CLIC3 protein levels increase following Rab25 expression and even 
more so with Rab25 expression and exposure to a three-dimensional 
matrix 
It was next important to determine whether the previously described alterations 
in CLIC3 gene expression were also reflected by changes in the levels of CLIC3 
protein. To do this I plated A2780-DNA3 and A2780-Rab25 cells on plastic and 
CDM surfaces for 16 hours, harvested protein samples, resolved them by SDS-
PAGE and determined CLIC3 proteins levels by Western blotting (Fig. 3.15). 
CLIC3 protein was largely undetectable in A2780-DNA3 cells, and allowing these 
cells to attach to CDM did not noticeably alter this.  On the other hand, A2780-
Rab25 cells expressed detectable quantities of CLIC3 protein when cultured on 
plastic and this was only slightly increased when these cells were plated onto 
CDM. This indicated that the levels of CLIC3 protein did not accurately reflect 
the alterations in CLIC3 mRNA that were described in previous sections. 
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Figure 3-15 CLIC3 protein is upregulated in a Rab25 and CDM-dependent manner.   
A2780-DNA3 and A2780-Rab25 cells were plated onto either plastic or CDM substrates for 18 
hours, at which point protein lysates were collected and 40µg were analysed by Western-blotting 
using antibodies against HA-tag (recognising Rab25) and against CLIC3. Protein loading was 
verified by immunoblotting against vinculin. 
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3.2.3.3 Expression of CLIC family members other than CLIC3 is not affected 
by Rab25 or CDM 
The family of human chloride intracellular channel proteins (CLICs) comprises six 
closely related homologues; CLIC1, CLIC2, CLIC3, CLIC4, CLIC5 and CLIC6 
(Littler, Harrop et al.). To determine whether more than one CLIC family 
member was regulated by Rab25 I reviewed the microarray data with respect to 
the expression of other CLICs in the A2780 cell line upon expression of Rab25 and 
cultivation on CDM. CLIC1 and CLIC4 were expressed by A2780 cells (Fig. 3.16A), 
whereas CLICs 2, 5, & 6 were undetectable (Fig. 3.16B). Furthermore, no 
significant changes in the levels of CLIC2 1 & 4 were detectable either following 
Rab25 expression or exposure to the CDM (Fig. 3.16A). These data indicate that 
CLIC3 is the sole member of the CLIC family whose expression is regulated by 
Rab25 in A2780 cells. 
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Figure 3-16 Expression of the other CLIC family members in A2780 cells.  
Absolute fluorescence values were derived from the microarray data sets, averaged and plotted on 
the graphs (mean of 3 experiments ±SEM). In (A) shown are mRNA levels of the CLIC family 
members, which are expressed in A2780 cells: CLIC1 and CLIC4. In (B) shown are mRNA levels of 
CLICs that are not expressed: CLIC2, CLIC5 and CLIC6. Affymetrix chip probe numbers 
recognising the said genes are listed at the bottom of the graphs. A2780-DNA3 cells on plastic 
(DNA3 plastic) in red, A2780-Rab25 on plastic (Rab25 plastic) in green, A2780-DNA3 cells on 
CDM (DNA3 CDM) in blue, A2780-Rab25 on CDM (Rab25 CDM) in orange. 
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3.2.3.4 Suppressing the function of β1 integrin with blocking antibodies 
increases CLIC3 mRNA level 
Given the previously established physical association between Rab25 and α5β1, 
and the role that this integrin plays in Rab25-driven invasion, I wished to 
determine its requirement in Rab25’s ability to upregulate CLIC3.  To oppose 
α5β1 function I used antibodies which bind to the extracellular portion of the 
integrin or to the integrin binding site (RGD) in fibronectin and they have been 
shown to inhibit Rab25-driven invasion into three dimensional matrices (Caswell, 
Spence et al. 2007). As a control I utilised an antibody that blocks the function 
of an unrelated αv integrin. To confirm the efficacy of these antibodies I used 
immunofluorescence to assess the fibronectin fibril network, which is known to 
rely upon the continued presence of active α5β1 for its integrity. Indeed, 
antibodies that blocked α5, β1 or the RGD site in fibronectin (but not those that 
targetted αvβ3) reduced fibronectin fibrillogenesis (Fig. 3.17A). I then seeded 
cells onto plastic and CDM coated substrates, allowed them to adhere and 
hindered α5β1 function with the blocking antibodies (Fig. 3.17B). It quickly 
became apparent that the function of β1 integrin is imperative to the cells’ 
ability to form contacts with the extracellular matrix and to adhere to the 
substratum, as exemplified by a large number of rounded cells and impaired cell 
spreading. Q-PCR analysis of CLIC3 mRNA levels following blocking antibody 
treatment revealed no alterations in CLIC3 expression when cells were grown on 
plastic surfaces. However, β1 integrin blocking antibodies lead to a significant 
increase in CLIC3 mRNA levels when cells were plated onto CDM (Fig. 3.17C), 
indicating that the activity of β1 integrins play a role in the maintenance of 
CLIC3 levels in A2780 cells.   
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Figure 3-17 Suppressing β1 integrin function increases CLIC3 mRNA levels. 
A2780-Rab25 were seeded either onto glass cover slips (A), plastic surfaces or CDMs (B). Cells 
were allowed to adhere for 2 hours and then were incubated overnight with 1µg/ml of αv integrin, 
fibronectin (FN), α5 integrin and β1 integrin blocking antibodies, respectively. Cells on cover slips 
were fixed in 4% PFA, fibrillar fibronectin (FN) was visualised with a rabbit antibody and Cy-3 
conjugated secondary antibody (red), α5 with a mouse antibody and Cy-2 conjugated secondary 
antibody (green) and Phalloidin –Texas Red was used to visualise F-actin (blue). Scale bar, 20µm 
(A). Cells plated onto plastic or CDM were imaged using a bright field microscope, scale bar 100µm 
(B). RNA was then harvested and changes in CLIC3 level were analysed by qPCR. Q-PCR data 
are mean ±SEM of three independent experiments and were normalised to β-actin (C). 
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3.3 Discussion 
3.3.1 Summary 
Here, I have performed a gene expression analysis, which identified candidate 
genes that have the potential to act downstream of Rab25 and α5β1 integrin to 
drive invasive migration of ovarian adenocarcinoma cells. I have characterised 
the gene signature of Rab25 expressing cells to be composed of 18 genes and 
confirmed the upregulation of three of them; CLIC3, SLC16A6 and KCNJ2 on 
mRNA level by qPCR. I also showed that, even though the expression of all three 
validated genes appeared to be Rab25 and CDM mediated, only the upregulation 
of CLIC3 was reversed by Rab25 suppression. Furthermore, I demonstrated that 
CLIC3 amplification occurred on protein level. 
3.3.2 How could upregulation of CLIC3 mRNA occur? 
In this chapter I provide a clear demonstration of the augmentation of CLIC3 
mRNA levels following Rab25 expression and the extracellular matrix 
involvement in this process. Due to my primary interest in tumour invasion and 
progression I chose not to investigate the reasons for CLIC3 transcript 
upregulation and to instead focus on the cellular role of CLIC3 and its possible 
implication in human disease. Nonetheless, there are a number of processes that 
likely are affected by the Rab25 and extracellular matrix axis, which confer 
changes in CLIC3 mRNA levels. Here, I will briefly discuss a few stages at which 
gene expression regulation could occur. 
Gene expression is a multistep process which results in information from a DNA 
sequence being transformed into a functional gene product. Any stage of this 
cascade can be regulated and lead to changes in the levels of the protein. Gene 
expression is controlled by gene copy number and amplifications of chromosomal 
regions have been reported to be responsible for upregulation of transcript 
levels and to be implicated in tumour aggressiveness and progression. Indeed, 
Rab25 has been shown to be a component of 1q22 amplicon whose copy number 
increases in 54% of advanced serous epithelial ovarian carcinomas. Linear 
regression analysis of 21 epithelial ovarian cancers, for which both comparative 
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genomic hybridisation (CGH) and expression data were compiled has revealed a 
direct relationship between Rab25 gene copy number and mRNA levels (Cheng, 
Lahad et al. 2004). The increase in CLIC3 mRNA levels could result from 
amplified 9q34.3 chromosomal region in which it resides. However, examination 
of the chromosomal locations of the remaining 17 Rab25 and matrix-specific hits 
did not reveal any convergences with the chromosomal site of CLIC3, hence 
contravening the possible regulation of its expression at the gene copy level. 
Interestingly, the other two Rab25 and matrix upregulated transcripts, namely 
SLC16A6 and KCNJ2 occupy neighbouring loci, 17q24.2 and 17q23.1-24.2, 
respectively. This, in concert with the inability of Rab25 suppression to diminish 
their expression, could indicate chromosomal amplification as the mechanism of 
upregulation of these transporters.  
The second level at which gene expression can be modulated is the accessibility 
of DNA for transcription, which is controlled by epigenetic modifications of DNA 
and its associated histones (Zhang and Meaney). There is mounting evidence that 
epigenetic control of gene expression is employed by cancer cells and it can 
contribute to tumour invasion and progression (Kim, Jang et al. 2008; Moncada-
Pazos, Obaya et al. 2009). Additionally, there is evidence that the engagement 
of cancer cells with the extracellular matrix can orchestrate changes in gene 
expression by epigenetic mechanisms (Kim, Lee et al. 2007). Given the 
regulatory role that epigenetic regulation can exert on gene transcription, it is 
tempting to speculate that the ligation of α5β1 integrin to its ligand fibronectin 
and its interaction with Rab25 could drive cancer cell invasion by exerting 
epigenetic regulation on gene expression. The next layer of transcriptional 
regulation encompasses the transcription process itself, as well as mRNA 
processing. The levels of a given cytoplasmic mRNA are a balance between 
nuclear synthesis rates, processing and cytoplasmic degradation and it is thought 
that mRNA decay is the major orchestrator of gene expression (Guhaniyogi and 
Brewer 2001). Indeed, eukaryotic messenger RNA is subject to cotranscriptional 
processing which involves three events that affect transcript stability; 5’ 
capping, 3’ polyadenylation and splicing (Proudfoot, Furger et al. 2002). Further 
investigation will be required to determine whether Rab25 and α5β1 integrin 
axis affect one or more of these processes thus increasing the half live of CLIC3 
mRNA. 
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It has been recently shown that about 95% of multiexon transcripts are 
alternatively spliced (Pan, Shai et al. 2008). During splicing, the non-coding 
introns are removed from the pre-mRNA, which results in the maturing of the 
transcript and generation of exon-only containing mRNA. Alternative splicing can 
be an important regulatory step and it can affect the coding sequence, change 
the reading frame and even lead to nonsense mediated decay of the gene 
product (Kim, Jang et al. 2008). Alternative splicing of tumour protein p53 
inducible nuclear protein 2 (TP53INP2) has been implicated in ovarian tumour 
cell invasion into three dimensional matrices (Moran-Jones, Grindlay et al. 
2009). Interestingly, one of the CLIC3 homologues, CLIC5, exists in two splice 
forms, as CLIC5A and CLIC5B.  My preliminary data demonstrates that a novel 
alternative splice variant of CLIC3, with a 81 nucleotide intronic insertion 
prevails in A2780-DNA3 cells when plated on plastic, but is absent in A2780-
Rab25 cells cultured on CDMs, in which the well-characterised variant lacking 
the insertion predominates (data not shown). One possibility could be that the 
intron-containing transcript arises as a result of inefficient splicing and is 
destined for degradation, whereas the combination of Rab25 expression and the 
appropriate 3D microenvironment favours correct splicing and the generation of 
a functional transcript. The above observations suggest that fluctuations in 
splicing events could contribute to the variation in functional CLIC3 mRNA levels. 
It is also worth considering the role of α5β1 integrin in the regulation of CLIC3 
expression. Given the requirement for the ligation of the integrin with the ECM 
and Rab25 in invasive cell migration and the prerequisite for the collaboration 
between the GTPase and the matrix in the upregulation of CLIC3, it was 
surprising to detect an augmentation in CLIC3 levels following the obstruction of 
β1 integrin function. This was unexpected because if the integrin were to act as 
part of the Rab25 and CDM axis, the suppression of its function would have likely 
resulted in a decrease in CLIC3 mRNA similar to that seen upon inhibition of 
Rab25 levels. The β1-block induced augmentation of CLIC3 mRNA hints at an 
alternative scenario, where blocking β1 integrin function and thus disabling 
cancer cell adherence and invasion through a three dimensional matrix leads to 
a compensatory increase in CLIC3 mRNA. By increasing the levels of CLIC3, a 
potentially pro-invasive gene that might be acting downstream of the integrin, 
the cell might be attempting to counteract the disfunctionality of the integrin 
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and maintain its migratory potential. Interestingly, α5 integrin blockade doesn’t 
result in alterations in CLIC3 mRNA, which could be suggestive of β1 ligation 
with more than just α5 subunit being needed for CLIC3 induction. 
3.3.3 What is the source of discrepancy between CLIC3 mRNA 
and protein level? 
When measured by qPCR, Rab25 alone drives an approximately 5 fold increase in 
CLIC3 mRNA on plastic, but when cells are plated onto CDM this is increased to 
nearly 20 fold. However, although Rab25 is clearly able to drive the expression 
of CLIC3 protein in A2780 cells, the ability that CDM has to augment this is not as 
great as when CLIC3 expression is assessed by measuring mRNA levels. Lack of 
concordance in the expression between mRNA and protein levels of a given gene 
product is not uncommon. Lichtinghagen and colleagues found no correlation 
between the mRNA expression and protein levels of MMP-2, MMP-9 and TIMP-1, 
respectively, in 17 prostatic adenocarcinoma patients (Lichtinghagen, Musholt et 
al. 2002). Moreover, a study of 76 lung adenocarcinomas  and 9 normal lung 
tissues has revealed that mRNA abundance of only 21% genes could be 
significantly correlated with protein concentrations (Chen, Gharib et al. 2002).  
These discrepancies are likely attributable to mRNA turnover, protein synthesis 
regulation, post-translational modifications and protein degradation. These 
processes are not mutually exclusive and could all affect protein accumulation in 
the cell and its half live. It is therefore conceivable that introduction of the 
interaction between a cell and cell-derived matrix in the presence of Rab25 
alters the synthesis or stability of CLIC3 protein thus making protein abundance 
an inaccurate reflection of CLIC3 transcription.  
3.3.4 Other potentially interesting hits 
Although I only chose three genes from the list of 18 that I identified as potential 
downstream effectors of Rab25 driven invasion, and only proved that one of 
them, CLIC3, was specifically upregulated by Rab25, it is highly likely that more 
than one effector contributes to the effects of Rab25 and α5β1 integrin on 
invasive tumour cell migration. Amongst the other candidate genes are some 
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that are still poorly characterised, such as NLRC3, TRIM2 or FAM49A. Others have 
been extensively studied and their role in cancer is well established. 
Cyclooxygenase (COX2), also known as prostaglandin-endoperoxide synthase 2 
(PTGS2) has been implicated in the metastasis of breast cancer to bone (Li, 
Schem et al. 2008; Lucci, Krishnamurthy et al. 2009) and brain (Bos, Zhang et al. 
2009). HtrA serine peptidase1 (HTRA1) has been implicated in ovarian (Chien, 
Staub et al. 2004; Narkiewicz, Klasa-Mazurkiewicz et al. 2008), and endometrial 
cancers (Bowden, Di Nezza-Cossens et al. 2006). Intriguingly, these studies 
suggest that this serine protease is a candidate tumour suppressor and that it 
correlates inversely with tumour progression and grade.  
Two genes, ADAMTS5 and SYTL1, stand out from the list due to their role in 
extracellular matrix degradation and their indirect connection to vesicle 
trafficking, respectively. ADAMTS5 encodes a secreted extracellular matrix 
degrading enzyme, which is a member of a disintegrin and metalloproteinase 
with thrombospondin motifs family. ADAMTS5 (aggrecanase 2) has been 
implicated in aggrecan cleavage and it has been shown to be activated by 
syndecan 4. Syndecans are transmembrane heparan sulphate proteoglycans that 
interact with a plethora of growth factors and extracellular matrix proteins. 
Syndecan 4 has been implicated in the regulation of ADAMTS5 activation through 
both a direct interaction with this protease and via activation of ERK1/2-
mediated synthesis of matrix metalloproteinase-3 (MMP-3) (Echtermeyer, 
Bertrand et al. 2009). ADAMTS5 like other aggrecanases is inhibited by binding to 
tissue inhibitor of matrix metalloproteinases -3 (TIMP-3) (Kashiwagi, Tortorella 
et al. 2001; Troeberg, Fushimi et al. 2009). Interestingly, TIMP-3 is amongst one 
of the most prominent Rab25-downregulated genes in my microarray screen.  
Even though the contribution of ADAMTS family of proteases to cancer 
progression and metastasis remains unclear, there has been an indication of 
ADAMTS-1,5,8,9 and 15’s implication in the invasiveness of head and neck 
cancer, as exemplified by their higher expression in the metastatic foci when 
compared to the primary tumours (Demircan, Gunduz et al. 2009). In light of the 
potential involvement of ADAMTS5 in tumour metastasis and its regulation by the 
syndecan 4 axis, which can exert modulatory effects on the persistence of 
tumour cell migration on cell derived matrix (Bass, Roach et al. 2007) and which 
collaborates with α5β1 integrin in the formation of focal adhesions (Bass, Morgan 
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et al. 2008), it is tempting to speculate that ADAMTS5 might also confer Rab25 
and CDM driven invasive phenotype.  
Another Rab25 and CDM upregulated gene with interesting implications is 
synaptotagmin-like 1 (SYTL1, also SLP1). It specifically and directly binds a GTP-
occupied form of Rab27A, but not other Rab proteins (Kuroda, Fukuda et al. 
2002). More recently, SLP1 has been shown to form a trimeric complex with 
Rap1GAP2, the GTPase activator of Rap1 and with Rab27A and to control 
platelet granule secretion (Neumuller, Hoffmeister et al. 2009). Rab27A is a 
component of the membrane trafficking machinery and SLP1 is thought to 
collaborate with Rab27A in the secretion of lysosomes from cytotoxic T 
lymphocytes (CTL) (Holt, Kanno et al. 2008). Given the role of Rab27A in vesicle 
traffic and the involvement of Rab25 in integrin trafficking and its contribution 
to invasive migration, it might be worth investigating the potential role that 
SLP1 could play in these processes. It is even more tempting to examine SLP1’s 
role in tumour invasion in view of the parallelisms between SLP’s connection to 
lysosomal secretion and CLIC3’s localisation and function, which will be 
described in the following chapter.  
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4 CLIC3 is a late endosomal/lysosomal protein 
and controls the return of lysosomally-targeted 
active-conformation integrins to the plasma 
membrane 
4.1 Introduction 
In the previous chapter I have identified chloride intracellular channel 3 (CLIC3) 
as a gene that is upregulated in A2780 cells stably expressing Rab25, and I have 
described the contribution that the ECM makes to its expression. Although 
proteins of the CLIC family have been named for their reported ability to 
transport chloride ions across artificial lipid bilayers, there is little consensus in 
the literature as to the biochemical and cellular function of these proteins. In 
this chapter, I will therefore introduce what is known about the structure and 
function of the CLICs and the controversies surrounding their cellular role. I will 
then present data examining CLIC3’s involvement in tumour cell invasion into 
three dimensional matrices and describe imaging experiments that delineate the 
subcellular localisation of CLIC3 and how it acts to traffic α5β1 integrin.  
4.1.1 Phylogeny and structural conservation of CLICs 
Chloride intracellular channel (CLIC) proteins constitute a new and still poorly 
characterised family of chloride ion channels, whose structure contains a GST 
omega class family fold. All known CLIC paralogues share a high degree of 
sequence conservation and CLIC-like proteins appear already at early 
evolutionary stages. A single CLIC protein paralogue is already present in lower 
organisms such as Hydra magnipapillata (phylum Cnidaria), Schistosoma mansoni 
(phylum Platyhelminthes), Drosophila melanogaster (phylum Arthropoda) or 
Ciona intestinalis (phylum Chordata). In the Nematodes, such as Caenorhabditis 
elegans, CLIC-like family members share approximately 35% sequence identity 
with their vertebrate counterparts and are represented by two proteins: EXC-4 
and EXL-1. The vertebrate CLIC family of proteins encompasses six paralogues 
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(CLIC1-CLIC6), with CLIC2, CLIC5 and CLIC6 existing in alternative splice forms 
(Littler, Harrop et al.). 
All six mammalian family members are highly conserved and share between 47 
and 76% sequence identity. Human CLICs contain a well-conserved 240 amino 
acid stretch, which forms a glutathione S-transferase (GST) fold (Fig. 4.1A&B). 
CLIC5B and CLIC6 are significantly longer than the remaining CLICs in that they 
possess an N-terminal domain attached to the conserved GST fold. To date, 
crystal structures of four vertebrate CLICs: CLIC1, CLIC2, CLIC3 and CLIC4, in 
their soluble state, have been determined and show strong homology. They 
comprise 10 α-helices and 4 β-sheets, and between helix 5 and helix 6 they 
contain a highly negatively charged loop, which extrudes from the globular 
domain and is positioned between Pro147 and Gln164 in CLIC1 (Fig. 4.2). This 
loop, which appears to be the sole region of structural divergence, constitutes 
the putative site protein interactions involving CLIC1, and could account for 
varying cellular roles of different CLICs (Singh). 
The high degree of sequence and structural conservation between the six CLIC 
family members indicates that they may have arisen through duplication events 
from a single protein in an ancient organism. In favour of that notion is the high 
homology (45% sequence identity) between the Ciona intestinalis’s CLIC-like 
protein and the vertebrate paralogues (Littler, Harrop et al.). 
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Figure 4-1 The human CLICs share a high level of sequence conservation.  
CLIC protein sequences were derived from the NCBI protein data bank and aligned using Vector 
NTI (Invitrogen) software. Yellow boxes indicate amino acids conserved throughout the family, blue 
correspond to residues common for some, but not all CLICs, amino acids highlighted in green show 
the same properties. Regions that are not shaded are those of highest divergence. Highlighted in 
red is the divergent region of CLIC3. The first 124 and 399 amino acids from CLIC5 and CLIC6 
sequences respectively were omitted from the alignment (A). CLIC3 is most identical with CLIC1, 
CLIC2 and CLIC4 and less identical to CLIC5 or CLIC6 (B). 
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Figure 4-2 X-ray crystal structures of human CLICs: CLIC1, CLIC2, CLIC3 and CLIC4.  
The atomic coordinates were retrieved from the RCSB Protein Data Bank (www.rcsb.org/pdb/), the 
structures were superimposed in COOT software and graphical representations of tertiary 
structures were generated in PYMOL. Shown in green, blue, red and brown are structures of 
CLIC1, CLIC2, CLIC3 and CLIC4 respectively. Encircled is the divergent loop. 
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4.1.2 CLICs as membrane-inserted proteins 
Since CLICs do not appear to contain a stretch of hydrophobic residues that 
could conform to a canonical transmembrane domain, it is clear that non-
orthodox models must be invoked to account for their apparent ability to 
transport chloride ions across membranes.  
CLIC1 is thought to exist in two forms, soluble cytoplasmic and membrane-
associated, and to be capable of switching between the two. Exactly how the 
translocation from the aqueous milieu into phospholipid membranes occurs is not 
clear, but Litter and colleagues have proposed a possible mechanism of 
membrane insertion. Upon oxidation CLIC1 can undergo a structural transition 
from a soluble, monomeric and globular state to a non-covalent dimeric form. 
This transition forces an altered conformation of the entire N-terminal domain, 
which contains the thioredoxin motif. The thioredoxin β-sheet, which in a 
reduced state comprises four strands, is now transformed into helices and loops. 
This process is reversible and relies on the formation of an intramolecular 
disulfide bond between Cys-24 and Cys-59, which then exposes a large 
hydrophobic region on the dimer interface. The acquisition of the dimeric 
oxidised conformation is then utilised for membrane anchorage and chloride ion 
channel activity (Littler, Harrop et al. 2004). Consistent with this, there is 
mounting evidence that CLIC family members can undergo a structural transition 
that allows their N-terminus to insert into membranes. A recent study employing 
fluorescence resonance energy transfer (FRET) has observed differences in the 
distance between an N-terminally located tryptophan 35 (Trp35) and C-terminal 
cysteine residues (Cys89, Cys178 and Cys223) upon addition of lipid membranes, 
suggestive of conformational changes being induced in parallel to the transition 
of the protein from an aqueous to membrane interactive state (Goodchild, 
Howell et al.). Furthermore, studies in EXC-4 null C.elegans have identified a 66 
amino acid N-terminal domain, so called PTM domain, whose name derives from 
‘putative transmembrane’ amphipatic helix within it, to be responsible for 
targeting of distinct CLIC-like proteins to distinct subcellular localisations (Berry, 
Bulow et al. 2003; Berry and Hobert 2006).   
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It is still not entirely clear what controls the structural transition of CLICs and 
their membrane insertion. As it was mentioned earlier, some CLICs can undergo 
structural transition and membrane insertion under oxidising conditions, but 
CLIC4 has been shown to insert into lipid bilayers under both reducing and 
oxidising conditions (Singh and Ashley 2007). To add more complexity to the 
mechanism of structural transition, CLIC2 has been reported to be insensitive to 
the redox state, but instead its ion conducting properties are promoted by low 
pH (Cromer, Gorman et al. 2007). Thus, further work will be necessary to 
unravel the exact mechanism of CLICs’ insertion into lipid bilayers, and to 
determine whether this process contributes to chloride ion conductance across 
cellular membranes. 
4.1.3 Biochemical diversity 
4.1.3.1 Ion conductance 
The discovery of a 64kDa bovine chloride channel protein, p64, which is 
homologous to human CLIC5B (Landry, Akabas et al. 1989), has biased the view 
of the potential role of CLIC family of proteins by directing investigators towards 
characterising their ion channel activity. The proposed ion channel role has since 
been studied in electrophysiological assays upon CLIC protein incorporation into 
lipid bilayers, in patch clamp experiments and in whole cell current approaches 
performed on mammalian cells. In spite of numerous efforts to characterise ion 
conductivity of this family of proteins, their role in this process is still a subject 
of debate (Table 4.1). 
In a study performed by Tulk and colleagues, a pure and detergent free 
preparation of water-soluble CLIC1 protein was mixed with preformed vesicles 
and this led to and enhanced chloride permeability of the vesicle membranes. 
Also, addition of CLIC1 protein to preformed planar lipid bilayers resulted in 
increased chloride ion conductance as measured in an efflux assay, consistent 
with a role for CLICs in specific anion permeability  (Tulk, Kapadia et al. 2002). 
In addition to the above mentioned studies with isolated membrane systems, 
there are some limited indications that CLICs may play a role in chloride 
transport in living cells. Studies in osteoclasts indicate that CLIC5B may 
contribute to the acidification of the osteoclasts bone resorption compartment 
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by allowing a passive flow of Cl- ions to short-circuit the electrogenic gradient 
generated by an ATP-dependent proton pump. Consistent with this, CLIC5B 
demonstrates affinity for the SH2 and SH3 domains of c-Src, and this tyrosine 
kinase appears to be necessary for the functional colocalisation of the proton 
pump and the chloride channel in the osteoclasts (Edwards, Cohen et al. 2006). 
Although it is possible that CLIC proteins can act as selective chloride ion 
transporters, recent reports indicating that CLIC2 may act to suppress cardiac 
ryanodine receptor (RyR2) Ca2+ channels (Board, Coggan et al. 2004; Jalilian, 
Gallant et al. 2008), call their role as primary and selective transporters of 
chloride into question. Indeed there are numerous reports that argue against the 
chloride selectivity of CLIC-mediated ion transport, or even against any role for 
CLICs in ion permeability. For instance CLIC4, although capable of inserting into 
lipid bilayers, can not specifically promote chloride transport, rather it mediates 
increased non-specific ion permeability (Singh and Ashley 2007). Also, CLIC5 
even though capable of inserting into lipid bilayers is only able to form poorly 
selective, multiconductance ion channels that are equally permeable to Na+, K+ 
as they are to Cl- (Singh, Cousin et al. 2007). Furthermore, despite attempts to 
characterise its potential chloride conducting ability, no channel activity could 
be assigned to CLIC6 when tested in voltage clamp assay performed on Xenopus 
oocytes (Friedli, Guipponi et al. 2003). CLIC5A, in spite of inducing chloride 
channel activity when reconstituted into liposomes, fails to drive increased 
anion permeability when exogenously expressed in mammalian cells (Berryman, 
Bruno et al. 2004). Moreover, in contradiction to the reports linking CLIC4 to ion 
conductance, the recent study of Ponsioen indicates clearly that although CLIC4 
is recruited to the plasma membrane, it does not span the bilayer, nor does it 
modulate chloride ion currents (Ponsioen, van Zeijl et al. 2009). 
In summary, it is beyond doubt that some CLIC proteins can insert into lipid 
bilayers and promote anion permeability in vitro. However, the specificity of 
CLIC-mediated ion conductance, its relevance to ion transport in vivo and its 
contribution to cell biological and physiological function of CLICs is still under 
debate. 
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Table 4-1 Biophysical properties of CLICs based on the available literature. 
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4.1.3.2 CLICs as glutathione transferases? 
The CLIC family of proteins has an approximately 15% sequence identity with 
Omega class glutathione transferases (GSTs) and belongs to the GST structural 
fold superfamily (Dulhunty, Gage et al. 2001). It has therefore been proposed 
that they can fulfil, amongst a plethora of other roles, an enzymatic one. 
Typically, GST proteins catalyse the conjugation of reduced tripeptide 
(glutamine, cysteine, glycine) glutathione (GSH) to electrophilic regions of other 
molecules. This occurs through the activation of the thiol group of the GSH, 
which then allows for high-affinity non-covalent binding to its substrates. The 
GST module consists of two domains: an all-helical domain at the C-terminus, 
and a thioredoxin domain at the N-terminus. The latter is well-conserved 
amongst multiple families of redox-active proteins, whose active sites frequently 
centre around a cysteine, which is a component of the Cys-X-X-Cys motif. This 
motif has been shown to be present in the redox-active site of CLIC1 resembling 
glutaredoxin (Harrop, DeMaere et al. 2001) and all CLICs are thought to contain 
a cysteine residue (approximately Cys24), which becomes activated by the 
protein itself and forms a disulfide bridge with GSH. (Littler, Harrop et al.). 
Indeed, Ponsioen and colleagues suggest that the conserved Cys-35 in CLIC4, 
which is necessary for membrane translocation of that CLIC, might be 
responsible for its yet unidentified transferase activity and might serve as a 
catalytic residue to bind and process potential substrates (Ponsioen, van Zeijl et 
al. 2009). 
4.1.4 Functional diversity 
4.1.4.1 CLICs in membrane remodelling and tubulogenesis 
Morphogenesis of highly-ordered endothelial tubes is a prerequisite for the 
formation of functional excretory, respiratory and vasculatory systems. The 
creation of vascular lumen, also sometimes referred to as cell-hollowing 
tubulogenesis, is thought to be driven by coordinated intracellular and 
intercellular fusion events. It has been proposed that this process necessitates 
signalling downstream of integrin-ECM interaction and is initiated by the 
integrin- and cdc42/Rac1-dependent formation of pinocytic intracellular 
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vesicles. This is followed by the fusion of multiple pinocytic vacuoles into a large 
intracellular vacuole, which then fuses with its counterparts in the neighbouring 
cells leading to the formation of an extracellular lumen of a multicellular tube. 
Each step of the intercellular lumen formation is thought to require efficient 
intracellular membrane trafficking and vacuolar acidification events (Kamei, 
Saunders et al. 2006).  
A C.elegans CLIC-like protein, EXC-4, has been implicated in establishing and 
maintaining tubular architecture during and after cell hollowing. The excretory 
canal of this nematode consists of a single cell which extends four long and 
narrow canals along the length of the body. These canals contain a lumen, which 
is thought to collect fluids and waste that are later transferred to the excretory 
duct. In the exc-4 null animals the morphology of the excretory tube is altered in 
that it presents with cyst-like swelling and enlargement of the canal’s lumen. 
Ectopic introduction of GFP-tagged EXC-4 into exc-4 null animals rescues the 
mutant phenotype and localises EXC-4 to the membrane of the excretory cell 
and the duct. Interestingly, EXC-4 has been shown to act during early stages of 
lumen formation, when the vacuole is being formed, rather than during 
subsequent tubule flattening and lumen remodelling. Moreover, expression of 
GFP-EXC-4 in exc-4 null animals at different larval stages reveals continuous 
requirement for that CLIC-like protein in the maintenance of the tubular 
architecture even following the development and outgrowth of the excretory 
canal. The only other CLIC-like protein orthologue thought to be present in the 
C.elegans genome is termed EXL-1 (for EXC-4-like) and localisation studies 
performed with fluorescently-labelled EXL-1 revealed its abundance in lysosomal 
membranes and the Golgi apparatus, thus also implicating it in membrane 
dynamics and remodelling (Berry, Bulow et al. 2003).  
Work of Ulmasov and colleagues performed on Clic4-/- mice have implicated 
CLIC4 in the tubulogenic pathway in mammals. Mice deprived of CLIC4 show 
strong angiogenic defects as exemplified by in vivo matrigel assays, and by 
decreased spontaneous development of retinal blood vessels as well as an 
attenuated vascular response to oxygen challenge in the retina. Additionally, 
endothelial cells derived from the Clic4-null mice exhibit defects in the cell-
hollowing tubulogenic pathway in vitro, as measured by the extent of 
vacuolisation. Moreover, vacuolar acidification in these cells is impaired. The 
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authors show similar defects in endothelial cells derived from wild-type mice by 
the application of a generic chloride channel inhibitor, IAA-94, and by the 
inhibition of vacuolar type ATPase with bafilomycin A1. Based on these 
observations, they propose that CLIC4 map play a role in a short-circuiting anion 
conductance, which permits vacuolar proton ATPase-mediated acidification 
along the cell-hollowing pathway. These data lend support to the proposed role 
for CLICs in tubulogenesis, but should be interpreted with caution owing to the 
broad spectrum of processes that the non-specific chloride channel inhibitor and 
a very potent proton pump inhibitor may impinge on (Ulmasov, Bruno et al. 
2009). 
Angiogenesis is a process of new vasculature formation from pre-existing vessels 
and requires the activation of endothelial cells by angiogenic factors such as the 
vascular endothelial growth factor-A (VEGF-A), which binds to and activates the 
VEGF receptor-2. This in turn allows capillary sprouting or splitting, both of 
which result in the formation of new vasculature. Human CLIC4 has been shown 
to be regulated in the process of angiogenesis in a proteomic screen, which 
utilised VEGF for the induction of endothelial cell tubulogenesis. CLIC4 
suppression by siRNA revealed its requirement for efficient tube formation and 
extension. Interestingly, whilst CLIC4 expression is high in resting vessels, it is 
decreased at later stages of tubular morphogenesis in collagen gels and during 
pathological angiogenesis in tumour vessels, thus indicating the need for tight 
regulation of CLIC4 levels throughout multiple stages of tubule morphogenesis. 
(Bohman, Matsumoto et al. 2005).  
Finally, in a study performed by Suginta and colleagues, CLIC4 has been shown 
to partially coexist with caveolin and has been implicated in caveolar 
endocytosis (Suginta, Karoulias et al. 2001), thus further substantiating the 
notion that CLIC family of proteins may indeed play a role in membrane 
dynamics and remodelling.  
4.1.4.2 Cell growth and survival 
CLIC family members, in particular CLIC4 have also been implicated in apoptosis 
and nuclear signalling processes. Indeed, in keratinocytes, CLIC4 has been 
observed in the nucleus and induction of apoptosis by etoposide, a DNA 
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damaging agent, or overexpression of tumour suppressor protein p53, increases 
expression of CLIC4. Not only does induction of apoptosis augment CLIC4 
expression, but also its ectopic expression can drive alterations in the 
mitochondrial membrane potential and the initiation of apoptosis (Fernandez-
Salas, Suh et al. 2002). This is supported by another study, which links CLIC4 to 
nuclear transport complexes and reports its translocation from the cytoplasm to 
the nucleus where it might contribute to the initiation of the apoptotic cascade 
(Suh, Mutoh et al. 2004). In contrast to the above studies, which ascribe a pro-
apoptotic role to CLIC4, is a report by Sue and colleagues that argues an anti-
apoptotic role for CLIC4. Their findings show that tumour necrosis factor (TNFα)-
induced apoptosis leads to a decrease in CLIC4 protein levels and that off-target 
inhibition of CLIC1, CLIC4 and CLIC5 proteins by antisense expression in 
osteosarcoma lines, results in TNFα-induced apoptosis. Additionally, suppressing 
the above CLIC proteins in tumour grafts inhibits tumour growth and leads to 
apoptosis (Suh, Mutoh et al. 2005).  
CLIC4 has also been implicated in sustaining nuclear signalling downstream of 
transforming growth factor β (TGF-β). CLIC4 and transcription factor that 
participates in TGF-β signalling, Schnurri-2, associate in the cytoplasm and 
cooperatively translocate to the nucleus in a TGF-β dependent fashion. Once in 
the nucleus, CLIC4 interacts with phospho(p)-Smad2 and p-Smad3 and acts as a 
shield against nuclear phosphatases such as protein phosphatase 1a (PPM1a), 
thus stabilizing these transcription factors and maintaining nuclear signalling 
downstream of TGF-β (Shukla, Malik et al. 2009). Consistent with a role for 
CLIC4 in prolonging nuclear signalling events is the ability of TGF-β1 to induce 
the upregulation of CLIC4 mRNA levels (Ronnov-Jessen, Villadsen et al. 2002). 
4.1.4.3 Other functions 
Multiple physiological functions other than membrane trafficking and cell 
survival have been ascribed to CLIC family members, and these include their 
ability to function as scaffolds, their contribution to maintaining cell polarity 
during cell division as well as a role in cell migration (Table 4.2). 
CLICs have been shown to be enriched at sites comprising large complexes of 
scaffold and signalling molecules, suggestive of their role as adaptor proteins in 
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the context of a plethora of cellular processes. Indeed, CLIC4 interacts with 
protein kinase A-anchoring protein 350 (AKAP350) at the centrosome, midbody 
and in the apical region of polarized epithelial cells and is enriched in a variety 
of subcellular sites such as mitochondria, nuclear matrix and cytoskeletal, actin-
based structures at the cell cortex (Berryman and Goldenring 2003). Not only 
does CLIC4 interact with AKAP350, CLIC4 amino acids 121-253 have been shown 
to mediate its interaction with the C-termini of one of the G protein-coupled 
receptors (GPCRs), histamine H3 receptor (H3R) (Maeda, Haraguchi et al. 2008). 
Moreover, CLIC5B also associates at the Golgi apparatus with AKAP350 (Shanks, 
Larocca et al. 2002), further strengthening the notion that CLIC proteins could 
act primarily as adaptors or scaffolding proteins. Another member of CLIC 
family, CLIC5A, acts as a cytoskeletal component or regulator. When expressed 
in bacteria, it recruits actin, α-actinin, ezrin and IQ-GAP1 complexes from 
placental microvilli extracts. In line with that finding, ectopic expression of 
CLIC5A in JEG-3 choriocarcinoma cells confirms its coincidence with the cortical 
actin cytoskeleton (Berryman, Bruno et al. 2004). 
CLICs have also been implicated in cell movement. Indeed, CLIC4 has been 
demonstrated to alter the alignment of myosin heavy chain IIA and actin 
filaments. Suppression of its levels opposes the activation of small GTPases, 
RhoA and Rac1, that are necessary for cell retraction and formation of 
protruding processes in moving cells, whilst also affecting the cellular 
distribution of the latter (Spiekerkoetter, Guignabert et al. 2009).  
Given the plethora of cellular localisations and physiological functions of CLIC 
proteins, further studies will be required to interrogate their ability to form 
chloride channels in vivo and to determine whether the resultant ion 
conductance contributes to the roles played by these proteins in the cells and 
organisms. 
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Table 4-2 Diversity in the cellular functions fulfilled by CLIC family members. 
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4.1.5 CLIC3 
CLIC3 was first identified by Qian et al in a yeast two hybrid screen with the C-
terminal tail of a member of mitogen-activated protein kinase family, ERK7, 
used as bait. Northern blot analysis of a panel of tissues revealed very high 
expression of CLIC3 in human placenta, lung and heart tissues. The association 
between ERK7 and CLIC3 has been confirmed by co-immunoprecipitation and 
CLIC3 has been localised mainly to the nucleus, but also to the cytoplasm and its 
ectopic expression has been linked to enhanced chloride conductance  (Qian, 
Okuhara et al. 1999). Almost a decade later, the placental abundance of CLIC3 
was confirmed in a gene expression profiling study, which identified CLIC3 to be 
highly expressed in placenta-derived trophoblast cells at two different 
gestational stages. Also, when probed with anti-CLIC3 antibody, placental 
extracts showed evidence of high CLIC3 distribution. When analysed by 
immunohistochemistry, CLIC3 expression was most prevalent in the apical 
membrane and the cytoplasm, but also in the nucleus (Money, King et al. 2007). 
Interestingly, stimulation of explanted normal breast fibroblasts with 20% fetal 
calf serum, which is known to drive fibroblast to myofibroblast transition, 
resulted in transcriptional upregulation of CLIC3 and CLIC4, but not other CLIC 
family members. When their levels were investigated upon TGF-β1 stimulation, 
only the levels of CLIC4 were augmented, which could be indicative of CLIC3 
upregulation in differentiated fibroblast by a component of the serum, other 
than TGF-β1(Ronnov-Jessen, Villadsen et al. 2002). 
The crystal structure of CLIC3, lacking the 5 C-terminal amino acids has been 
resolved at the resolution of 1.95Å, in both reduced and oxidised states (Fig. 
4.3). Even though CLIC3 is monomeric in solution, the crystal form comprises 
two molecules, suggesting that it adopts a similar fold to the other CLICs. It 
presents with a more open and polar GST-like active site than that of other 
CLICs, which opens the possibility for this member of the family to form distinct 
interactions with other proteins and to play unique cellular roles. Also, the foot-
loop region, which in other family members is flexible, seems well ordered in 
CLIC3, yet again suggesting that this member of the family might be functionally 
divergent (Littler, Brown et al.).  
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Figure 4-3 X-ray crystal structure of CLIC3 
Molecular representation of the crystal structure of human CLIC3 protein shows α-helices and β-
sheets, with N-terminal elements of the structure in blue and C-terminal in red. Encircled is the 
region of sequence and structural diversity. 
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4.2 Results 
4.2.1 CLIC3 is necessary for Rab25-driven invasion into 
fibronectin-supplemented matrigel 
Rab25 has been previously shown to drive tumour cell invasion into three-
dimensional matrices and this process relies on the binding of this GTPase to 
α5β1 integrin and the ligation of the heterodimer to its ligand, fibronectin 
(Caswell, Spence et al. 2007). Given the Rab25 and CDM-mediated upregulation 
of CLIC3 expression (which was described in the previous chapter), I wanted to 
investigate the possible involvement of CLIC3 in tumour cell invasion. To that 
end, I developed reagents for the suppression and enhancement of CLIC3 levels. 
I tested the efficacy of four individual short interfering RNA oligonucleotides 
(siRNAs) as well as a SMART pool siRNA, which is a pool of the four individual 
sequences. I transfected A2780-Rab25 cells with the above mentioned 
preparations, as well as with non targetting (NT siRNA) oligonucleotides and 
examined the levels of CLIC3 mRNA (upper panel) and protein (lower panel) 48 
(Fig. 4.4A) and 72 (Fig. 4.4B) hours after transfection. When mRNA expression 
was analysed, both β-actin and GAPDH served as internal loading controls and 
relative transcript levels were calculated using the ΔΔCT method, as described in 
the previous chapter. It became apparent that siRNA SMART Pool and 
oligonucleotides #3 and #4 were most effective at reducing levels of the CLIC3 
transcript, irrespective of which housekeeping gene was used for normalisation. 
After 48 hours of siRNA introduction, the suppression reached an average of 
about 75% for the three siRNA preparations in question, when compared to NT 
siRNA. Extending that period to 72 hours further decreased CLIC3 mRNA levels to 
about 20% for siRNA SMART Pool and to approximately 10% for siRNAs #3 and #4 
when compared to NT siRNA.  
The ability of these siRNAs to suppress CLIC3 levels was mirrored at the protein 
level, as illustrated by the Western blot analysis of CLIC3 protein expression, 
where vinculin was used to ensure equal loading. Indeed, 48 hours after 
transfection of cells with siRNA SMART Pool or oligonucleotides #3 or #4, the 
CLIC3 protein levels were substantially reduced, and 72 hours following 
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transfection, oligos #3 and #4 abrogated CLIC3 protein expression virtually 
completely.  
Having confirmed the efficacy of CLIC3 suppression in A2780-Rab25 cells, I 
tested whether suppressing its expression would affect tumour cell invasion into 
three dimensional matrices. I employed an inverse invasion assay (Hennigan, 
Hawker et al. 1994), in which tumour cells were plated on the underside of a 
matrigel plug that was supplemented with 25µg/ml fibronectin (N.B. The 
inclusion of fibronectin has previously been shown to be necessary for Rab25-
driven invasion (Caswell, Spence et al. 2007)). The cells were allowed to migrate 
through the porous membrane of the inset that separates them from the 
matrigel. Subsequently, the ECM plugs were placed in a chemoattractant 
gradient, which in the case of the present study was provided by the inclusion of 
10% serum and 25ng/ml epidermal growth factor (EGF) in the upper chamber 
(Fig. 4.5A). 48 hours later, living cells were stained using a fluorescent label 
(calcein-AM) and imaged with a confocal microscope. Optical sectioning was 
performed in a step-wise fashion, every 15µm, starting at the porous membrane 
and moving upwards in the direction of cell invasion. Since the SMART Pool siRNA 
and oligo #3 and #4 siRNAs proved to be most efficient at suppressing CLIC3 
expression, I used them to examine the role of CLIC3 in Rab25-driven invasion. 
Figure 4.2B shows representative strips of matrigel, which were assembled from 
individual images obtained during optical sectioning of the ECM plug. Cells are 
stained green and their migration from left to right on the matrigel strips, as 
indicated by the arrow, corresponds to their upward migration through the ECM. 
Quantification of at least three independent experiments, within which each 
experimental condition was represented by three ECM plugs and three regions 
(corresponding to different x,y positions) of each plug were imaged, was 
performed using Image J software. The invasive potential of the cells was 
expressed as the percentage of the cells that migrated beyond 45µm relative to 
the total number of cells in the ECM plug. Suppression of CLIC3 with SMART Pool, 
oligo #3 and oligo #4 siRNA resulted in a marked reduction in invasiveness of 
A2780-Rab25 cells and is shown in figure 4.5C. CLIC3 suppression was validated 
by Western blotting at the end point of the assay and vinculin was used to 
confirm equal loading (Fig. 4.5D). 
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Figure 4-4 Suppression of CLIC3 with siRNA smart pool and individual oligonucleotides.  
A2780-Rab25 cells were nucleofected with 1µM of the indicated siRNA duplexes and cells were 
harvested at 48h (A) and 72h (B) following transfection. CLIC3 mRNA suppression was verified by 
quantitative PCR (qPCR) and expression levels were normalised to two housekeeping genes; β-
actin and GAPDH (top panel). The efficiency of CLIC3 suppression was also validated on protein 
level by Western blotting (bottom panel). 
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Figure 4-5 Suppression of CLIC3 levels reduces invasiveness of A2780-Rab25 cells. 
A schematic explaining inverse invasion assays (A). Matrigel plugs were enriched with 25µg/ml 
fibronectin and 4x104 cells were plated onto the underside of each transwell 24h post-nucleofection 
with smart pool siRNA and two individual oligonucleotides. Following a 48h period cells were 
stained with calcein-AM and visualised by confocal microscopy. For each condition three series of 
optical sections were captured every 15µm. The consecutive images were assembled into a 
sequence in which the depth of the matrigel increases from left to right (B). The invasive migration 
is expressed as the percentage of cells that migrate further than 45µm. Data are mean ± SEM from 
at least three individual experiments, each performed in triplicate (C). CLIC3 suppression was 
assessed by Western blotting at the end point of the invasion assay (D). 
Chapter 4  148 
Having demonstrated a requirement for CLIC3 in Rab25-driven invasion, I wanted 
to establish whether it is on its own sufficient to drive invasion in cells lacking 
Rab25 expression. To that end, I constructed a Flag-tagged CLIC3 expression 
vector (Appendix 4.1A) and confirmed that its transfection into A2780 cells 
yielded high CLIC3 protein expression levels (Fig. 4.6C). I then overexpressed 
CLIC3 in A2780-DNA3 cells and allowed them to invade for 72 hours into matrigel 
plugs that were either supplemented with fibronectin or in which fibronectin 
was omitted (Fig. 4.6A). The quantification of the invasive capacity beyond 
45µm indicated that CLIC3 increased invasiveness by approximately 50% (Fig. 
4.6B). Strikingly, the invasive capacity of CLIC3 was strongly dependent on 
fibronectin, and in the absence of this component of the extracellular matrix 
CLIC3 had no effect on the invasiveness of cancer cells. Interestingly, it appears 
that fibronectin itself hinders A2780-DNA3 cell invasion.   
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Figure 4-6 CLIC3 drives invasion of A2780-DNA3 cells into fibronectin-rich matrigel. 
Four hours after nucleofection with Flag-CLIC3, 4x104 cells were plated onto the underside of a 
transwell containing fibronectin-enriched (25µg/ml) matrigel. Cells were allowed to invade for 72 
hours and were then stained with calcein-AM and visualised by confocal microscopy. For each 
condition three series of optical sections were captured every 15µm. The consecutive images were 
assembled into a sequence in which the depth of the matrigel increases from left to right (A). The 
invasive migration of cells is expressed as the percentage of cells that migrate further than 45µm. 
Data are mean ± SEM from three experiments, each performed in triplicate (B). The 
overexpression of CLIC3 was verified by Western blotting 24, 48 and 72 hours after transfection 
(C). 
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4.2.2 CLIC3 is localised to vesicular-like structures but not to 
early or recycling endosomes 
To study the localisation and dynamics of CLIC3 in live cells it was necessary to 
tag the CLIC3 protein with a fluorescent reporter. To this end, I introduced the 
gene sequence for the red fluorescent protein, mCherry, into a mammalian 
expression vector for CLIC3, such that the fluorescent tag would be attached to 
the N-terminus of CLIC3 (Appendix 4.1B). Western blotting confirmed that 
transfection of this construct into A2780 cells led to the production of a Cherry-
CLIC3 fusion protein of the appropriate molecular weight, and its expression 
persisted for at least 72h following transfection (Fig. 4.7A). Live cell imaging 
using a fluorescence confocal microscopy indicated that, although a small 
fraction of the fusion protein was diffusely distributed within the cytoplasm and 
the nucleus, the bulk of the ectopically expressed Cherry-CLIC3 localised to 
vesicular-type structures that were dynamic and in constant movement both 
within the cell body, as well as travelling into and out of an extended pseudopod 
(Fig. 4.7B & Movie1). 
As outlined previously, CLIC3 is expressed in A2780 cells in response to 
expression of a GTPase, Rab25, which is known to be involved in controlling the 
dynamics of endosomal membranes and the recycling of α5β1 integrin in the 
context of cell migration. I therefore investigated the possibility that the 
vesicular-type distribution adopted by Cherry-CLIC3 may represent an endosomal 
compartment, or other element of the endomembrane trafficking system that 
may be involved in integrin transport. I therefore co-expressed Cherry-CLIC3 
with markers of early (GFP-EEA1 and GFP-Rab4, Fig. 4.8A&B) or recycling (GFP-
Rab11A, Fig. 4.9A) endosomes and also with GFP-Rab25 (Fig. 4.9B) and assessed 
their distribution using confocal microscopy. However, there was no clear 
colocalisation between Cherry-CLIC3 and these endosomal markers indicating 
that CLIC3 is not recruited to early or recycling endosomal membranes.  
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Figure 4-7 Cherry-CLIC3 expression and localisation in A2780-Rab25 cells. 
A2780-Rab25 cells were transfected with 3µg of Cherry or Cherry-CLIC3 and expression assessed 
by Western blotting 24, 48 and 72 hours after transfection (A). A2780-Rab25 cells transfected with 
Cherry-CLIC3 were seeded sparsely onto CDMs. 24 hours after transfection Cherry-CLIC3 was 
directly visualised in living cells using a confocal microscope. Time-lapse movies were recorded 
over a period of 120 seconds. Stills from a movie corresponding to 22 second intervals are 
presented. Scale bar, 10µm (B). 
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Figure 4-8 CLIC3 does not colocalise with early endosomal markers: EEA1 or Rab4. 
A2780-Rab25 cells were co-transfected with 1.5µg of Cherry-CLIC3 (red) and 1.5µg GFP-EEA1 
(green) (A) or with 1.5µg of Cherry-CLIC3 (red) and 1.5 µg GFP-Rab4 (green) (B). 24 hours after 
transfection the overexpressed fluorescent proteins were directly visualised in living cells using a 
confocal microscope. Scale bars, 10µm. 
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Figure 4-9 CLIC3 does not colocalise with recycling endosomal markers: Rab11 or Rab25. 
A2780-Rab25 cells were co-transfected with 1.5µg of Cherry-CLIC3 (red) and 1.5µg GFP-Rab11 
(green) (A) or with 1.5 µg of Cherry-CLIC3 (red) and 1.5 µg GFP-Rab25 (green) (B). The 
fluorescent proteins were directly visualised in living cells after 24 hours with a confocal 
microscope. Scale bars, 10µm. 
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4.2.3 CLIC3 is localised to late endosomes/lysosomes 
To determine whether CLIC3 was localised to other elements of the endosomal 
pathway, I transfected Cherry-CLIC3 in combination with GFP-Rab7, a GTPase 
that is present on late endosomes and plays a role in the maturation of this 
compartment and ultimate delivery of endocytosed material to lysosomal 
compartments (Chavrier, Parton et al. 1990; Meresse, Gorvel et al. 1995). 
Clearly, there was a marked colocalisation between Cherry-CLIC3 and Rab7 (Fig. 
4.10A), indicating that CLIC3 is recruited to late, rather than early endosomes. 
To further substantiate CLIC3’s presence at later endosomal elements, I 
examined its distribution with respect to lysosomal markers such as Lysosomal-
associated membrane protein 1 (LAMP1, Fig. 4.11A) (Rohrer, Schweizer et al. 
1996), sialin (Fig. 4.12A) (Morin, Sagne et al. 2004), and the acidotropic dye 
LysoTracker-Green (Fig. 4.13A) (MacIntyre and Cutler 1988) that is known to 
accumulate in the highly acidic environment of lysosomes. Indeed, there was a 
near complete colocalisation between CLIC3 and these markers, indicating that 
CLIC3 is localised primarily to late endosomes/lysosomes.  
As mentioned previously, the ability of CLIC3 and Rab25 to increase invasion is 
dependent on the presence of fibronectin within the extracellular matrix. Cell 
movement through the ECM is known to be accompanied by remodelling and 
degradation of the fibronectin within the matrix, which is followed by its 
subsequent internalisation via an α5β1-dependent mechanism. Following 
internalisation fibronectin is routed to lysosomes and degraded within this 
compartment (Sottile and Chandler 2005). To determine the intracellular fate of 
the internalised fibronectin with respect to CLIC3, I conjugated the Alexa647 
fluorophore to soluble fibronectin and allowed its internalisation by A2780-Rab25 
cells that had been transfected with Cherry-CLIC3 (Fig. 4.13B) alone or in 
combination with GFP-tagged markers of late endosomes/lysosomes (Fig. 4.10B, 
4.11B, 4.12B). Consistent with previous reports, internalised fibronectin 
accumulated within late endosomes/lysosomes and therein colocalised closely 
with CLIC3 and other markers of this compartment. 
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Figure 4-10 CLIC3 colocalises with a late endosomal/lysosomal marker, Rab7.  
A2780-Rab25 cells were co-transfected with 1.5µg of Cherry-CLIC3 and 1.5µg of GFP-Rab7. 24 
hours after transfection Rab7 (green) and CLIC3 (red) were visualised directly in living cells using a 
confocal microscope (A). Alternatively, cells were incubated with soluble fibronectin-Alexa-647 for 3 
hours (2.5µg/ml) prior to visualisation. Rab7 (green), CLIC3 (red) and fibronectin (cyan) were 
visualised directly in living cells using a confocal microscope (B). Scale bars, 10µm. 
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Figure 4-11 CLIC3 colocalises with a lysosomal marker, LAMP1.  
A2780-Rab25 cells were co-transfected with 1.5µg of Cherry-CLIC3 and 1.5µg of YFP-LAMP1. 24 
hours after transfection LAMP1 (green) and CLIC3 (red) were visualised directly in living cells using 
a confocal microscope (A). Cells were transfected as in (A) and after 24hours were incubated with 
soluble fibronectin conjugated to Alexa-647 fluorophore for 3 hours (2.5µg/ml) prior to visualisation. 
LAMP1 (green), CLIC3 (red) and fibronectin (cyan) were visualised directly in living cells using a 
confocal microscope (B). Scale bars, 10µm. 
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Figure 4-12 CLIC3 colocalises with a lysosomal protein, sialin.  
1.5µg of Cherry-CLIC3 (red) and 1.5µg of GFP-sialin (green) were introduced into A2780-Rab25 
cells and after 24 hours they were visualised directly in living cells using a confocal microscope (A). 
ated with soluble fibronectin Cells were transfected as in (A) and after 24hours were incub
conjugated to Alexa-647 fluorophore for 3 hours (2.5µg/ml) prior to visualisation. Sialin (green), 
CLIC3 (red) and fibronectin (cyan) were visualised directly in living cells using a confocal 
microscope (B). Scale bars, 10µm. 
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Figure 4-13 CLIC3 colocalises with internalised fibronectin and lysotracker. 
A2780-Rab25 cells were transfected with 3µg of Cherry-CLIC3. 24 hours after transfection cells 
were incubated with 100nM Lysotracker –FITC for 20 minutes prior to visualisation. Lysotracker 
(green) and CLIC3 (red) were directly visualised in living cells using a confocal microscope (A). 
Fibronectin-Alexa-647 (2.5µg/ml) was added 24 hours after nucleofection for a period of 3 hours 
prior to visualisation. Fibronectin (green) and CLIC3 (red) were directly visualised in living cells 
using a confocal microscope (B). Scale bars, 10µm. 
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A remaining issue that I wished to address was whether CLIC3’s ability to localise 
to lysosomes was dependent on the presence of Rab25. I therefore expressed 
Cherry-CLIC3 in A2780 cells lacking Rab25 expression and looked at its 
distribution with respect to GFP-sialin and internalised fibronectin (Fig. 4.14 
A&B). This indicated clearly that the ability of CLIC3 to be recruited to late 
endosomes/lysosomes is independent of the cell’s Rab25 status. 
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Figure 4-14 Late endosomal/lysosomal localisation of CLIC3 is independent of Rab25 
expression. 
A2780-DNA3 cells were co-transfected with 1.5µg of Cherry-CLIC3 and 1.5µg of GFP-sialin. 24 
hours after transfection sialin (green) and CLIC3 (red) were visualised directly in living cells using a 
confocal microscope (A). Cells were transfected as in (A) and after 24hours were incubated with 
soluble fibronectin conjugated to Alexa-647 fluorophore for 3 hours (2.5µg/ml) prior to visualisation. 
Sialin (green), CLIC3 (red) and fibronectin (cyan) were visualised directly in living cells using a 
confocal microscope (B). Scale bars, 10µm. 
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4.2.4 Active α5 integrin is routed to CLIC3-positive late 
endosomes/lysosomes in a Rab25-dependent manner 
Given the colocalisation of CLIC3 with internalised fibronectin, I investigated the 
possibility that α5β1 integrin may be trafficked to the CLIC3-positive 
compartment. However, under basal conditions, there was clearly little 
colocalisation between CLIC3 and α5 integrin in A2780-Rab25 (Fig. 4.15A). 
Integrins are transmembrane heterodimeric molecules that adopt active and 
inactive conformations. Ligand binding to integrins can favour their active 
conformations and this leads to the transduction of signals into the cell, which 
can lead to enhancement of a number of intracellular signalling axes; this is 
termed outside-in signalling (Schwartz, Schaller et al. 1995). α5β1 integrin can 
bind to its ligand, fibronectin, not only when the latter is present as a 
component of a well-organised fibrillar extracellular matrix, but it also shows 
affinity for soluble fibronectin monomers (Huveneers, Truong et al. 2008). I 
therefore decided to use soluble fibronectin as a tool to activate surface α5β1 
and thus determine whether active conformation integrins are preferentially 
trafficked to lysosomes that are CLIC3-positive. Indeed, live cell imaging showed 
that addition of fibronectin to A2780-Rab25 cells increased the colocalisation of 
internalised α5β1 integrin with CLIC3 (Fig. 4.15A&B). I then deployed an image 
analysis approach to obtain a quantitative estimate of the degree to which 
fibronectin can increase delivery of α5β1 to the CLIC3 compartment. Confocal 
images from at least 4 independent experiments and of at least 30 cells were 
subjected to a series of manipulations using the Image J software. Briefly, 
images in both the green (α5 integrin) and the red (CLIC3) channel were 
contrast-enhanced and threshold adjustment was performed. The images were 
then merged and colocalisation between CLIC3 and α5 was expressed as the ratio 
of yellow versus red pixels. These analyses revealed that occupation of α5β1 
with its ligand, fibronectin, led to >2-fold increase in the appearance of α5 
within the CLIC3 compartment (Fig. 4.15D).  
n the conformation of integrins be altered by occupation of their Not only ca
ligand-binding site, it can also be induced from within the cell. This is mediated 
by interaction of cytoplasmic proteins, such as talin, with the intracellular 
portions of the integrin, and can also be artificially promoted by introduction of 
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point mutations that weaken intermolecular associations, which are
by a salt-bridge that forms between the α and β integrin cytotails. Indee
 established 
d, it is 
well-established that mutation of the juxtamembrane salt-bridge promotes 
inside-out activation of the platelet integrin, αIIbβ3 (Hughes, Diaz-Gonzalez et 
al. 1996), and this has also been reported to be achievable for α5β1. In α5β1 the 
membrane proximal salt-bridge is thought to be formed by a GFFKR sequence in 
the α subunit. Mutation of this sequence to GAFKR (F1025A) has been shown to 
induce the phosphorylation of focal adhesion kinase (FAK) and paxillin when cells 
are in suspension (Webb, Zhang et al. 2007), thus indicating that this mutation 
can lock α5β1 into an active conformation and induce downstream signalling, 
irrespective of ligand occupancy. The F1025A mutant of α5, may therefore be 
considered to be constitutively active (CAα5). I therefore used GFP-tagged CAα5 
(GFP-CAα5) to determine whether fibronectin’s ability to promote the delivery 
of α5β1 to lysosomes may be due to alterations in the heterodimer 
conformation. Indeed, GFP-CAα5 integrin colocalised with CLIC3, to a much 
higher extent than wild type integrin (wt-α5) (Fig. 4.15A&C). Quantification 
revealed an almost 2-fold increase in the routing of the constitutively active α5 
to the CLIC3 compartment when compared to wild type integrin (Fig. 4.15D). 
This indicated that it is the active conformation of the integrin that dictates 
α5β1’s routing to late endosomes/lysosomes. 
To determine whether there was a requirement for Rab25 for the lysosomal 
routing of active α5 integrin, I looked at the distribution of GFP-α5 in A2780-
DNA3 cells, which lack Rab25 expression. In contrast to the observations in 
Rab25-expressing cells, no discernable colocalisation between GFP-α5 and 
Cherry-CLIC3 was seen in A2780-DNA cells, and this was not augmented by 
addition of soluble fibronectin (Fig. 4.16A,B&C). This suggested that Rab25 is 
necessary for the routing of active α5 integrin to the late endosomal/lysosomal 
CLIC3-positive compartment. 
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Figure 4-15 Addition of soluble fibronectin and expression of a constitutively active mutant 
of α5 integrin enhances colocalisation between CLIC3 and α5 integrin vesicles. 
A2780-Rab25 cells were transfected with 1.2µg of Cherry-CLIC3 in combination with 4.8µg of GFP-
α5 (A&B) or with 4.8µg of constitutively active integrin; GFP-CAα5 (C). 24 hours after transfection 
α5 integrin (green) and CLIC3 (red) were visualised directly in living cells without fibronectin (FN) 
treatment (A&C) or after cells were treated with 2.5µg/ml of soluble FN for 3 hours (B). Scale bars, 
10µm. Shown in (D) are representative images, corresponding to these in (A-C), as obtained in 
Image J software, where colocalisation between CLIC3 (red) and α5 integrin (green) was quantified 
and expressed as percentage of yellow pixels versus red pixels (D). Data are mean ± SEM from at 
least 4 experiments, n>30 cells. 
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Figure 4-16 Fibronectin-induced enhancement of colocalisation between CLIC3 and α5 
integrin vesicles requires Rab25. 
A2780-DNA3 cells were co-transfected with 1.2µg of Cherry-CLIC3 and 4.8µg of GFP-α5. 24 hours 
after transfection α5 integrin (green) and CLIC3 (red) were visualised directly in living cells without 
fibronectin (FN) treatment (A) or after cells were treated with 2.5µg/ml of soluble FN for 3 hours (B). 
Scale bars, 10µm. Shown in (C) are representative images, corresponding to these in (A&B), 
generated with Image J software, where colocalisation between CLIC3 (red) and α5 integrin 
(green) was quantified and expressed as percentage of yellow pixels versus red pixels (C). Data 
are mean ± SEM from 2 experiments, n=13 cells.  
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I then wished to test the hypothesis that lysosomally-routed α5β1 would come 
into close physical proximity with CLIC3 within this compartment, and to his end 
I used a fluorescence resonance energy transfer (FRET) approach. Fluorescence 
is a process initiated by the absorption of a photon, which takes the molecule 
into an excited state, and is then followed by the emission of a photon with a 
longer wavelength, which in turn brings the molecule back to its ground state. 
The time required for the return to the ground state is referred to as the 
fluorescence life time (τ) and can be used as a determinant of interaction 
between proteins. This is due to the ability of a fluorescent donor molecule to 
return to its ground state by transferring its energy to the acceptor molecule, 
which resides nearby (within 10 nm distance), a process referred to as FRET. The 
fluorescence lifetime of the donor will be shorter when FRET occurs, because 
the donor can lose its surplus energy and exit the excited state faster by 
comparison with a donor that is not within a FRET-able distance of an acceptor 
molecule. The FRET efficiency (E) therefore depends on the distance between 
the donor and the acceptor molecule and can be deduced from the comparison 
of the lifetime of the donor in the presence of acceptor (τDA) and the lifetime of 
the donor alone (τD), according to the following formula: E=1- τDA/D (Lambert 
instruments manual). 
I transfected A2780-Rab25 cells with GFP-α5 integrin (to act as the fluorescence 
donor), either alone or in combination with Cherry-CLIC3 or Cherry (potential 
fluorescence acceptors), and measured the lifetime of the GFP donor both in the
bsence of added fibronectin and also following addition of 2.5µg/ml, 25µg/ml 
 the 
alterations in the fluorescent integrin’s lifetime were specifically owing to its 
proximity to Cherry-CLIC3 and not simply to the presence of the Cherry protein 
in the cell. By using these lifetime measurements to calculate the FRET 
efficiency, I found that addition of fibronectin was able to drive an 
approximately 8-fold increase in FRET between GFP-α5 and Cherry-CLIC3 (Fig. 
4.17D).  I then used the same approach to determine the FRET between GFP-
 
a
and 50µg/ml soluble fibronectin (Fig. 4.17A). When Cherry-CLIC3 was used as
acceptor, a dose-dependent decrease in the lifetime of GFP-α5 was observed 
following fibronectin addition (Fig. 4.17C).  However, when unconjugated Cherry 
was used as the acceptor, the fluorescence lifetime of GFP-α5 remained 
unchanged following the addition of fibronectin, thus indicating that the 
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CAα5 and Cherry-CLIC3 and found that this constitutively active mutant had an 
approximately 5-fold greater FRET efficiency with CLIC3 than did the wild-type 
integrin and that this was not affected by the addition of fibronectin.  In the 
previously outlined immunofluorescence colocalisation experiments, it appeared 
that α5β1 was not routed to CLIC3-positive late endosomes/lysosomes in cells 
that lacked expression of Rab25. To confirm this result using the FRET approach, 
I expressed GFP-α5 or GFP-CAα5 (donors) and Cherry-CLIC3 or Cherry (acceptors) 
in A2780-DNA3 cells and measured the lifetime of GFP following addition of 
25µg/ml soluble fibronectin (Fig. 4.18A). Expression of Cherry-CLIC3 did not 
suppress the lifetime of GFP-α5 or GFP-CAα5 (in the presence or absence of 
fibronectin) indicating that the integrin and CLIC3 do not come into close 
proximity in cells that do not express Rab25. Taken together, these data 
indicate that active-conformation α5β1 heterodimers are transported to late 
endosomes/lysosomes via a mechanism that requires Rab25. Then, upon arrival 
at this compartment, active α5β1 comes into close proximity with CLIC3 in a way 
that can be detected by FRET.   
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Figure 4-17 FLIM-FRET analysis of the proximity of α5 integrin and CLIC3 in Rab25 
expressing cells. 
A2780-Rab25 cells were transfected with 4.8µg of GFP-α5 (donor) alone or in combination with 
1.2µg of Cherry-CLIC3 (acceptor) (A) or with 4.8µg of constitutively active integrin (GFP-CAα5, 
donor) alone or together with 1.2µg of Cherry-CLIC3 (acceptor) (B). Cells were either left untreated 
or treated with indicated concentrations of fibronectin (FN) for 3 hours and donor lifetime was 
recorded. Shown in pseudocolor are GFP life time maps, with low life time in blue and high life time 
in red, as indicated on the colour gradient bar. Scale bar, 10µm. Donor life times are shown in (C). 
In (D) shown are FRET efficiencies. Life time and FRET efficiency values are mean ±SEM from 
three independent experiments, n>45.  
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Figure 4-18 FLIM-FRET analysis of the relationship between α5 integrin and CLIC3 in
DNA3 cells. 
 A2780-
A2780-DNA3 cells (lacking Rab25 expression) were transfected with 4.8µg of GFP-α5 (donor) 
alone or in combination with 1.2µg of Cherry-CLIC3 (acceptor) (A) or with 4.8µg of constitutively 
active integrin (GFP-CAα5, donor) alone or together with 1.2µg of Cherry-CLIC3 (acceptor) (B). 
Cells were either left untreated or treated for 3 hours with 25µg/ml fibronectin (FN) and then donor 
life time measurements were taken.  Shown in pseudocolor are GFP life time maps, with low life 
time in blue and high life time in red. Scale bar, 10µm. Donor life times are shown in (C). In (D) 
shown are FRET efficiencies. Life time and FRET efficiency values are mean ±SEM from three 
independent experiments, n>45. 
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4.2.5 α5β1 integrin is trafficked from CLIC3-positive late 
endosomes/lysosomes to the plasma membrane 
Lysosomes are thought to be the final destination for proteins that are intended 
for degradation. I therefore used a membrane-impermeant biotinylation reagent 
to label α5β1 at the cell surface. I then allowed the integrin to be internalised in 
the presence and absence of fibronectin and used a capture-ELISA to measure 
the quantity of labelled integrin remaining in the cells over a 60 min period 
(Appendix 4.2).  Surprisingly, α5β1 was not degraded within this period, 
suggesting the possibility that lysosomally-targetted integrins are being returned 
to the plasma membrane from the CLIC3 compartment for reengagement with 
the extracellular matrix. To test this hypothesis I utilised a photoactivatable 
mutant of α5 integrin (paGFP-α5). This mutant is engineered by the substitution 
of histidine to threonine, H203T and it exhibits very little emission under basal 
conditions. However, upon irradiation with violet light (390-415nm), it 
undergoes conformational change that leads to a 70-fold increase in 
fluorescence emission at 504nm (green) (Lippincott-Schwartz and Patterson 
2009). The combination of photostability of the paGFP and the ability to ‘switch 
on’ the fluorescence of the fusion protein in a specific region allow for a spatio-
temporal dissection of the route taken by labelled cargo from defined 
subcellular compartments.  
I therefore expressed paGFP-α5 integrin in A2780-Rab25 cells in combination 
with Cherry-CLIC3, and added soluble fibronectin to induce targetting of the
tegrin to the CLIC3-positive late endosomes/lysosomes. I then aimed a pulse of 
 
nt region of the plasma membrane (Fig. 4.19A&D, 
Movie 2).  
As indicated in the previous section, it is the activated conformation of α5β1 
that dictates its routing to CLIC3-positive late endosomes/lysosomes.  It is 
 
in
405nm laser light at a ‘single point’ corresponding to a Cherry-CLIC3-positive
vesicle, and this led to photoactivation of late endosomally/lysosomally-
localised integrin within the confines of this structure. During the following 
couple of minutes, green fluorescence of α5 integrin was rapidly lost from the 
photoactivated vesicles, and this was accompanied by increased green 
fluorescence at an adjace
Chapter 4  170 
possible that the integrin must return to the inactive conformation t
the plasma membrane. To address this issue, I utilised a pho
o return to 
toactivatable 
version of the constitutively active mutant of α5 (paGFP-CAα5). Interestingly, 
ovie 4).  
CAα5 traffics from the CLIC3 late endosomal/lysosomal compartment to the 
adjacent region of the plasma membrane (Fig. 4.19B, Movie 3), and 
quantification of images from at least 8 independent experiments indicated that 
both wild-type and constitutively active α5 integrin recycled at rates that were 
indistinguishable from one another (Fig. 4.19D). Conversely, when 
photoactivation of a single-point adjacent, but not overlapping with the CLIC3 
compartment was performed it resulted in negligible photoactivation within the 
confocal section in question (although subsequent activation of a larger region 
confirmed the expression of paGFP-α5), and did not yield the accumulation of 
green fluorescence at the plasma membrane. This suggested that integrin 
activated in figure 4.19A and B did indeed traffic to the membrane from the 
photoactivated CLIC3-positive structures and did not simply translocate from the 
plasma membrane above and below the imaged confocal sections (Appendix 
4.3). It is also interesting to note that upon arrival at the cell surface, the 
photoactivated integrin did not disperse in a way that would be expected if it 
was freely diffusible in the plasma membrane.  This indicates that recycled α5β1 
remains spatially-restricted within a region of the cell surface that is near to the 
site of exocytosis.  
To confirm whether photoactivated integrin appeared at the plasma membrane 
by following a defined recycling pathway, rather than simply by consequence of 
non-specific diffusion of the fluorophore from the lysosomal membrane I 
employed bafilomycin A1, which blocks V-type ATPase and thus also acidification 
of the endosomal system. Due to its ability to perturb pH gradients within the 
endosomes, bafilomycin A1 is also believed to block endosomal trafficking 
events. Indeed, upon bafilomycin A1 treatment I observed no delivery of 
photoactivated integrin to the plasma membrane, nor did I find decay in the 
fluorescence the integrin within the photoactivated CLIC3 compartment (Fig. 
4.19C&D, M
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Figure 4-19 Photoactivation shows that α5 integrin returns to the plasma membrane from 
CLIC3 vesicles. 
Figure legend continues on the following page. 
Chapter 4  172 
Figure 4.19 Photoactivation shows that α5 integrin returns to the plasma membrane from 
CLIC3 vesicles. A2780-Rab25 cells were co-transfected with 1.2µg of Cherry-CLIC3 and 4.8µg of 
photoactivatable wild type α5 integrin; paGFP-α5 (A&C) or with 1.2µg of Cherry-CLIC3 and 4.8µg 
of photoactivatable, constitutively active integrin; paGFP-CA-α5 (B). Photoactivation was aimed at 
CLIC3-positive vesicles, as indicated by the white arrows. Images were then captured with a 
confocal microscope every 2 seconds over a period of 120 seconds and movies were generated. 
Still images from a representative movie are presented and include a frame prior to 
photoactivation, one immediately after photoactivation (0 sec) and subsequent ones at 15 second 
intervals. Top panels show α5 integrin in grey, bottom panels are merged images with α5 in green 
and CLIC3 in red. In (A) 2.5µg/ml of soluble fibronectin (FN) was used for 1.5 hours prior to 
photoactivation to increase colocalisation between CLIC3 and α5 integrin. In (C) 2.5µg/ml of 
soluble FN and 100nM Bafilomycin A1 (BAF) were used for 2 hours to block endosomal recycling. 
Scale bars, 10µm. The integrated fluorescence intensities of the photoactivated region and 
adjacent plasma membrane were plotted against time (D). Shown is loss of fluorescence in the 
activated region (vesicle) and its gain in the proximal plasma membrane region (membrane), both 
regions indicated by yellow shapes in (A, B, C). Values are mean fluorescence ±SEM from 8 
individual experiments, n=14 for paGFP-α5 +FN (A, black), n=43 for paGFP-CAα5 (B, red), n=8 for 
paGFP-α5 +FN +BAF (C, blue). 
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4.2.6 CLIC3 facilitates the recycling of active α5β1 integrin back 
to the plasma membrane 
I then used a modification of the recycling assay described by Roberts and 
colleagues (Roberts, Barry et al. 2001) to determine whether recycling of 
lysosomally-routed α5β1 might require the presence of CLIC3. When surface-
labelled α5β1 was endocytosed in the absence of added fibronectin, it returned 
to the plasma membrane with largely single order kinetics, and this was 
unaffected by knockdown of CLIC3 (Fig.4.20A).  However, following inclusion of 
fibronectin during the internalisation period, or expression of CAα5 – two 
situations under which transport of α5β1 to late endosomes/lysosomes is 
promoted - the integrin recycled with altered kinetics. Under these 
circumstances, there was an initial, rapid component to α5β1’s return to the 
plasma membrane which was reduced either by suppression of CLIC3 levels with 
siRNA (Fig.4.20B, 4.22A), or by addition of bafilomycin (Fig. 4.21A); a drug that 
opposes endosomal acidification.  
Given the importance of α5β1 activity status in its delivery to late 
endosomes/lysosomes, I performed recycling assays using the 9EG7 antibody, 
which specifically recognises the extracellular inducible epitope of β1 integrin 
heterodimers (Wennerberg, Fassler et al. 1998), so as to detect recycling of only 
the active β1 heterodimers. This revealed that active β1 integrins were returned 
to the plasma membrane with kinetics that corresponded to the rapid, CLIC3-
dependent component of recycling.  Moreover, recycling of active integrin was 
strongly opposed by knockdown of CLIC3 (Fig.4.20C) or by addition of 
bafilomycin (Fig. 4.21B), and this was particularly apparent following expression 
of CAα5 (Fig. 4.22B).    
Taken together, these data indicate a requirement for CLIC3 in the recycling of 
active conformation, lysosomally-targetted α5β1 heterodimers and corroborate 
the observation from the previous section, that active integrin can return to the 
cell surface from the late endosomal/lysosomal compartment.  
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Figure 4-20 Inhibition of CLIC3 suppresses recycling of lysosomally-targetted α5β1. 
black) or with smart pool siRNA targeting CLIC3 (siRNA-CLIC3, red). 48 hours after transfection 
was allowed 
-exposed to MesNa, 
lysed and biotinylated integrin was determined by ELISA-capture on microtitre plates previously 
coated with antibodies recognising GFP (A&B), or active β1 integrin (9EG7) (C). The proportion of 
integrin recycled to the plasma membrane is expressed as a percentage of the internal pool. 
Values are mean ±SEM from thee independent experiments. 
A2780-Rab25 cells were co-transfected with GFP-α5 and either non-targetting siRNA (siRNA-NT, 
cells were serum starved, surface labelled with 0.2mg/ml NHS-S-S-Biotin at 4ºC and internalisation 
was then allowed to proceed for 30min at 37ºC in the presence of serum, and the presence (B&C) 
or absence (A) of soluble fibronectin (FN, 2.5µg/ml). Biotin remaining at the cell surface after 
internalisation was removed by treatment with MesNa at 4ºC and internalised integrin 
to return to the cell surface at 37ºC for the indicated times. Cells were then re
Chapter 4  175 
 
Figure 4-21 Inhibition of CLIC3 or addition of bafilomycin A1 suppress recycling of 
lysosomally-targetted α5β1. 
 smart A2780-Rab25 cells were transfected with non-targeting siRNA (siRNA-NT, black) or with
pool siRNA targeting CLIC3 (siRNA-CLIC3, red) or left untransfected. 48 hours after transfection 
cells were serum starved, surface labelled with 0.2mg/ml NHS-S-S-Biotin at 4ºC and internalisation 
was then allowed to proceed for 30min at 37ºC in the presence of serum and additional soluble 
fibronectin (FN, 2.5µg/ml). The untransfected cells were treated with either 0.001% DMSO (blue) or 
100nM bafilomycin A1 (yellow) during the internalisation stage. Biotin remaining at the cell surface 
after internalisation was removed by treatment with MesNa at 4ºC and internalised integrin was 
allowed to return to the cell surface at 37ºC for the indicated times. Cells were then re-exposed to 
MesNa, lysed and biotinylated integrin was determined by ELISA-capture on microtitre plates 
previously coated with antibodies recognising α5 integrin (A), or active β1 integrin (9EG7) (B). The 
proportion of integrin recycled to the plasma membrane is expressed as a percentage of the 
internal pool. Values are mean ±SEM from thee independent experiments. 
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Figure 4-22 Inhibition of CLIC3 suppresses recycling of constitutively active α5β1. 
A2780-Rab25 cells were co-transfected with GFP-CAα5 and either non-targeting siRNA (siRNA-
NT, black) or with smart pool siRNA targeting CLIC3 (siRNA-CLIC3, red). 48 hours after 
transfection cells were serum starved, surface labelled with 0.2mg/ml NHS-S-S_Biotin at 4ºC and 
internalisation was then allowed to proceed for 30min at 37ºC in the presence of serum. Biotin 
remaining at the cell surface was removed by treatment with MesNa at 4ºC and internalised 
integrin was allowed to return to the cell surface at 37ºC for the indicated times. Cells were then re-
exposed to MesNa, lysed and biotinylated integrin was determined by ELISA-capture on microtitre 
plates previously coated with antibodies recognising GFP (A), or active β1 integrin (9EG7) (B). The 
proportion of integrin recycled to the plasma membrane is expressed as a percentage of the 
internal pool. Values are mean ±SEM from thee independent experiments. 
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4.3 Discussion 
4.3.1 Summary and general points 
Here I describe a novel role for CLIC3 in Rab25-driven and α5β1-dependent 
invasion of ovarian adenocarcinoma cells into fibronectin-rich, three dimensional 
matrices. Using live cell imaging I localised CLIC3 to a vesicular compartment, 
which coincided with markers of late endosomes/lysosomes. Moreover, I have 
found that both Rab25 and the conformation of the integrin determine the 
targetting of the former to the CLIC3-positive late endosomes/lysosomes, and 
that these heterodimers can return to the plasma membrane in a CLIC3-
dependent fashion (Fig. 4.23). 
The experiments addressing subcellular localisation of CLIC3 were performed 
with ectopically expressed and fluorescently tagged protein. This approach 
offers the advantage of enabling visualisation of live cells and bypasses the need 
for cell fixation and permeabilisation and obviates problems of artefacts 
resulting from uneven epitope exposure. On the other hand, studies carried out 
with overexpressed proteins pose a risk of distorting the correct localisation of 
the endogenous protein. At the outset of the project, I attempted to determine 
the localisation of endogenous CLIC3 in cultured cells using immunofluorescence 
(IF). However, in spite of employing a number of different fixing and 
permeabilisation reagents, varying blocking solutions and antibody 
concentrations, the antibodies I developed were not suitable for IF. 
Nevertheless, there is some evidence supporting endosomal localisation of 
CLIC3. Firstly, another group has independently identified CLIC3 whilst searching 
for endosome-associated proteins (personal communication with Jean 
 Gruenberg). Secondly, immunohistochemical staining of ovarian and pancreatic
tumour sections (see next chapter) and of peritoneal and subcutaneous tumour 
xenografts generated using A2780-Rab25 cells indicate that endogenous CLIC3 is 
localised to punctuate structures within the cytoplasm, which are reminiscent of 
endosomes.  
Chapter 4  178 
 
Figure 4-23 Working paradigm. 
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Having observed an augmentation in the colocalisation of CLIC3 and α5 integrin 
endosomal fractions by confocal microscopy and having quantified those 
changes, I wanted to support that observation using FRET. Even though the FRET 
map does not spatially resolve the distribution of donor-acceptor proximity, the 
observed changes in donor life time corroborate lysosomal targetting of active 
integrins. Ideally, I would like to supplement the FRET data, where the donor 
life time was measured, with ratiometric FRET data, whereby changes in 
emission intensities of both donor and acceptor are recorded. During FRET the 
emission intensity from the donor decreases, whilst the amount of photons 
emitted from the acceptor increases. FRET efficiency is therefore calculated as 
a ratio of emission intensities from both entities. This method however, requires 
a plethora of optimisation steps prior to data acquisition, due to the 
measurements being affected by fluorophore intensities and local concentrations 
as well as bleed through problems originating from overlapping emission and 
wo fluorophores. Moreover, the close proximity of 
CLIC3 and α5, as determined by FRET, may indicate that the two proteins 
interact physically. I therefore attempted to test this using immunoprecipitation 
protocols. I performed experiments where I tried to co-immunoprecipitate CLIC3 
with both endogenous and ectopically expressed integrin from cells that 
underwent treatments, which were seen to lead to the accumulation of α5β1 in 
the CLIC3 compartment (fibronectin and/or bafilomycin A1 addition). Also, the 
reversible crosslinking agent DTBP, which had been found to stabilise weak 
intermolecular associations was used. Additionally, I coupled GST-CLIC3 to 
sepharose beads and incubated these with lysates from cells expressing Rab25. 
Notwithstanding these measures, I have been unable to demonstrate co-
immunoprecipitation or pulldown of α5β1 with CLIC3. Taken together these 
findings indicate that although the integrin and CLIC3 come into very close 
proximity within the same endosomal niche, they do not necessarily physically 
interact with one another.  
excitation spectra for the t
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4.3.2 Fibronectin uptake and sorting of α5β1 integrin to late 
endosomes/lysosomes 
An important step in the metastatic cascade is the breaching of tissue barriers 
by invasive tumour cells. Cancer cells migrate through the extracellular matrix 
(ECM) by degrading its components, such as collagen or fibronectin. ECM 
degradation may be mediated by extracellular proteases (such as MMPs) and by 
endocytosis of matrix proteins and their intracellular degradation by lysosomal 
proteases.  In regard of fibronectin, these two routes to ECM turnover are likely 
to occur in sequence, with extracellular proteolysis liberating soluble fibronectin 
fragments from the insoluble, cross-linked ECM, which are then internalised for 
destruction within cellular lysosomes (Sottile and Chandler 2005). The main 
transmembrane receptor that binds fibronectin is α5β1 integrin and it is through 
the endocytosis of this heterodimer that fibronectin can enter the endocytic 
pathway (Shi and Sottile 2008). The internalisation of integrin heterodimers can 
occur via clathrin-dependent and non-clathrin dependent pathways. Indeed, 
even though α5β1 integrin is thought to be normally endocytosed into clathrin 
coated structures, it has been shown that overexpression of Rab21 can activate 
alternative caveolar routes to increase clathrin-independent endocytosis of this 
integrin (Pellinen, Tuomi et al. 2008).  Moreover, it has recently become 
apparent that divergent endocytosis pathways could be employed for 
internalisation of integrins in different conformations and that both inactive and 
active conformation integrins can be endocytosed. For instance, disabled 2 
(Dab2) has been implicated in clathrin-mediated endocytosis of inactive β1 
integrins (Teckchandani, Toida et al. 2009). On the other hand, clathrin and 
disabled 2 (Dab2) have also been shown to control the internalisation of ligand-
activated β1 integrins (12G10 epitope) at sites of focal adhesion disassembly 
(Chao and Kunz 2009). Additionally, a recent study by Valdembri and colleagues 
supports proposed separate internalisation routes of active and inactive 
integrins. It has been shown in endothelial cells, that active α5β1 integrin 
(SNAKA51 epitope) is endocytosed from fibrillar adhesions via a neuropilin 1 
(Nrp1)-dependent route, whereas internalisation of inactive integrin shows no 
requirement for Nrp1 in the same cell type (Valdembri, Caswell et al. 2009).  
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My data indicate that an important factor in the delivery of fibronectin 
endosomes/lysosomes is the differential sorting of
to late 
 active and inactive α5β1 
heterodimers within the endosomal pathway. Here I show that, in an ovarian 
Ms 
(Caswell, Spence et al. 2007). This may indicate that Rab25 preferentially binds 
to α5β1 upon its engagement with its ligand (thus when in an active 
adenocarcinoma cell line, fibronectin occupancy or mutation of the ‘salt-bridge’ 
sequence in the α5 cytodomain - two manipulations which favour the active 
conformation of α5β1 integrin - promote late endosomal/lysosomal routing of 
the active receptor and, presumably, its fibronectin ligand. This is consistent 
with the findings that a fraction of the internalised α5β1 integrin is sorted, 
together with its ligand fibronectin, to multivesicular bodies, to then be 
trafficked to lysosomes (Lobert, Brech et al.). However, these authors show that 
fibronectin occupancy of the heterodimer results in the ubiqitination of the 
latter and this serves as a cue for integrin degradation, a process that involves 
the endosomal sorting complex required for transport (ESCRT). They therefore 
propose that whilst inactive integrins are trafficked via the perinuclear recycling 
compartment back to the cell surface, active conformation integrins are routed 
for degradation. In contrast to these observations, my data indicate that late 
endosomal/lysosomal active conformation integrins are not degraded, but can 
rapidly return to the plasma membrane. Lobert and colleagues report that the 
half life of integrin degradation in fibroblasts is of the order of several hours and 
is fully dependent on fibronectin having been added to the cells for at least 24 
hours (Lobert, Brech et al.). The fact that, in the course of my studies I added 
fibronectin to the cultured cells for much shorter periods (1.5-3h) and at lower 
concentrations (2.5µg/ml instead of 10µg/ml), could account for the inability to 
detect integrin ubiqitination. It is therefore possible that a small proportion of 
active, fibronectin-bound integrin is subject to lysosomal degradation in ovarian 
adenocarcinoma cells, but this is beyond detection under the experimental 
conditions that I employed.  
Given that α5β1 integrin is not ubiquitinated in A2780 cells, it is likely that other 
signals mediate its Rab25-dependent sorting to lysosomes. Previous work has 
shown that Rab25, when in GTP-bound form, directly associates with β1 
cytoplasmic tail, and FRET/FLIM analyses of living cells indicate that this 
interaction is markedly enhanced when cells are plated on fibronectin-rich CD
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conformation) and suggests that active conformation integrins are routed to the 
lysosomes by the virtue of their association with Rab25. It is not completely 
clear how non-ubiquitinated receptors are sorted to the limiting membrane of 
late endosomes, but one school of thought is that they arrive there by default 
because they lack signals for sorting to the recycling pathway. α5β1 integrin is 
known to recycle via the Rab coupling protein (RCP)-regulated and Rab11 
dependent pathway. It has also recently been found that RCP and Rab25 interact 
with the same portion of the β1 cytoplasmic tail (P.Caswell, personal 
communication), indicating the possibility that the two proteins compete for 
integrin binding. Thus, when α5β1 is in its active conformation, Rab25 may 
preferentially bind to the heterodimer and oppose its RCP-mediated recycling, 
and therefore promote its delivery to the late endosomal/lysosomal pathway.  
4.3.3 Return of α5β1 to the plasma membrane 
As early as in 1987 it was suggested that lysosomes should not be considered to 
exclusively be a degradative compartment for endocytosed material. Indeed, the 
integral membrane glycoprotein, LEP100, has been shown to be present at three 
cellular locations; lysosomes, endosomes and at the plasma membrane. Constant 
transport of LEP100 between endosomes and lysosomes as well as lysosomes and 
the cell surface has been reported, and this suggests the existence of a 
considerable bi-directional flux between these compartments. Moreover this flux 
has been reported to be refractory to inhibition by lysosomotropic agents, such 
as chloroquine  (Lippincott-Schwartz and Fambrough 1987). Almost a decade 
later, a pathway mediating the direct transport of MHC class II receptors from 
lysosomes to the plasma membrane, without passage through early endosomes, 
was characterised in B-cells (Wubbolts, Fernandez-Borja et al. 1996).  
Exocytosis of late endosomes and lysosomes is known to lead to the release of 
their luminal contents from the cell (Idone, Tam et al. 2008). It has been 
proposed that tumour endosomal exocytosis results in the release of matrix-
degrading enzymes and can therefore contribute to cancer metastasis (Bernacki, 
Niedbala et al. 1985). During lysosome exocytosis, the limiting membrane fuses 
with the plasma membrane and the contents of lysosomal lumen is en masse 
released from the cell. However, it is unlikely that lysosome exocytosis 
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accompanies the recycling of integrins, since the CLIC3-positive compartment 
from which α5β1 returns to the cell surface, seems relatively immobile and does 
not visibly undergo incorporation into the plasma membrane. Also, preliminary 
experiments indicate that fluorescently-labelled fibronectin does not exocytose 
from lysosomes, from which integrins are actively recycling. 
It is possible that the retromer complex may be involved in the return of late 
endosomal/lysosomal fraction of α5β1 to the cell surface. The cytoplasmic 
domain of the cation-independent mannose 6-phosphate receptor (CI-MPR) has 
been shown to interact with a subunit of the endosomally-resident 
heteropentameric retromer complex. The retromer complex forms tubular-
vesicular extensions along the endocytic pathway, into which the CI-MPR can be 
sequestered and in that way rescued from lysosomal degradation and delivered 
 the return to the cell 
surface (Arighi, Hartnell et al. 2004). However, upon photoactivation, α5β1 
es formed 
by the action of the retromer. Further investigation will be required to establish 
gradients generated by the vacuolar type proton pump (Edwards, Cohen et al. 
to the Trans Golgi Network (TGN) for further sorting and
seems to travel directly from late endosomes/lysosomes to the plasma 
membrane, without passing through other subcellular domains, such as the TGN. 
It is therefore unlikely that it follows the same route to the cell surface as does 
the CI-MPR.  Nonetheless, this does not necessarily exclude the involvement of a 
retromer-like complex in the transport of lysosmally-targetted α5β1 to the 
plasma membrane. Retromer has been implicated in transcytosis of polymeric 
immunoglobulin receptor (pIgR) and its cargo, a process of transporting 
endocytosed material from apical to basolateral surface of epithelial cells 
(Verges, Luton et al. 2004), which does not proceed via the TGN, but involves 
tubular endosomes (Bonifacino and Hurley 2008). I have often observed CLIC3 to 
be present in tubular membraneous structures that protrude from late 
endosomes/lysosomes and which could be analogous to endosomal tub
whether a retromer-like complex is involved in the transport of integrins 
between components of the endocytic pathway and the plasma membrane.  
As it was mentioned in more detail in the introduction to this chapter, CLICs 
have been named for their ability to transport chloride ions across lipid 
membranes (Littler, Harrop et al.). They are thought to contribute to the 
acidification of subcellular compartments by short-circuiting the electrogenic 
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2006). I therefore considered the possibility that CLIC3 may be regulating 
intracellular membrane dynamics and trafficking events by affecting the pH of 
the lysosomal compartment in which it resides. However, I did not detect 
alterations in the pH of the lysosomal niche following CLIC3 overexpression (Fig. 
4.24A) or suppression (Fig. 4.24B). This suggested that even though CLIC3 might 
be contributing to small local pH changes within endosomal subdomains, it does 
not control the acidification of the lysosomal compartment as such and further 
investigations will be required to determine biochemical processes that underlie 
CLIC3-mediated membrane dynamics regulation. 
Furthermore, a more detailed investigation of the relation between α5β1/CLIC3 
and Rab27 and its effector, SLP1 (which was identified alongside CLIC3 to be 
upregulated by Rab25 and CDM) might shed some light onto the mechanism by 
which α5β1 recycles from late endosomes/lysosomes. Other CLIC family 
members have been reported to act as scaffolds and it is possible that CLIC3 also 
acts to recruit the recycling machinery to integrin-containing lysosomes. Indeed, 
preliminary experiments indicate a relationship between CLIC3 and Rab27, which 
is a constituent of membrane trafficking machinery and is known to regulate 
exocytosis of secretory lysosomes (Izumi, Gomi et al. 2003). 
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Figure 4-24 CLIC3 does not affect lysosomal pH. 
A2780-Rab25 cells were transfected with 3µg of an empty vector (DNA3, green) or 3µg of Flag-
tagged CLIC3 (Flag-CLIC3, blue) and overexpression was assessed by immunoblotting. 
Untransfected cells were either left untreated (black) or subjected to autophagy-inducing amino 
acid withdrawal (red) for 3 hours (A). Alternatively, non-targetting siRNA (siRNA-NT, green) or 
siRNA targeting CLIC3 (siRNA-CLIC3, blue) was introduced and CLIC3 suppression was analysed 
by immunoblotting. Untransfected cells were either treated with 0.001% DMSO (untreated, black) 
or challenged with 100nM bafilomycin A1 (red), to oppose acidification of lysosomes (B). Cells 
were allowed to take up acidotropic agent; Lysotracker-Red (100nM) for 20 minutes, the uptake 
was confirmed by fluorescence microscopy, scale bar, 50μm (C) and cells were then trypsinised 
and analysed by Fluorescence Assisted Cell Sorting (FACS). Representative histograms show the 
distribution of fluorescence for each cell population obtained after lysotracker staining. 
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A further interesting aspect of my work is that α5β1 returns to the cell surface 
from the late endosomal/lysosomal compartment in its active conformation, and 
it would be interesting to speculate how this may occur. Although it appears 
that fibronectin and the integrin dissociate prior to the return of the receptor to 
the cell surface, the experiments with paGFP-CAα5 indicate that return to an 
inactive conformation is not a prerequisite for α5β1 recycling. How does the 
integrin maintain its active conformation in the absence of its ligand? It is 
possible that the association of the β integrin cytoplasmic tail with talin and/or 
kindlin persists upon the internalisation of the receptor and is sufficient to 
maintain its active conformation, even following disengagement of fibronectin 
(Moser, Legate et al. 2009). It is also conceivable that lysosomal targetting of 
active integrins would perturb their interaction with hypothetical and yet 
unidentified integrin deactivators, thus locking them in an active state. More 
experimental work will be needed to determine how integrins maintain their 
active conformation when recycling to the cell surface from the late 
endosomal/lysosomal compartment.  
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5 CLIC3 drives tumour progression in vivo and is 
an independent prognostic factor in PDAC 
5.1 Introduction 
5.1.1 CLICs in cancer 
There have been a number of reports connecting CLIC family members, in 
particular CLIC1, to carcinomas in vivo and indicating their potential suitability 
to serve as cancer biomarkers. In a proteomic study performed on 56 patients, 
CLIC1 has been identified to be upregulated by 1.95 fold in 67.9% of gastric 
cancers when compared to matched non-cancerous adjacent mucosa. Increased 
expression of CLIC1 correlated with lymph node metastasis, perineural invasion 
and tumour staging as well as with lower 5-year survival (Chen, Wang et al. 
2007). A small study of 6 colorectal cancer patients confirmed tumour-
associated upregulation of CLIC1 when cancerous tissue was compared to its 
healthy neighbouring counterpart (Petrova, Asif et al. 2008). The above 
observations can influence the management of the disease and can be 
informative in terms of patients’ prognosis, but do not offer the advantage of 
early disease detection and prompt medical intervention. From the early 
diagnostic point of view, it is more imperative to identify novel plasma tumour 
biomarkers, which offer the opportunity of early stage disease detection through 
a simple blood test, in contrast to tissue biomarkers, which can be assayed 
following a biopsy or surgical resection and therefore do not bear such a high 
diagnostic potential. The release of cancer specific proteins during the disease 
progression into the tumour microenvironment and the bloodstream, such as for 
example secretion of the glycoprotein CA-125 by ovarian epithelial cancers, has 
been successfully used for post-operative monitoring and also partially for 
cancer screening.  Interestingly, CLIC1 has been observed to be secreted by 
cancer cells and to be detectable in serum and plasma samples of cancer 
patients. In a study performed by Chang and colleagues this chloride 
intracellular channel has been indicated to be a potential plasma marker for 
nasopharyngeal carcinoma (NPC). Three quarters of the analysed NPC samples 
have shown CLIC1 positivity when assessed by IHC and in line with that the 
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plasma levels of CLIC1 were significantly higher in NPC patients than in healthy 
individuals. When CLIC1 plasma concentration cut-off of 2.58µg/ml was applied,
CLIC1 was capable of discriminating between NPC patients and healthy s
 
ubjects, 
thus suggesting it could be applicable for early detection of NPC (Chang, Wu et 
lysis of tumour interstitial fluids and normal interstitial 
fluids identified CLIC1, amongst 25 other likely markers, to be potentially 
logical detection of breast carcinomas (Gromov, 
Gromova et al.).  
steep increase in the incidence in women who have been through menopause 
al. 2009). Also, the ana
applicable for early sero
Two independent lines of evidence implicate CLIC1 in tumour metastasis. Liu 
and co-workers have identified CLIC1 as a potential tissue biomarker for 
lymphatic metastasis of mouse hepatocarcinoma in a study performed on two 
murine cell lines, Hca-F and Hca-P, both derived from mouse hepatocarcinoma 
but displaying high (75%) and low (25%) lymphatic metastatic potentials, 
respectively (Liu, Sun et al. 2008). A similar approach was used by Wand and 
colleagues to identify the upregulation of CLIC1 in highly metastatic gallbladder 
carcinoma line GBC-SD when compared to its low metastatic counterpart (Wang, 
Peng et al. 2009).  
In addition to cell biological studies, which suggest that CLIC4 may contribute to 
signalling in cancer (as outlined in the introduction to chapter 4), CLIC4 has also 
been correlated with cancer progression in vivo. The level of CLIC4 protein is 
significantly decreased in tumours and its predominantly nuclear localisation in 
normal tissue is replaced by mostly cytoplasmic abundance in tumours. 
Interestingly, its expression in normal stromal tissue is low, but elevated in 
tumour-activated stroma (Suh, Malik et al. 2007). Additionally, immunochemical 
staining of breast carcinoma myofibroblasts revealed CLIC4 expression, which 
was absent in normal breast stroma (Ronnov-Jessen, Villadsen et al. 2002). 
5.1.2 Ovarian and pancreatic cancer 
Ovarian cancer is the fifth most common cancer in women in the UK and the 
fourth most common cause of cancer-related death. In the last three years, 6850 
women have been diagnosed with ovarian cancer annually and 4370 died each 
year. Worldwide, over 204,000 new cases are diagnosed each year and there is a 
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with 80% of cases in females age 50 or older. Over the last three decades, 
ovarian cancer incidence rate has been increasing, peaked in 2001, and is 
currently 17% higher than it was in 1975. Interestingly, the mortality rate has 
decreased by approximately 20% from 1975 to 2008. In line with this, the 5 year 
survival rates have been gradually increasing from 20% in the 1970s to almost 
40% in 2006. As with most cancers, the main discriminator of survival is the stage 
of the disease at diagnosis. Indeed, 5 year survival rates reach 70% when 
diagnosed early, but drop to 15% when patient presents with distant metastases 
at diagnosis, which is the case for a third of the ovarian cancer patients. 
Amongst risk factors predisposing an individual to developing ovarian cancer are 
mutations in BRCA1, BRCA2 and HNPCC genes, but this group of ovarian cancer 
patients only constitutes 10% of the cases (Cancer Stats, Cancer Research UK, 
http://info.cancerresearchuk.org/cancerstats/index.htm). 
There are four main stages of ovarian cancer: stage I, with the tumour confined 
to one or both ovaries, stage II, when the tumour extends to other pelvic organs, 
stage III presents with peritoneal micrometastases beyond the pelvis and/or 
local lymph node involvement and stage IV is determined by the presence of 
distant metastases. Early stage ovarian cancer is amenable to non-radical 
 the 
latter three types is much better than for women with serous cancers (Naora 
 
grade (Type I pathway) and high grade (Type II pathway). Low grade serous 
surgical intervention whilst advanced carcinoma requires surgical debulking 
combined with chemotherapy. Epithelial ovarian cancer comprises a 
heterogeneous group of tumours according to their histological differentiation. 
The most prevalent histological subtype, serous, is histologically similar to 
cancers of fallopian tubes and accounts for approximately 50% of cases. The less 
common types of ovarian cancer encompass endometroid (15-20% cases), 
characterised by the presence of glandular structures and mucinous (10% cases), 
which are composed of glands and cysts lined by mucin-rich cells as well as even 
less common clear cell cancers. Generally, the prognosis for patients with
2007). The most prevalent subtype, serous carcinoma is subdivided into low
carcinomas arise from adenofibromas or serous cystadenomas and have frequent 
mutations in the K-Ras, B-Raf and ErbB2 genes, which are upstream regulators of 
the mitogen-activated protein kinase (MAPK), whilst lacking p53 mutations. 
Their progression to invasive carcinomas occurs slowly and in a step-wise 
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fashion, which entails progression to an atypical proliferative serous tumour 
(APST), also sometimes referred to as typical serous borderline tumour, then to 
non-invasive micropapillary serous borderline tumour (MPSC) and then to 
invasive MPSC. This gradual development determines a better outcome of these 
tumours than that of high grade cancers. High grade serous carcinomas develop 
rapidly, making the identification of precursor lesions challenging. These 
tumours have been thought to originate from the single layer of cells in the 
surface epithelium or from epithelial inclusions in the ovary, but it has been 
suggested that a significant proportion of such carcinomas could originate from 
intraepithelial lesions in the fallopian tube. Approximately 80% of high-grade 
tumours harbour mutations in p53 and are characterised by high level of 
chromosomal instability and high proliferative index but lack mutations in the K-
Ras, B-Raf and ErbB2 genes (Vang, Shih Ie et al. 2009). 
Pancreatic cancer is the eleventh most common cancer in the UK with 7800 
people diagnosed each year and is the fifth most common cause of cancer-
related death. The incidence rates increase drastically over the age of 45 and 
80% of cases are diagnosed in people aged 60 and over. In 2002 more than 
230,000 people were diagnosed worldwide. Interestingly, over the last three 
decades the incidence in males has decreased, whilst the incidence in females 
remained unchanged. This is in agreement with the decline in smoking in men, 
which is thought to account for 20% of pancreatic tumours. The prognosis for 
pancreatic cancer patients is poor, owing to its mostly late detection and its 
hardly accessible localisation in the body (Fig. 5.1A). Due to the very poor 
prognosis the mortality rates closely reflect the incidence rates and 
unfortunately the mortality trend hasn’t improved in the past decades (Fig. 5.1B 
& C). The one year survival has almost doubled since the 1970s, but still remains 
low at 16%, with the five year survival being as low as 3% and ten year survival at 
2%. Median survival for patients whose disease was detected early enough to 
qualify them for surgical resection amounts to 11-20 months whilst patients with 
irresectable, stage III pancreatic carcinoma, whose disease has locally spread 
show median survival of 6-11 months and those with metastatic disease only 
survive for 2-6 months (Cancer Stats, Cancer Research UK, 
http://info.cancerresearchuk.org/cancerstats/index.htm). 
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Figure 5-1 Incidence and mortality rates for pancreatic cancer. 
Location of pancreas in the human body (http://faculty.ksu.edu.sa/1877) (A). Age standardised 
incidence rates of pancreatic cancer by sex in Great Britain between 1975 and 2007 (Cancer Stats, 
http://info.cancerresearchuk.org/cancerstats/index.htm) (B). Age standardised mortality rates for 
pancreatic cancer by sex in the UK, 1971-2008 (Cancer Stats, 
http://info.cancerresearchuk.org/cancerstats/index.htm) (C). 
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The pancreatic parenchyma can be divided into two distinct parts, exocrine 
tissue, which is composed of ducts and acini, and endocrine portion made of 
Langerhans islets which harbour hormone-secreting cells. Most commonly 
pancreatic cancer originates from the exocrine part of the gland through the de-
differentiation of the epithelial lining of the duct, and ductal adenocarcinoma 
accounts for 85% of diagnosed pancreatic cancers (Coppola 2000). Because this 
disease is almost always diagnosed at an advanced stage it is difficult to identify 
lesions from which it arises. It is however thought that pancreatic ductal 
adenocarcinoma arises from precursor lesions called pancreatic intraepithelial 
neoplasia (PanIN), which harbour similar genetic abnormalities as invasive 
pancreatic carcinoma. A proposed definition of PanIN describes it as a 
microscopic papillary or flat non-invasive epithelial neoplasm originating from 
the pancreatic ducts, usually smaller than 5mm in diameter and composed of 
cells with varying amounts of mucin and degrees of cytoarchitectural atypia. 
PanINs are divided into thee grades depending on the severity of the epithelial 
atypia, PanIN 1 (minimal atypia with retained nuclear polarity), which is further 
subdivided into 1A (flat lesions) and 1B (papillary lesions), PanIN2 (moderate 
atypia with multitude of nuclear abnormalities) and PanIN3, also designated 
‘carcinoma in situ’ (marked atypia with marked nuclear atypia, loss of nuclear 
polarity and frequent mitoses). The three step classification system reflects 
their histological progression to an invasive neoplasia, whereupon the 
hyperplastic cells breach the basement membrane (Fig. 5.2). PanIN lesions are 
very common and their incidence increases with age. They not only exist in 
pancreas affected by invasive carcinoma but are also associated with chronic 
pancreatitis. Even though PanINs are considered to be precursory to pancreatic 
ductal adenocarcinoma, the frequency and rate of their conversion into invasive 
carcinoma has not been determined (Hruban, Maitra et al. 2007; Koorstra, 
Feldmann et al. 2008) 
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Diagram depicting a step-wise development of pancreatic lesions (PanIN-1A, PanIN-1B, PanIN-2 
and PanIN-3) to invasive tumour (adapted from Koorstra et al. 2008) (A). Examples of a normal 
pancreatic duct, PanIN-1B, PanIN-2 and PanIN-3 (Hruban et al 2007) (B). 
Figure 5-2 Multistep progression from PanINs to invasive pancreatic ductal carcinoma. 
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Pancreatic cancers, similarly to other epithelial cancers, such as those of the 
ovary, do not arise de novo but rather as a consequence of a sequential 
histological and genetic progression of precursor hyperplasia. Activating 
mutations on the K-Ras oncogene, particularly in codon 12, are the most 
common genetic abnormality in pancreatic cancer and occur with a high 
frequency of approximately 90-95%. They are also thought to be one of the 
earliest changes to occur in the progressive PanIN cascade, as they have been 
observed in 36%, 44% and 87% of cancer-related PanIN-1A, PanIN-1B and PanIN-
2/3, respectively and therefore to be an initiating event in the formation of 
carcinoma (Maitra and Hruban 2008). Also, the accumulation of mutations in 
TP53, MADH4/SMAD4/DPC4 has been implicated in the step-wise progression 
from PanINs to aggressive ductal carcinoma (Takaori 2007). 
It seems that the best strategy to improving pancreatic cancer patients’ 
outcome is the early identification of curable pancreatic neoplasms before they 
develop into incurable invasive cancer. However, the current imaging technology 
does not allow detection of these tiny lesions, further underscoring the need for 
the identification of molecular markers predicting the invasive disease in order 
to allow early detection in asymptomatic patients who are still amenable to 
treatment.  
Tissue microarray (TMA) technology was first introduced in 1987 by Wan and 
colleagues (Wan, Fortuna et al. 1987) and 10 years later further developed into 
a technique that allowed rapid and reproducible generation of high quality TMA 
and simultaneous analysis of up to 1000 samples (Kononen, Bubendorf et al. 
1998). TMAs are an ordered array of cylindrical tissue cores mounted onto a glass 
slide, which allow the analysis of protein and gene expression of numerous 
biomarkers under identical experimental conditions. During TMA generation, a 
core of tissue (0.6-2mm in diameter) is lifted from a formalin-fixed and paraffin 
embedded whole section and placed in a pre-prepared hole in a recipient 
paraffin block. A resulting block can contain a multitude of histospots with 
known coordinates allowing easy linkage to clinicopathological data and it can 
be sectioned up to hundreds of times for multiple analyses (Fig. 5.3A & B). TMAs 
5.1.3 Tissue microarrays 
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are ordinarily used for immunohistochemical evaluation of biomarkers in various 
tumour types and present a number of benefits over standard whole-section 
studies. Firstly, examination of the tissue section by the pathologist occurs only 
once and prior to core sampling, ensuring that appropriate and representative 
areas of the tumour are being arrayed on the recipient paraffin block. Secondly, 
each histologic section on the TMA uses only a small fraction of the donor 
tumour block, which can therefore be used for the construction of numerous 
TMAs. Another advantage of analysing a cohort of tumours on a TMA is the 
internal consistency of immunohistochemical staining, which occurs under the 
same conditions and with the same antibody concentration for each core. 
Moreover, the portability of TMA slides encourages their sharing with other 
research centres thus allowing multifaceted analysis of the same cohort of 
tumours. However, in spite of clear benefits, there are also a number of pitfalls 
nt locations within the tumour. To tackle the heterogeneous nature 
of carcinomas, multiple histospots should be sampled from each tissue in order 
he study. One other limitation in the application 
of TMAs for biomarker validation is the analysis of the TMA, which requires a 
associated with the use of TMAs, which are mostly shared with the weaknesses 
of whole section analysis, such as the dependency on good quality tissue and the 
availability of suitable antibodies or potentially detrimental effects of tissue 
oxidation on antigenicity. An additional concern arises when intra-tumour 
heterogeneity is taken into account. The analysis of a single core might not yield 
a representative result or allow for the detection of varying levels of biomarker 
in the differe
to improve the significance of t
trained eye to discriminate tumour from stromal tissue and a rigorous linking of 
the histospot score to the correct coordinate and patient information. 
Furthermore, the scoring process itself is subjective and semi-quantitative, 
regardless of whether definite score of 0 to 3 is assigned or whether a 
continuous value ranging form 0 to 300 is calculated based on the percentage of 
cells showing different staining intensities. (Rimm, Camp et al. 2001; Camp, 
Neumeister et al. 2008). Despite their possible limitations, TMAs are widely 
applied not only to immunohistochemical or immunofluorescent analysis of 
protein levels or localisation, they can also be employed for in situ 
hybridization, which allows the detection of gene expression or chromosomal 
abnormalities (Mobasheri, Airley et al. 2004). TMAs have the potential to 
accelerate translational research by serving as a platform for validation of the 
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involvement of novel genes in tumour progression. Such Progression Model TMAs 
utilise tumour samples collected during the clinical progression of the disease 
and allow the assessment of gene expression at various disease stages. Outcome 
TMAs on the other hand contain tumour samples which are linked to 
clinicopathological data of the patient that they were derived from thus 
facilitating the evaluation of the marker as a potential prognostic factor, 
molecular target or therapeutic response determinant (Henshall 2003). 
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Figure 5-3 Construction of tissue microarrays (TMAs). 
Schematic illustration of TMA generation from donor paraffin embedded tissue sections (Rimm et 
al. 2001) (A). Example of immunohistochemically-stained TMA (B). 
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5.2 Results 
Thus far, CLIC3 has not been associated with tumour progression or metastasis in 
vivo and has not been suggested as a diagnostic or prognostic marker for any 
types of carcinoma. Due to my identification of CLIC3 in an ovarian 
adenocarcinoma cell line, and owing to the contribution of Rab25 to the 
aggressiveness of ovarian tumours (Cheng, Lahad et al. 2004) I sought to 
evaluate its involvement in that type of cancer as well as in pancreatic cancer, 
which shares a number of similarities to its ovarian counterpart.  
5.2.1 Generation of a CLIC3 specific antibody 
In light of the lack of commercially available CLIC3 specific antibody, I had to 
generate one myself in order to evaluate the expression of CLIC3 in tumour 
samples, and its correlation with disease progression and patient survival. As it 
was mentioned in the introduction to the previous chapter, alignment of the 
protein sequences and crystal structures for CLIC family members revealed high 
level of sequence and structural similarity between CLIC3 and CLIC1, CLIC2 and 
CLIC4 (Fig. 4.1 & 4.2). The high level of sequence conservation makes it difficult 
to produce antibodies that specifically recognise individual members of the 
family. I therefore searched for a region that would be divergent in the CLIC3 
sequence and identified a 12 amino acid stretch from glutamic acid 147 to 
glutamic acid 158 (E147-E158) that displayed different properties to the 
corresponding sequences in the remaining CLICs (Fig. 4.1). Interestingly, a close 
inspection of overlaid crystal structures revealed that this divergent region in 
CLIC3 and its counterparts in the other CLICs form a loop that extrudes from the 
globular domain (Fig. 4.2 & 4.3). The ability of this unique region to form a 
highly ordered fold on the surface of the molecule suggested its potential high 
antigenicity and suitability for the generation of a CLIC3-specific antibody. 
However, the utilisation of that peptide as the antigen failed to yield antibodies 
which would efficiently recognize CLIC3 (data not shown). Consequently, I 
attempted antibody generation using a full length CLIC3 protein. To that end I 
constructed a pGEX-6P-1-CLIC3 vector in which CLIC3 is fused to GST and 
 Ion and ompT proteases 
separated from it by a protease cleavage site (Appendix 4.1C). BL21(DE3)pLysS 
E.coli cells are engineered in such a way that they lack
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that can degrade proteins during the purification process and they also allow a 
controlled induction of exogenous protein expression with Isopropyl-1-thio-β-D-
ected in three 
elution fractions (Fig. 5.4A). The three fractions were pooled and the resulting 
tease treatment, which 
removed the GST-tag from the recombinant protein. The CLIC3 protein was then 
galactopyranoside (IPTG). I therefore transformed these competent cells with 
pGEX-6P-1 and grew the bacterial culture in LB medium supplemented with 
100µg/ml ampicillin. When the density of the culture reached OD600 of 0.8, 
protein expression was induced with 1mM IPTG and expression verified one, two 
and three hours later. Both soluble and insoluble protein fractions appeared to 
contain GST-CLIC3, which runs as a 50kDa band on an SDS-PAGE gel. 
Subsequently, GST-CLIC3 was purified on a GST-resin and coll
GST-CLIC3 preparation was subjected to PreScission Pro
purified in two consecutive affinity purification steps on a GST-resin, whereby 
GST-tagged protease and GST itself were trapped on the column whilst CLIC3 
was collected in the flow-through as the final, near homogenous solution at 
1.35mg/ml concentration (Fig. 5.4B). The absence of GST and the presence of 
pure CLIC3 in the final preparation was confirmed by Western blotting with a 
GST specific and commercially available CLIC3 specific antibody, respectively 
(Fig. 5.4C). The CLIC3 protein solution was then dispatched to Eurogentec for 
the inoculation of two rabbits that were used for the production of antibodies 
targetting that antigen and the resulting sera were affinity purified on a GST-
resin column coupled with GST-CLIC3. 
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Figure 5-4 Bacterial expression and affinity purification of GST-CLIC3. 
Pelleted BL21(DE3)pLysS bacterial cells were resuspended in PBS and resolved by SDS-PAGE 
and Coomassie stained. Soluble GST-CLIC3 was affinity purified on GST-resin and collected in 
three elution fractions (A). A Coomassie stain of GST-CLIC3 prior to PreScission protease 
cleavage and of CLIC3 after digestion and two consecutive purification steps (B). Western Blotting 
of the same samples as in (B) with a commercially available chicken antibody against CLIC3 and 
an antibody against GST (C). 
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5.2.2 CLIC3 antibody specifically recognises CLIC3, but not other 
members of the CLIC family 
To validate the two batches of anti-CLIC3 antibody, each originating from an 
immunised rabbit, designated 1543 and 1544 respectively, I produced GST-CLIC1, 
GST-CLIC4 and GST-CLIC3 (Fig. 5.5A & B). 500ng of these preparations along with 
GST and CLIC3 proteins were analysed by Western blotting with the 1543 
antibody batch, at 1:1000, 1:5000, 1:10 000 and 1:20 000 dilutions. The 1543 
antibody showed very high affinity for both recombinant GST-CLIC3 and CLIC3, 
but also bound to GST and GST-CLIC1 and GST-CLIC4 (Fig. 5.6A). When the same 
antibody dilutions were tested on lysates derived from A2780-DNA3 and A2780-
Rab25 cells, which were confirmed to either lack or express CLIC3 by 
immunoblotting with a commercial chicken anti-CLIC3 antibody (Fig. 5.6C), and 
failed to recognise CLIC3 (Fig. 5.6B). 1544 antibody batch was then tested in the 
same manner and revealed high affinity for both GST-CLIC3 and CLIC3, whilst 
showing no binding to either GST-CLIC1, GST-CLIC4 or GST (Fig. 5.7A). 
Importantly, when applied at 1:5000 dilution, 1544 antibody specifically 
recognised a band of approximately 27kDa in A2780-Rab25 cell lysates, which 
was absent in A2780-DNA3 lysates (Fig. 5.7B).  
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Figure 5-5 Bacterial expression of GST-CLIC3, GST-CLIC1 and CLIC4 for antibody 
purification and validation. 
BL21(DE3)pLysS bacterial culture, transformed with pGEX-6P-1-CLIC3, pGEX-2T-CLIC1 and 
pGEX-2T-CLIC4 respectively was grown in LB medium with 100µg/ml ampicillin. At OD600 = 0.8 
protein expression was induced with 1mM IPTG. At 4 hours cells were pelleted, resuspended in 
PBS, resolved by SDS-PAGE and Coomassie stained. Soluble GST-CLICs were captured on GST-
resin, eluted in four steps (A), elution fractions were pooled and subjected to a subsequent affinity 
purification step, which led to the production of highly homogenous GST-CLIC1, GST-CLIC3 and 
GST-CLIC4 protein solutions (B). 
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Figure 5-6 Validation of the antibody from 1543 serum. 
500ng of recombinant GST-CLIC1, GST-CLIC4, GST-CLIC3, GST and CLIC3 were subjected to 
Western blotting and probed with 1543 anti-CLIC3 antibody at the indicated antibody dilutions. 
Protein loading was confirmed by probing with GST-HRP antibody at 1:5000 dilution (A). 40µg of 
A2780-DNA3 and A2780-Rab25 cell lysates were analysed by Western Blotting with the 1543 anti-
CLIC3 antibody at the same dilutions as for the recombinant proteins. Equal lysate loading verified 
by probing for Vinculin (B). The same lysates were subjected to Western blotting with commercial 
chicken anti-CLIC3 antibody at 1:2500 dilution (C).  
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Figure 5-7 Antibody from 1544 serum specifically recognises CLIC. 
The same protein preparations and antibody dilutions were used as in Fig. 5.6.  
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5.2.3 Optimisation of the antibody for immunohistochemistry 
To identify the most suitable conditions for performing immunohistochemical 
staining with the 1544 CLIC3-specific antibody in tissue samples, I performed a 
number of optimisation steps on mouse tissue, which is more readily available 
than human specimens. Firstly, I used Western blotting to confirm that the 1544 
antibody was able to recognise the mouse CLIC3 protein and this was possible 
due to very high degree of sequence homology between the human and murine 
CLIC3 protein. To that end, I harvested various tissue from 3 month old FVB 
female mice. Mouse tissue samples were then either fixed in 10% Neutral 
Buffered Fromalin (NBF) and paraffin embedded, or homogenised and subjected 
to Western blotting with the CLIC3 antibody at 1:5000 dilution. This allowed me 
to identify three tissues: pancreas, kidney and lung, which respectively 
exhibited low, moderate and high CLIC3 protein abundance, and which I 
subsequently utilised to determine antibody dilution and antigen retrieval 
method to be used for IHC (Fig. 5.8A). Antigen retrieval is required to expose 
epitopes that have been masked by the tissue fixation process. Most commonly, 
heat induced epitope retrieval (HIER) in combination with a buffer of choice is 
successfully used to break protein cross-links on formalin fixed and paraffin 
embedded tissue. A trial IHC was performed in 10mM Na citrate buffer (pH6), 
with the omission of primary antibody or with the antibody at 1:30, 1:100 and 
1:1000.  The lowest antibody concentration revealed CLIC3 expression pattern in 
fixed tissue similar to that observed by Western blotting (Fig. 5.8B). When the 
antigen retrieval step was omitted (Fig. 5.9A) or when Proteinase K (Fig. 5.9B) 
was applied to induce enzymatic epitope recovery, no CLIC3 staining was
gent, namely 
ethylenediaminetetraacetic acid (EDTA) buffer (pH8) and found that it enhanced 
the CLIC3 epitope exposure more efficiently than did citrate buffer, even at 
dilutions as high as 1:2000. Importantly, CLIC3 IHC performed under these 
conditions yielded expression patterns largely comparable to that seen by 
Western blotting; i.e. lung exhibited very high CLIC3 abundance, kidney 
displayed some CLIC3-positivity, while pancreas lacked expression (Fig. 5.10). 
CLIC3 IHC on human placental tissue confirmed the unsuitability of Proteinase K 
retrieval method and validated efficient epitope recovery with both citrate and 
 
observed. I then exploited another antigen retrieval a
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EDTA buffers, with the latter in combination with 1:500 antibody dilution being 
the most optimal condition (Fig. 5.11A).  
I had previously established that the 1544 CLIC3 antibody recognises CLIC3 by 
Western blotting and shows no affinity for its near homologues, CLIC1 or CLIC4. 
To be certain that the staining pattern obtained in human tissue was specific to 
CLIC3, I performed preabsorption experiments. Prior to probing the tissue with 
CLIC3 antibody, I pre-incubated the latter with 5-fold excess of recombinant 
CLIC3, CLIC1 or CLIC4. Whereas pre-incubation of the antibody with either CLIC1 
or CLIC4 did not reduce the intensity of immunostaining, the signal was lost 
when the antibody was preabsorbed with CLIC3, thus confirming the specificity 
of the antibody for that family member only (Fig. 5.11B). To gain further support 
for the specificity of CLIC3 antibody and its suitability for tumour tissue analysis, 
I decided to stain sections from a range of tumours and to compare the staining 
intensity obtained with the antibody with the tumour’s CLIC3 mRNA content, as 
determined by qPCR analysis of matching RNA and tissue block samples. I 
selected four pancreatic ductal adenocarcinomas (PDAC), designated 112T, 
110T, 11PD and 21PD, which had previously been determined in an independent 
microarray screen, to have low and high CLIC3 expression, respectively (data not 
shown, Nigel Jamieson). Using qPCR I confirmed very low CLIC3 transcript levels 
in the 112T and 110T patients, and high CLIC3 mRNA abundance in the 11PD and 
21PD samples (Fig. 5.12A). CLIC3 IHC performed on matching tumour sections 
confirmed very low CLIC3 protein abundance in 112T and 110T tumours and very 
high and high expression in 11PD and 21PD patients, respectively, thus further 
substantiating the specificity of the antibody (Fig. 5.12B). This correlation 
between the mRNA levels and tissue content of CLIC3 lent further support to the 
antibody-specificity studies presented earlier in this section. 
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Figure 5-8 Trial CLIC3 immunohistochemistry (IHC) on mouse tissue.  
40µg of protein homogenates were subjected to Western blotting with anti-CLIC3 antibody at 
1:5000 dilution. Protein loading was verified by probing with anti β-actin antibody, 1:10 000 (A). 
CLIC3 IHC was performed on mouse lung, kidney and pancreas tissue, in 10mM Na Citrate buffer 
(pH6) with the omission of primary antibody (no antibody) as well as with the antibody at 1:30, 
1:100 and 1:1000 dilutions (B). 
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Figure 5-9 CLIC3 IHC with no antigen retrieval and with Proteinase K retrieval on mouse 
tissue. 
Mouse tissue was fixed in 10% Neutral Buffered Formalin (NBF), paraffin embedded and 
processed as per IHC protocol, with the omission of antigen retrieval step (A) or antigen retrieval 
was performed with Proteinase K (B). The CLIC3 antibody was used at 1:75, 1:500 and 1:4000 
dilutions on mouse lung, kidney and pancreas tissue. 
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Figure 5-10 CLIC3 IHC on mouse tissue using EDTA buffer (pH8). 
Heat-induced epitope retrieval in conjunction with EDTA buffer (pH8) was used to expose the 
antigen. The CLIC3 antibody was used at 1:500 and 1:2000 dilutions on mouse lung, kidney and 
pancreas tissue. 
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Figure 5-11 CLIC3 IHC on human placenta. 
No retrieval, Proteinase K, Citrate buffer (pH6) or EDTA buffer (pH8) were used respectively to 
reveal the antigen. CLIC3 antibody was applied at 1:75, 1:500 and 1:4000 dilutions (A). Antigen 
retrieval was performed with EDTA buffer (pH8). Prior to probing the tissue with the antibody, the 
antibody was pre-incubated with 5M excess of recombinant GST-CLIC3, GST-CLIC1 and GST-
CLIC4, respectively. The antibody-protein complex was used instead of the neat antibody at 1:500 
dilution (B). 
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Figure 5-12 CLIC3 mRNA and protein in matching pancreatic tumour samples. 
Relative CLIC3 mRNA expression was validated by qPCR for two low CLIC3 expressors; patients 
112T (black) and 110T (red), and two high expressors, patients 11PD (blue) and 21PD (green) and 
was normalised to either β-actin or GAPDH (A). Tissue blocks corresponding to the RNA samples 
from (A) were subjected to CLIC3 IHC, where the antibody was used at 1:500 dilution. In the top
panel a lower and in the bottom a higher magnification of the tissue sections are shown (B). 
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5.2.4 CLIC3 expression in ovarian carcinomas 
Prior to determining the relevance of CLIC3 in ovarian cancer progression I 
endeavoured to confirm the suitability of the antibody for TMA staining. It is not 
uncommon for the antibody concentration and antigen retrieval method to 
require adjustment when minute tissue cores are being immunohistochemically 
stained instead of whole tissue sections which had thus far been used. 
Therefore, I performed CLIC3 IHC on a trial TMA containing 5 tumour tissue 
cores, using two antigen retrieval methods, citrate pH6 and EDTA pH8, as well as 
two antibody dilutions, 1:500 and 1:750 (Fig. 5.13). Epitope recovery with EDTA 
and antibody dilution 1:500 appeared to have been unaffected by the transition 
from whole tissue sections to TMA cores and were therefore utilised for CLIC3 
immunohistochemistry on a TMA containing 472 cases of ovarian carcinoma.  
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Figure 5-13 CLIC3 IHC on a practice TMA. 
CLIC3 IHC was performed on a pancreatic practice TMA containing 5 cores. Antigen retrieval 
carried out with Citrate pH6 or EDTA pH8 buffers and CLIC3 antibody was used at 1:500 or 1:750 
dilutions. Two randomly selected cores are shown and the green box is drawn around the most 
optimal immunohistochemical staining method.  
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CLIC3 was mostly observed as multiple puncta in the cytoplasm of the tumour 
cells, but was also evident in the nucleus, especially when CLIC3 expression was 
high (Fig. 5.14A). To obtain a quantitative index of CLIC3 abundance a scoring 
guide was devised, which aided in the determination of staining intensity 
throughout the TMA. A four-step score was used, where 0 corresponded to no 
expression, 1 to low expression, 2 to medium and 3 to high (Fig. 5.14B). Due to 
observed intra-tumour heterogeneity of CLIC3 abundance, a histoscore was 
calculated for each core. The histoscore was designed to reflect the percentage 
of tumour cells within the core which fell into each staining category, thus 
generating a continuous score ranging from 0 to 300. Even though most tumour 
cores displayed some CLIC3 positivity, in most cases the abundance was low and 
no correlation between CLIC3 expression and survival was detected, regardless 
of whether all ovarian tumour types were considered cooperatively or whether 
they were split into individual subtypes (data not shown). However, a connection 
between CLIC3 and tumour invasion was established by categorising ovarian 
tumours into Type I (which encompass low grade serous, endometroid, clear cell 
and mucinous carcinomas), or Type II (comprising high grade serous tumours that 
are more aggressive and more likely to progress to metastatic disease). CLIC3 
protein levels, as indicated by the histoscore, were significantly higher in Type II 
than in Type I ovarian tumours (Fig. 5.14C), thus lending support to the proposal 
that this chloride intracellular channel could contribute to tumour 
aggressiveness and invasion in vivo. 
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Figure 5-14 CLIC3 expression in ovarian tumours. 
The ovarian TMA was stained with CLIC3 antibody at 1:500 dilution. High magnification of granular 
cytoplasmic and nuclear CLIC3 staining in ovarian tumours (A). Tumour cores representing CLIC3 
staining intensity of 0 (no staining), 1 (weak staining), 2 (medium staining) and 3 (strong staining). 
Underneath shown are corresponding H&E stained sections (B). CLIC3 IHC of low grade serous, 
endometroid, clear cell, mucinous (all type I) and high grade serous (type II) ovarian cancers. 
Graph illustrating the difference in the mean histoscore between type I and type II ovarian tumours 
(C). Scoring and data analysis performed in conjunction with Charlie Gourley. 
Chapter 5  216 
5.2.5 CLIC3 is expressed in Pancreatic Intraepithelial Neoplasia 
(PanIN) and invasive pancreatic ductal adenocarcinomas 
(PDAC) but not in normal pancreatic ducts 
Due to the histopathological resemblance between ovarian and pancreatic 
tumours, I extended the analysis of CLIC3 expression to pancreatic carcinoma. I 
initially performed CLIC3 immunohistochemistry on whole pancreatic tumour 
sections and normal human pancreatic tissue. Consistent with the observations 
in the mouse pancreas, CLIC3 was undetectable in normal human pancreatic 
ducts or acinar tissue, but was present in precursor lesions (PanINs) and high 
grade ductal carcinomas (Fig. 5.15A). CLIC3 was localised to cytoplasmic puncta 
as well as in the nucleus of those tumour cells that expressed high CLIC3 levels 
(Fig. 5.15B). Interestingly, in the well organised regions of PanINs, CLIC3 was at 
low abundance, but enriched in the more dysplastic regions of these tumour 
precursor lesions (Fig. 5.15A). Furthermore, CLIC3 was noticeably enriched at 
the invasive edge of tumours, where infiltration of the healthy tissue can be 
clearly observed (Fig. 5.15C).  
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Figure 5-15 CLIC3 IHC of normal pancreatic ducts, Pancreatic Intraepithelial Neoplasia 
(PanIN) and high grade and invasive pancreatic ductal adenocarcinomas (PDAC).  
CLIC3 IHC of the above mentioned tissues performed at 1:500 antibody dilution. Normal pancreas, 
PanIN and high grade PDAC in (A). Invasive PDAC was additionally Haematoxylin and Eosin 
(H&E) counterstained. The blue line indicates the boundary of normal and cancerous tissue (B). 
High magnification of CLIC3 immunostaining in PDAC shows granular cytoplasmic and nuclear 
abundance (C). 
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5.2.6 CLIC3 predicts poor PDAC patient survival  
Having observed elevated CLIC3 expression in high grade and invasive pancreatic 
tumours, I sought to establish whether there was a relationship between CLIC3 
expression and pancreatic ductal adenocarcinoma (PDAC) aggressiveness. I 
performed immunohistochemistry on a pancreatic TMA containing 118 cases of 
PDAC, each represented by 6 cores. Primary visual inspection revealed a broad 
spectrum of CLIC3 staining intensity; from tumours lacking CLIC3 protein to 
those expressing it at a very high level. For the purpose of linking the expression 
levels to the clinicopathological data I needed to obtain a quantitative index of 
CLIC3 abundance. To that end I have picked four tumour cores which 
represented an average score of 0 (no expression), 1 (low expression), 2 
(medium expression) and 3 (high expression) (Fig. 5.16) and utilised them as a 
guide when calculating a continuous histoscore for each tumour sample. CLIC3 
expression levels did not differ when tumour stage, size, grade, vascular 
invasion or resection status were considered. Univariate analysis, which divided 
PDAC patients into low CLIC3 expressors (histoscore<100, n=33) and high CLIC3 
expressors (histoscore>100, n=85) revealed that high CLIC3 expression was 
associated with significantly decreased cumulative survival following PDAC 
resection, when compared to low expression (p=0.01, Fig. 5.17A). Median 
survival for high CLIC3 expressors amounted to 11.5 months (95% CI: 7.9-15.1) 
and was greatly increased to 20.1 months (95% CI: 15.6-24.6) when CLIC3 
expression was low (Fig. 5.17B). Moreover, tumours presenting with no lymph 
core 
histoscore 66.5), by comparison with the LN>50% tumours (p=0.01, Fig. 5.17C). 
More importantly, multivariate Cox proportional-hazards regression analysis 
identified CLIC3 expression, along with tumour stage, size, grade and margin 
involvement, as an independent predictor of poor survival with a hazard ratio of 
1.35 (95% CI: 1.08-1.81, p=0.028, Fig. 5.18).  
node involvement (LN0, n=24) exhibited lower CLIC3 expression (mean histos
54.5) than those with more than 50% lymph node involvement (LN>50%, n=12, 
mean histoscore 125.8, p=0.005). Likewise, tumours with less than 50% lymph 
node invasion (LN<50%, n=82) had significantly lower levels of CLIC3 (mean 
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Figure 5-16 Scoring guide for the pancreatic ductal adenocarcinoma (PDAC) tissue 
microarray (TMA). 
Shown are tumour cores selected from the TMA to represent staining intensity scores of 0 (no 
staining), 1 (weak staining), 2 (medium staining) and 3 (strong staining). The panel on the left 
shows the cores with CLIC3 immunostaining (1:500 antibody dilution), while the panel on the right 
shows corresponding Haematoxylin and Eosin (H&E) staining.  
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Figure 5-17 High CLIC3 protein expression renders poor survival in patients with operable 
pancreatic ductal adenocarcinoma (PDAC). 
Box plot illustrating stratification of PDAC patients into low and high CLIC3 expressors based on 
the histoscore and Kaplan-Meier analysis of survival for high and low CLIC3 expressors (A). 
 (B). Box 
 analysis 
Median survival data for low and high CLIC3 expressors with 95% Confidence Interval (CI)
plot of mean CLIC3 histoscore vs. lymph node metastasis (C). TMA scoring and data
performed in conjunction with Nigel Jamieson. 
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Figure 5-18 Predictors of survival in 118 patients with pancreatic ductal adenocarcinoma 
following pancreaticoduodenectomy according to multivariate Cox regression analysis.  
CLIC3 protein expression assessed by immunohistochemistry. 
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Given the subjectivity of TMA scoring and its semi-quantitative nature, I sought 
to use a more quantitative approach to validate the above correlation between 
CLIC3 and patient survival. A separate cohort of 48 PDAC patients that had 
undergone pancreaticoduodenectomy and for which outcome data was available, 
had previously been analysed by microarray gene expression profiling (Nigel 
Jamieson). Using the data from these analyses, PDAC patients were stratified 
into low (n=17) and high (n=31) CLIC3 expressors based on the normalised mean 
gene expression (log value 8.04, Fig. 5.19A). Kaplan-Meier analysis revealed that 
patients with low CLIC3 had a significantly increased survival by comparison with 
those that were high expressors (p=0.001, Fig. 5.19B). Median survival for high 
CLIC3 expressors amounted to 15.4 months (95% CI: 9.57-21.22), and this was 
increased over three fold, to 49 months (95% CI: 17.92-80.01), when CLIC3 
al-
xpression as an independent 
predictor of poor survival with a hazard ratio of 4.81 (95% CI: 1.86-12.3, 
p=0.001). Other predictors of poor outcome included margin involvement, 
tumour stage and size (Fig. 5.20).  
expression was low (Fig. 5.19C). Furthermore, multivariate Cox proportion
hazards regression analysis identified CLIC3 mRNA e
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Figure 5-19 High CLIC3 mRNA expression renders poor survival in patients with operable 
pancreatic ductal adenocarcinoma (PDAC). 
Box plot illustrating stratification of PDAC patients into low and high CLIC3 expressors based on 
normalised mean gene expression (A). Kaplan-Meier survival graph shows a statistically significant 
survival advantage for patients whose CLIC3 mRNA levels are low (blue) when compared to those 
whose CLIC3 mRNA levels are high (red). Log rank, p=0.001 (B). In (C) shown is median survival 
data for low and high CLIC3 expressors with 95% Confidence Interval (CI). Microarray screen and 
data analysis performed by Nigel Jamieson. 
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Figure 5-20 Predictors of survival in 48 patients with pancreatic ductal adenocarcinoma 
following pancreaticoduodenectomy according to multivariate Cox regression analysis.  
CLIC3 mRNA expression assessed by microarray hybridisation. 
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5.2.7 CLIC3 expression correlates with enhanced Src signalling in 
pancreatic tumour tissue 
Given the contribution of CLIC3 to the recycling of active conformation α5β1 
integrin in the A2780-Rab25 tumour cell line, I sought to determine whether 
CLIC3 expression correlated with indicators of activated integrin signalling in 
pancreatic tumours. It is well established that integrin activation leads to 
autophosphorylation of non-receptor tyrosine kinases, such as focal adhesion 
kinase (FAK) and Src (Brunton and Frame 2008). Src then activates a member of 
3, 
n turn, can contribute to 
transcription of cell cycle regulators such as D-type cyclins, in particular cyclin 
D1, or p21 (Sinibaldi, Wharton et al. 2000). Interestingly, the nuclear 
accumulation of cyclin D1, which regulates the transition from G1 to S phase of 
the cell cycle leads to concurrent nuclear stabilisation of p21 (Coleman, Marshall 
et al. 2003). To investigate a possible correlation between CLIC3 levels and the 
status of signalling pathways downstream of activated integrins in the pancreatic 
TMA, I examined the levels of autophosphorylated, active Src (phospho-Tyr416-
Src) with respect to CLIC3 expression. These analyses indicated that CLIC3 
histoscore correlated closely with membraneous phospho416-Src histoscore 
(Spearman’s rho correlation coefficient 0.47, p<0.001), which is consistent with 
a role for CLIC3 in integrin signalling (Fig. 5.21A). Furthermore, there was a 
clear correlation between CLIC3 expression and signalling downstream of Src, as 
evidenced by the nuclear abundance of phospho727-STAT3 (Spearman’s rho 
correlation coefficient 0.539, p<0.0001, Fig. 5.21B), cyclin D1 (Spearman’s rho 
correlation coefficient 0.391, p<0.001, Fig. 5.21C) and p21 (Spearman’s rho 
correlation coefficient 0.387, p<0.01, Fig. 5.21D). 
the signal transducers and activators of transcription (STAT) family, STAT
which is necessary for cell transformation and, i
Chapter 5  226 
 
 
Figure 5-21 CLIC3 expression correlates with that of Phospho -Src, Phospho -STAT3, 
cyclin D1 and p21 in pancreatic adenocarcinomas. 
Shown are Spearman’s correlation plots for cytoplasmic CLIC3 and membranous 
Phosphotyrosine416-Src (A), nuclear CLIC3 and nuclear Phosphoserine727-STAT3 (B), nuclear 
cyclin D1 (C) and p21 (D), respectively. Spearman’s rho correlations and p-values are indicated on 
the plots. Correlation plots generated in conjunction with Nigel Jamieson. 
416 727
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5.3 Discussion 
5.3.1 Summary 
Here, I generated an antibody that recognises CLIC3 but not other CLIC family 
members, and demonstrated that is it suitable for Western blotting and 
immunohistochemical staining of normal and cancerous tissues from humans and 
mice. I then utilised this reagent to examine CLIC3 protein expression in ovarian 
and pancreatic tumours. I found there to be higher CLIC3 expression in the more 
aggressive forms of high grade ovarian serous carcinomas, and a clear 
relationship between the abundance of CLIC3 and poor prognosis in operable 
cases of PDAC. Further analyses indicated that CLIC3 can be independently used 
as a predictor of poor overall survival in PDAC patients, and its expression in 
pancreatic tumours correlates with enhanced Src activity.  
5.3.2 How does CLIC3 contribute to tumour progression in vivo? 
The role played by CLIC3 in Rab25-driven invasiveness and integrin trafficking in
itro suggest that it could contribute to metastasis in vivo. Indeed, the 
h re 
and subsequent death from disseminated disease following surgical removal of 
the primary tumour. Previous studies have indicated that integrins can affect 
tumour cell migration and invasion not only by providing a mechanical link 
between the extracellular matrix and the actin cytoskeleton, but also by 
exerting effects on downstream signalling pathways. The recycling of α5β1 
integrin from the Rab11 compartment in a Rab-coupling protein (RCP)–
dependent manner has been shown to contribute to invasion by controlling the 
association of EGFR1 with RCP and by influencing signalling to protein kinase B 
(PKB/Akt) downstream of EGFR (Caswell, Chan et al. 2008). However, CLIC3 
expression did not correlate with levels of phospho-PKB/Akt in pancreatic 
tumours, nor with the activity of other kinases, such as mTOR and S6 kinase, 
that are known to be downstream of activated PKB/Akt (data not shown). This 
could indicate that the signalling downstream of integrins trafficked via either 
 
v
expression of this protein is higher in Type II ovarian tumours whic  are mo
likely to progress to disseminated disease. Moreover, CLIC3 is enriched at 
invasive tumour fronts and its expression correlates with lymph node metastasis 
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the lysosomal (CLIC3) or recycling endosome (RCP) pathways may be quite 
distinct. It is possible that integrins recycling via the RCP pathway communicate 
KB/Akt axis, whilst active heterodimers traversing the CLIC3 
compartment exert effects on the activation of Src. Indeed, the strong 
There is clear evidence that Rab25 can act both to promote and to inhibit 
 
are. It is possible that the expression of Rab25’s effectors can determine 
primarily with the P
correlation between CLIC3, active Src, STAT3 and cyclin D1 and poor patient 
survival indicates the possibility that increased cycling of active α5β1 integrin 
through the CLIC3 pathway may drive spread and growth of metastases by 
enhancing the ability of active α5β1 to signal through these effector pathways. 
Further work will be required to evaluate whether the above relationships can 
be reproduced in other human tumour types as well as in cancer cell lines in 
vitro. 
5.3.3 Could CLIC3 explain conflicting roles of Rab25 in cancer? 
tumourigenesis, but it is as yet unclear what the reasons for this discrepancy
whether it acts to promote or inhibit tumour progression. Indeed, a number of 
lines of evidence indicate that RCP could contribute to tumourigenesis (Caswell, 
Chan et al. 2008; Muller, Caswell et al. 2009; Zhang, Liu et al. 2009) and it has 
been suggested that this effector of Rab11 GTPases may alter Rab25’s ability to 
act as tumour promoter (Luen Tang B, 2010). My data suggest the possibility that 
CLIC3 could also influence the way in which Rab25 acts to promote or inhibit 
tumorigenesis. More specifically, in the presence of CLIC3, when cells can 
recycle lysosomally-routed integrins, Rab25 may promote α5β1-dependent 
invasion.  However, in tumours lacking the CLIC3 pathway, integrins trafficked 
to lysosomes will likely be retained within that compartment and this may 
promote their degradation. Under these circumstances, Rab25 loss may lead to 
unchecked β1-integrin expression and cause defects in polarity which could lead 
to tumour initiation and progression. To test this hypothesis, it will be necessary 
to examine the relationship between Rab25 and CLIC3 expression in a range of 
human tumour types. A study aimed at understanding the relationship between 
CLIC3, Rab25 and patient outcome in human ovarian and pancreatic tumours is 
currently underway in the lab, and preliminary data indicate that Rab25 is 
expressed in the majority of these tumours, particularly in those that show high 
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CLIC3 expression (Fig. 5.22). When this study is extended to cancers in which 
Rab25 is thought to be inhibitory to cancer progression (such as breast 
carcinoma), it should be possible to establish whether CLIC3 (or indeed other 
components of the CLIC3/lysosomal integrin recycling pathway) can determine 
the direction in which Rab25 pushes tumourigenesis. 
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Figure 5-22 CLIC3 and Rab25 expression in PDAC and ovarian carcinoma. 
(A) Immunohistochemical staining of the corresponding regions of a whole section of an invasive 
pancreatic ductal adenocarcinoma (B) randomly picked CLIC3-positive core from PDAC TMA (C) 
randomly picked CLIC3-positive core from ovarian TMA. IHC with antibodies recognising CLIC3 
(pH8 retrieval, 1:750 antibody dilution) or Rab25 (pH8 retrieval, 1:1000 antibody dilution). 
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6 Discussion 
6.1 Summary 
Rab25 has been shown to promote tumour invasion and aggressiveness as well as 
to suppress tumour progression (Cheng, Volk et al.; Nam, Lee et al.; Wang, 
Wyckoff et al. 2002; Cheng, Lahad et al. 2004; Wang, Goswami et al. 2004). To 
gain more insight into how Rab25 may act to promote tumour cell invasion and 
to further explore the possible reasons for apparently opposing roles of Rab25 in 
human cancers, I used a microarray approach to identify genes whose expression 
was associated with Rab25 in a human ovarian carcinoma line. These analyses 
revealed a marked, Rab25-dependent increase in CLIC3 expression when cells 
were cultured on CDMs, by comparison with plastic surfaces. Elevated CLIC3 
mRNA levels were specifically driven by Rab25 and not by other members of the 
Rab11 family. CLIC3 depletion in Rab25-expressing A2780 cells compromised 
invasion into fibronectin-supplemented matrigel, thus supporting a role for this 
protein in tumour invasion, and this view was reinforced by the ability of CLIC3 
to drive fibronectin-dependent invasion of A2780 cells that lacked Rab25 
expression. To examine the role of CLIC3 expression in human tumour 
progression and its correlation with patient outcome I developed an antibody 
that specifically recognised CLIC3, but not other members of the highly similar 
CLIC family, and used it in immunohistochemical staining of human ovarian and 
pancreatic tumour samples. Consistent with its role in tumour cell invasion in 
vitro, was high CLIC3 expression in highly metastatic Type II ovarian tumours and
ease. 
To unravel the cellular functions of CLIC3 underlying its role in tumour 
progression and invasion, I investigated its cellular localisation and its 
relationship to the trafficking of α5β1 integrin, a process which is controlled by 
a physical association of this integrin with Rab25 during tumour cell migration 
(Caswell, Spence et al. 2007). Live cell imaging studies indicated that CLIC3 was 
localised to a late endosomal/lysosomal compartment, which was positive for 
Rab7, LAMP1, sialin and lysotracker. Furthermore a proportion of internalised 
 
correlation between CLIC3 levels and poor patient outcome in operable cases of 
PDAC. Furthermore, CLIC3 expression correlated with the expression of active 
Src indicating that it is linked to activated integrin signalling in human dis
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α5β1 integrin colocalised with CLIC3-positive endosomes, and this colocalisation 
was increased when the integrin was in an active conformation, as indicated by 
h soluble fibronectin was used to prime the integrin, or 
y active integrin mutant was employed. Moreover, this late 
endosomal/lysosomal routing of active integrin heterodimers required the 
presence of Rab25, suggesting that this GTPase facilitates its sorting to this 
compartment. Not only was the active α5 integrin shown to be trafficked to 
requirement for CLIC3 in the return of active integrin to the plasma membrane.  
experiments in whic
when a constitutivel
CLIC3-positive late endosomes/lysosomes, but instead of being degraded, it 
recycled from this cellular compartment back to the plasma membrane, as 
indicated by live cell photoactivation experiments. This was further 
substantiated by biochemical recycling experiments, which confirmed the 
Taken together, the data presented in this thesis outline a novel role for CLIC3 
in integrin recycling, tumour cell invasion in vitro and cancer progression and 
invasion in vivo. 
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6.2 Future directions and preliminary observations 
6.2.1 CLIC3 in tumour invasion and progression 
Genetic tumour models offer a promising tool for recapitulating tumour 
development and progression in vivo, and they have been widely applied in the 
studies of pancreatic tumour development and progression. Pancreatic ductal 
adenocarcinoma (PDAC) arises from precursor lesions (PanINs), which in the 
course of their progression to malignancy accumulate genetic alterations, such 
as activation of K-Ras, loss of Ink4a, loss of p53 function or Smad4 (Hruban, 
Maitra et al. 2007). Recently, the loss of Lkb1 has also been shown to drive 
pancreatic tumour progression (Morton, Jamieson et al.). In 90% of PDAC, the 
progression of PanINs to invasive carcinoma is driven by the activation of the K-
uman pancreatic cancer (Scarpa, Capelli et al. 1993). Mutant 
p53 (p53(R172H)), has been shown to drive the progression of premalignant 
lesions harbouring the K-Ras mutation into PDAC and to promote metastasis 
(Morton, Timpson et al.). However, my immunohistochemical analyses of 
pancreatic precursor lesions and carcinomas from mice in which the KrasG12D and 
p53R172H alleles are driven by the pancreas specific Pdx-1-Cre (Hingorani, Wang 
et al. 2005), did not reveal CLIC3 expression. Given that mutant p53 is thought 
to promote invasion and metastasis through enhanced recycling of α5β1 integrin 
and EGFR1 in a way that requires Rab-coupling protein (RCP) (Muller, Caswell et 
al. 2009), and not Rab25, it may not be surprising that these tumours lack CLIC3 
expression. Genetic models of pancreatic cancer employing K-Ras mutation and 
Rab25 or CLIC3 overexpression might therefore be more suitable to study the 
contribution that these proteins make to tumour progression in vivo. 
Cell lines derived from such genetically engineered tumours could be used to 
significantly strengthen the role of CLIC3 in tumour invasion. Firstly, organotypic 
assays more closely represent the matrix through which tumour cells invade in 
vivo than do matrigel plugs, and this is due to the collagen matrix being pre-
conditioned by normal human fibroblasts, which are thought to lead the invading 
tumour cells in vivo (Gaggioli, Hooper et al. 2007). Secondly, CLIC3-driven 
Ras oncogene (Almoguera, Shibata et al. 1988). Following an initiating K-Ras 
activating G12D mutation, a mutation in TP53 tumour suppressor gene occurs in 
50-75% cases of h
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tumour spread, and in particular organ colonisation, could be assessed through 
in vivo approaches employing bioluminescent imaging, which evaluate 
t population of sites, 
such as lungs or liver (Elkin and Vlodavsky 2001). Finally, xenograft studies, 
ression of 
PTPN14, which will allow functional studies (Fig. 6.2B). Interestingly, 
metastatic spread of blood-borne cells and their subsequen
which involve subcutaneous or intraperitoneal inoculations of cultured tumour 
cells, offer a better opportunity of mimicking metastatic spread in vivo, than do 
tail vein injections. This is because cancer cells that form the primary tumour 
must escape from the cancerous mass, enter circulation and then populate 
secondary niches. Additionally this process can be monitored in real-time 
through the application of fluorescent proteins and optical imaging (Sahai 2007). 
6.2.2 CLIC3 interactome 
Proteins of the CLIC family share a high level of structural conservation, with the 
exception of an approximately 12 amino acid stretch, which forms a so called 
hypervariable loop that protrudes from the globular structure of CLICs. It has 
been speculated that this motif could serve as an adaptor site for specific 
protein-protein interactions (Singh). To initiate characterisation of the CLIC3 
interactome I performed pull down assays, where I used GST-tagged proteins as 
baits and incubated them with A2780-Rab25 cell lysates. The pull-downs were 
then subjected to separation by SDS-PAGE and mass spectrometry analyses. Two 
independent experiments identified a number of proteins that specifically 
interacted with GST-CLIC3, but not GST alone or GST-CLIC1 or GST-CLIC4 (Fig. 
6.1A&B, Appendix 6.1). One of the top hits, for which a consistently large 
number of peptides was identified in both mass spectrometry screens, was 
Tyrosine-protein phosphatase non-receptor type 14 (PTPN14). I confirmed the 
interaction of PTPN14 with recombinant CLIC3 by Western blotting (Fig. 6.2A). 
Additionally, I developed reagents for suppression and overexp
suppression of PTPN14 seemed to increase the ability of EGF to drive the 
phosphorylation of EGFR at Tyr 1045 (Fig. 6.2C). Phosphorylation at Tyr 1045 is 
required for docking of the E3 ubiquitin ligase – Cbl – to EGFR1, thus promoting 
ubiquitination and the ESCRT-mediated sorting of EGFR1 into luminal vesicles for 
degradation on the multivesicular endosomal pathway (Grovdal, Stang et al. 
2004; Marmor and Yarden 2004). Thus, it is possible that PTPN14 may oppose 
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phosphorylation of EGFR1 at Tyr 1045 thus reducing Cbl recruitment and the 
consequent receptor degradation, ultimately leading to prolonged signalling 
downstream of EGFR1 or even recycling of the receptor from late 
endosomes/lysosomes, which would be likely to be pro-invasive. Indeed, PTPN14 
has been observed to be enriched at the invasive fronts and in liver metastases 
of tumours generated with the human pancreatic tumour cell line MiaPaca2 in 
nude mice (Niedergethmann, Alves et al. 2007). Consistent with this, my 
preliminary findings have shown that suppression of PTPN14 with siRNA reduces 
the invasiveness of A2780-Rab25 cells into matrigel (Fig. 6.2D). Therefore these 
observations would suggest that PTPN14 and CLIC3 could collaborate to control 
the joint trafficking of α5β1 integrin and EGFR1 and the signalling downstream 
our cell invasion. of these receptors to drive tum
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Figure 6-1 CLIC3 interactome. 
A. Recombinant GST, GST-CLIC1, GST-CLIC4 and GST-CLIC3 were coupled to sepharose beads 
and tumbled with A2780-Rab25 cell lysates. Proteins that were pulled-down by the baits were then 
eluted from the column, subjected to SDS-PAGE separation and analysed by mass spectrometry. 
B. Proteins that specifically interacted with CLIC3 but not the other recombinant proteins are listed 
in the table. From left to right are: gene symbols, accession numbers, molecular weights and 
number of unique peptides identified in repeat 1 (I) and 2 (II) 
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Figure 6-2 Preliminary data on PTPN14. 
A. Interaction of PTPN14 with GST-CLIC3 was confirmed by Western blotting with a rabbit PTPN14 
specific antibody, GST antibody was used to verify protein loading. B. PTPN14 siRNA s.pool 
efficiently suppresses PTPN14 protein levels 48 hours after nucleofection and ectopic expression 
of Flag-PTPN14 persists for 48 hours. C. Depletion of PTPN14 leads to potentiation of EGFR 
phosphorylation on Tyr 1045. D. PTPN14 seems to drive invasion into fibronectin-rich collagen 
plugs. Shown are representative collagen strips and quantification of invasion beyond 45µm. Data 
are mean from 2 experiments. All experiments in this figure were performed with A2780-Rab25 
cells. 
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.3 Final discussion and conclusions 
6.3.1 Signalling from late endosomes/lysosomes 
Endosomal vesicles are pivotal sites of receptor-initiated signal transduction and 
can act as scaffolds for the assembly of new signalling platforms, thus affecting 
signalling downstream of active transmembrane receptors following their 
internalisation (von Zastrow and Sorkin 2007). Indeed, EGFR remains associated 
with Grb2 and Shc upon its endocytosis, which allows activation of Ras residing 
within these endosomes (Jiang and Sorkin 2002). Additionally, internalisation of 
EGFR1 has been shown to be required for prolonged activation of PKB/Akt, but 
not MAPK signalling (Goh, Huang et al.). Moreover, G-protein-coupled receptors 
(GPCRs) are thought to initiate MAPK signalling cascades from endosomes and 
this occurs mainly through their interaction with arrestin-1 and -2, which in turn 
bind components of MAPK pathway (Lefkowitz and Shenoy 2005). Indeed, the 
stability of the GPCR and β-arrestins association determines the extent of ERK 
activation (Tohgo, Choy et al. 2003). Furthermore, distinct internalisation and 
recycling routes of αvβ3, α5β1 integrin or EGFR can determine the way in which 
these receptors activate distinct signalling pathways (Caswell, Chan et al. 2008; 
Sigismund, Argenzio et al. 2008) and this is particularly evident for EGFR1. 
Indeed, when internalised via the CME route, this receptor is recycled to the cell 
surface, which prolongs signalling to Akt and ERK. On the other hand, clathrin-
independent internalisation commits EGFR1 for degradation thus attenuating 
signalling events (Sigismund, Argenzio et al. 2008). 
Lysosomes have been canonically considered to be a cul-de-sac of the 
endo/exocytic pathway, in which cargo proteins are degraded. However, studies 
of Lippincott-Schwarz reported a bi-directional flux of cargo between lysosomal 
and endosomal compartments as well as plasma membrane (Lippincott-Schwartz 
and Fambrough 1987), and those of Wubbolts suggested a direct delivery of
ing NGF binding, TrkA neurotrophin receptor undergoes internalisation, 
lysosomal contents to the cell surface (Wubbolts, Fernandez-Borja et al. 1996). 
Recently, trafficking of internalised receptors to late endosomes/lysosomes has 
been connected to cellular signalling events and lysosomes have been reported 
to be scaffolds for the assembly of numerous protein complexes. Indeed, 
follow
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transits through early endosomes to then arrive in late endosomes. At late 
endosomes, a tetrameric complex is formed, which involves the TrkA receptor 
ng (Hisata, Sakisaka 
et al. 2007). Also, components of the MAPK signalling pathway, MEK1-ERK, are 
grating Rac1 activation with 
Rab7 function, it plays a role in Arf6 dependent disassembly of junctions and 
and this induces sustained activation of Rap1 and ERK signalli
localised to Rab-7 and LAMP1-positive late endosomes/lysosomes through a p14-
MP1 scaffold complex, and such endosomal localisation is necessary for full 
activation of ERK (Wunderlich, Fialka et al. 2001; Teis, Wunderlich et al. 2002). 
Moreover, the anchoring of MEK1-ERK signalling pathway to late endosomes 
requires a lipid raft adaptor protein, p18 (Nada, Hondo et al. 2009). More 
recently, it has become clear that the Rag proteins, which are amino acid 
specific regulators of the growth-regulating mTORC1 pathway (Sancak, Peterson 
et al. 2008), reside at the cytoplasmic face of the lysosomal membrane. The 
trimeric complex composed of p14, MP1 and p18 (as mentioned above with 
respect to MEK1-ERK signalling, but which these authors termed Ragulator), 
interacts with Rag GTPases and this interaction mediates the translocation of 
mTORC1 to the lysosomal membrane, and this is necessary for the activation of 
the mTORC1 pathway in response to amino acids (Sancak, Bar-Peled et al.). It is 
worth noting, that the mTOR pathway has been implicated in human cancers and 
that rapamycin, an agent antagonising mTOR signalling, has been successfully 
used for the treatment of several cancers, thus suggesting that signalling from 
lysosomal membranes plays a role in human cancer (Sudarsanam and Johnson). 
Late endosomes have also been shown to provide a platform for a cross-talk 
between signalling from Rac1, Rab7 and Arf6. A TBC domain-containing RabGAP, 
Armus, interacts with activated Rac1, and by inte
promotes E-cadherin degradation (Frasa, Maximiano et al.). This in turn can 
facilitate EMT and tumour progression and metastasis, thus forming a link 
between the lysosomal compartment and tumour progression. 
K-Ras has been shown to translocate to intracellular endosomal membranes 
through a clathrin-mediated pathway and upon EGF stimulation. Following 
sorting in the early endosomal compartment, K-Ras is transported to Rab7- and 
LAMP1-positive late endosomes and lysosomes. This endo/lysosomal 
compartment acts as a platform for K-Ras activation, and K-Ras present on 
LAMP1-positive late endosomes/lysosomes can recruit its effector Raf1, 
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suggesting that it is capable of signalling from this endocytic compartment (Lu, 
Tebar et al. 2009). K-Ras is known to be a pivotal oncogene and to be frequently 
mutated in many epithelial human cancers and in mouse models of this disease. 
K-Ras activating G12D mutation occurs in 90% of human PDAC and it drives 
tumour progression (Almoguera, Shibata et al. 1988). Indeed, in a mouse model 
of pancreatic cancer it is G12D K-Ras that cooperates with R172H p53 to 
promote progression to metastatic disease (Hingorani, Wang et al. 2005). 
Interestingly, Singh and colleagues used pancreatic and lung cancer cell lines 
that harboured K-Ras mutation to deplete K-Ras with siRNA, and identified two 
classes of cell lines – one that relied on K-Ras for viability and one that did not. 
They then analysed the gene expression signature of the K-Ras dependent cell 
lines and identified a number of genes such as Syk or integrin β6, whose 
depletion can induce EMT. More importantly, Rab25 was also shown to be a 
component of the K-Ras dependency signature (Singh, Greninger et al. 2009). 
These reports and my findings could suggest that late endosomal/lysosomal 
compartment is a point of convergence for K-Ras, CLIC3 and Rab25 and that this 
is relevant to human cancer. 
The non-receptor tyrosine kinase Src localises to membraneous compartments, 
such as late endosomes or plasma membrane, with the active pool of Src mostly 
residing at focal adhesion sites (Fincham, Unlu et al. 1996). Delivery of activated 
Src to the cell surface has been shown to require not only Rab11, but also a late 
endosomal Rho family protein, RhoB (Sandilands, Cans et al. 2004). In keeping 
with this, the proper functioning of the late endosomal/lysosomal compartment 
is key for the trafficking of activated Src from endosomal compartments to the 
cell periphery and for its correct localisation to focal adhesions. Perturbation of 
ESCRT pathway or Rab7 function leads to the accumulation of active Src at 
aberrant late endosomes/lysosomes and this affects Src-mediated signalling and 
cell migration (Tu, Ortega-Cava et al.). Furthermore, depletion of a key 
component of the mammalian ESCRT-I complex, Tsg101, results in impaired Src-
mediated activation of its downstream effectors STAT3 (Turkson, Bowman et al. 
1998) and FAK (Schlaepfer and Hunter 1996), and this leads to reduced cell 
motility (Tu, Ortega-Cava et al.). Strikingly, the above observations share a 
number of parallels with my findings. Firstly, I have shown that recycling of 
active α5β1 integrin requires a late endosomal/lysosomal protein, as did the 
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trafficking of Src. Secondly, depletion of CLIC3 affects cell migration, as did the 
perturbation of ESCRT pathway. Thirdly, I have shown that high expression of 
late endosomal/lysosomal protein, CLIC3 correlates with active Src and STAT3, 
and so did Tsg101 in the above mentioned study.  
Taken together, the above reports suggest that late endosomal/lysosomal 
compartment is a key nexus point for integrating signalling from mTOR, K-Ras 
and Src. My findings indicate that α5β1 integrin passes through this 
compartment, and the possibility that this integrin could impinge directly on 
these signalling pathways and this could have relevance to human cancer. 
6.3.2 Exosomes and cancer 
Mammalian cells can secrete proteins from their biosynthetic pathways either 
through controlled release of secretory granules or via constitutive exocytosis of 
secretory vesicles (Simpson, Jensen et al. 2008). Exocytosis is a process of 
cellular secretion, in which the endosomal luminal contents are released from 
the cell through the fusion of vesicular membrane with the plasma membrane 
endosomal tetraspanin CD63 is enriched in exosomes secreted by human B-
(Idone, Tam et al. 2008). Exocytosis of multivesicular bodies (MVBs) proceeds 
through the fusion of their limiting membrane with the plasma membrane and 
can then lead to the release of their luminal contents, including exosomes, 
which are membrane vesicles of endocytic origin that are 40-100nm in diameter 
(Simpson, Lim et al. 2009).  
Exosomes have been found in multiple body fluids, such as urine, blood, 
malignant ascites, bronchoalveolar lavage or amniotic fluid and are thought to 
contribute to multiple biological functions, such as the immune response, 
intracellular communication or RNA and protein transfer (Simpson, Lim et al. 
2009). Exosomes have been reported to be secreted into the culture medium by 
a number of mammalian cancer cell lines and into tumour ascites by tumours in 
vivo (Wolfers, Lozier et al. 2001; Andre, Schartz et al. 2002; Hegmans, Bard et 
al. 2004; Mears, Craven et al. 2004; Koga, Matsumoto et al. 2005). Exosomes 
originating from different cell types have distinct molecular compositions, but 
late endosomal and lysosomal proteins have been consistently detected to be 
released from cells in association with exosomes. For example, the late 
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lymphocytes (Escola, Kleijmeer et al. 1998), platelets (Heijnen, Schiel et al. 
1999) or mast cell lines (Valadi, Ekstrom et al. 2007). Interestingly, multiple 
integrin family members are common components of secreted endosomes 
(Fevrier, Vilette et al. 2004), and specifically, α4 integrin is present in B-cell-
derived exosomes (Wubbolts, Leckie et al. 2003). Additionally, multiple integrin 
ents. 
Alix, is a well established marker of exosomes and it has been detected in 
anoma cell lines (Mears, Craven et al. 2004) 
and in dendritic cell-associated secretions (Thery, Boussac et al. 2001). It has 
Tumour-derived exosomes from malignant ascites of cancer patients may serve 
heterodimers have been detected in cancer cell-associated secretions, such as 
melanoma-derived exosomes (Mears, Craven et al. 2004) and those originating 
from colon cancer cell lines (Simpson, Jensen et al. 2008). The presence of 
integrins in exosomes is consistent with my observations and those of Lobert et 
al, that integrins can be abundant on late endosomal/lysosomal compartm
exosome lysates derived from mel
also been shown to promote α5β1 integrin-mediated cell adhesion and 
fibronectin matrix assembly (Pan, Wang et al. 2008), which might suggest an 
interesting link between integrins, exosomes and cell migration. Furthermore, 
an extracellular matrix protein thought to mediate adhesion of endothelial cells 
through αvβ3 integrin, DEL-1 (Hidai, Zupancic et al. 1998), has been seen in 
exosomes derived from mesothelioma cells (Hegmans, Bard et al. 2004). In light 
of all the above evidence, exosomes could be an attractive link between integrin 
function and recycling from late endosomes/lysosomes, and endocrine and 
paracrine processes involved in cancer metastasis. 
as an important diagnostic tool and could be used for biomarker discovery. 
Indeed, in some cancer types, certain tumour overexpressed proteins, have been 
also found in tumour-associated secretions. For example, HER2 has been seen in 
breast cancer exosomes (Koga, Matsumoto et al. 2005) and A33 antigen in colon 
cancer cell-line associated secretions (Heath, White et al. 1997). Interestingly, 
one of the CLIC family members, CLIC1, has been reported to be secreted by 
tumour cells and to be detectable in serum and plasma samples of 
nasopharyngeal cancer patients, suggesting it could be used as plasma biomarker 
of this carcinoma (Chang, Wu et al. 2009). It has also been proposed as a 
potential serological marker for early detection of breast carcinoma (Gromov, 
Gromova et al.). In preliminary experiments CLIC3 has been detected in A2780-
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Rab25 ovarian carcinoma cell culture supernatants, which suggests it may be a 
component of tumour secretome. It is possible that CLIC3 follows the route 
taken by the integrins recycling from late endosomes/lysosomes to then be 
released in association with exosomes, and Rab27 could play a role in that 
process. This GTPase has been shown to govern the exosome secretion pathway, 
and Rab27a and Rab27b have been found to facilitate MVEs docking at the 
plasma membrane and subsequent exosomes secretion, in a process that 
depends on Rab27 effectors, such as Slp4 (Ostrowski, Carmo et al.). My 
identification of Slp1 as a Rab25 and CDM-upregulated gene, alongside with 
CLIC3 (Chapter3), and reports on its binding to Rab27A (Kuroda, Fukuda et al. 
2002; Neumuller, Hoffmeister et al. 2009), further encourage exploration of this 
avenue. 
Finally, the observations that members of the CLIC family are components of the 
tumour-associated secretome and the correlation between CLIC3 expression in 
PDAC samples and patient outcome suggest that CLIC3 could potentially be used 
as a secreted biomarker in the clinic for early detection of PDAC and other 
aggressive carcinomas.  
6.3.3 Integrins in cancer progression and in the clinic 
Alterations in the expression or function of integrins result in aberrant cell 
adhesion and migration, and have been linked to a number of diseases, such as 
inflammatory bowel disease, asthma, cardiovascular diseases and cancer 
(Huveneers, Truong et al. 2007). High expression levels of integrins have been 
seen to correlate with tumour progression. Indeed, genetic disruption of β1 
integrin function in the mammary epithelium of a transgenic mouse model of 
human breast cancer inhibits the initiation and maintenance of breast 
malignancy (White, Kurpios et al. 2004). Similarly, integrin signalling is required 
for transition of premalignant hyperplasia to carcinomas and their subsequent 
metastases. This is evidenced by impaired mammary tumour progression 
following disrupted function of FAK (Lahlou, Sanguin-Gendreau et al. 2007), a 
protein which is a key component of integrin focal adhesion complexes and 
which regulates integrin-mediated adhesion and migration (Schlaepfer, Mitra et 
al. 2004). Furthermore, a recent study has shown that inhibition of integrin 
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signalling represses invasion of a pre-malignant epithelium into ECM, whilst 
forced integrin clustering triggers integrin-mediated signalling and invasion 
(Levental, Yu et al. 2009). These authors suggest that it is enhanced signalling 
downstream of integrins and not necessarily increased integrin expression that is 
required for tumour progression. Finally, β1 integrin has been shown to be 
dispensable for tumour initiation but β1-deficient mice have displayed lower 
capacity to metastasise to the lung and this was owing to abrogated adhesion 
signalling. These observations suggest that this integrin plays a key role in 
tumour progression (Huck, Pontier et al.).  
Thus many experiments conducted in animal models and other ex vivo systems 
have identified integrins as promising targets for cancer therapies and have 
encouraged the development of integrin antagonists for use in the clinic. These 
r the treatment of cancer, blocking of α5β1 and αvβ3 
integrin has been most widely studied (Huveneers, Truong et al. 2007).  
The RGD sequence is a component of several extracellular matrix proteins, such 
et al. 2002) and is being tested in clinical trials (Stupp and Ruegg 2007).  
molecules interfere with integrin binding to its natural ligands, thus preventing 
integrin-mediated signalling and potentially opposing tumour progression and 
metastasis (Mizejewski 1999). Integrin antagonists can be divided into three 
main groups: small molecule compounds, peptidomimetics and monoclonal 
antibodies (mAb), and fo
as fibronectin, and it serves as a recognition site for many integrins 
(Pierschbacher and Ruoslahti 1984). Disintegrins have been discovered in snake 
venoms and are RGD-containing cysteine-rich peptides, which can also bind to 
integrins thus blocking their function, and have been seen to inhibit tumour 
growth and angiogenesis in xenograft tumour models (Swenson, Costa et al. 
2005). However, the use of naturally occurring peptides as therapeutic agents is 
limited due to their relatively large size and low metabolic stability. These 
issues have been addressed by the use of cyclic structures, and cyclic RGD 
pentapeptides are commonly used to target αvβ3 integrin (Ruoslahti 1996). 
Indeed, cyclo (RGDfV) is highly effective at antagonising αvβ3 and has anti-
angiogenic potency (Friedlander, Brooks et al. 1995). Further modifications to 
the structure of this compound have led to the generation of a more potent and 
selective agent, Cilengitide (c(RGDf(NMe)V)) (Goodman, Holzemann et al. 2002), 
which induces apoptosis in glioblastoma and medulloblastoma cells (Taga, Suzuki 
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icart, Tolcher et al. 2008; Ng, Bai et 
al. 2009) has entered clinical trials as a potential anti-angiogenic therapeutic in 
timulate 
angiogenesis and tumour growth (Reynolds, Hart et al. 2009). This dichotomy in 
Peptidomimetics are a relatively new class of non-peptide chemical RGDs, and 
α5β1-specific antagonist, ATN-161, has been shown to decrease the occurrence 
of liver metastases in colorectal cancer cell line xenografts and to increase 
survival in mice (Stoeltzing, Liu et al. 2003). Another group of integrin blocking 
agents encompasses monoclonal antibodies that target the extracellular domain 
of the heterodimers, and those directed at α5β1 integrin have been shown to 
cause regression of human tumours in mouse models by acting as anti-
angiogenics (Kim, Bell et al. 2000). Volociximab (M200), a chimeric humanised 
antibody that shows high affinity for α5β1 (R
platinum resistant ovarian cancer, but this study has been terminated due to 
lack of efficacy (http://clinicaltrials.gov/ct2/home). 
Even though inhibition of αvβ3 integrin in in vitro and ex vivo models has 
indicated that this approach may be beneficial for opposing cell migration and 
angiogenesis, and could serve as a potential anti-cancer therapy, clinical trials 
with Cilengitide have not shown extraordinary results (Stupp and Ruegg 2007). 
This could be attributed to the recent findings demonstrating that αvβ3 
inhibition can be pro-invasive (Caswell, Chan et al. 2008) and can s
Cilengitide’s effect is thought to depend on the dose of this compound, and 
concentrations capable of blocking angiogenesis are much higher than those that 
enhance tumour growth and angiogenesis (Reynolds, Hart et al. 2009). Moreover, 
Cilengitide has been shown to drive the coordinate recycling of α5β1 and EGFR, 
which potentiates EGFR-mediated signalling and drives invasive migration of 
cancer cells (Caswell, Chan et al. 2008). This could suggest that the application 
of αvβ3 blocking agents would be beneficial but only in combination with 
regimens that target EGFR. 
The above reports of context-dependent efficacy of integrin blocking agents and 
the failures of integrin antagonists in clinical trials call for the determination of 
expression signature of individual tumours, which would help in assigning the 
most suitable therapeutic regimen for a particular individual. In that respect, 
CLIC3 may provide a powerful tool for the identification of patients that would 
benefit from integrin-targetting therapies.  
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7 Appendices 
 
CDM. 
Gene names corresponding to gene symbols of transcripts differentially expressed in A2780-Rab25 
cells as compared to A2780-DNA3 cells after both were seeded onto three dimensional cell derived 
matrices (CDM), as previously shown in figure 3.5 On
are corresponding gene names. 
Appendix 3.1 Genes differentially expressed in Rab25-expressing cells when plated onto 
 the left listed are gene symbols, on the right 
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Appendix 3.2 Genes differentially expressed in Rab25-expressing cells when plated onto 
CDM. 
Continuation of Appendix 3.1. 
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Appendix 3.3 Genes differentially expressed in Rab25-expressing cells when plated onto 
plastic surface. 
Gene names matching the gene symbols of transcripts whose expression is regulated by Rab25 on 
plastic, as previously shown in figure 3.6. Gene symbols are listed on the left and corresponding 
gene names are on the right. 
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Appendix 3.4 Genes differentially expressed in Rab25-expressing cells when plated onto 
plastic surface. 
Continuation of Appendix 3.3. 
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Appendix 4.1 CLIC3 expression vectors. 
A. Flag-CLIC3 B. Cherry-CLIC3 C. GST-CLIC3 
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Appendix 4.2 α5β1 integrin pool is not degraded in A2780-Rab25 cells. 
A2780-Rab25 cells were surface-labelled with o.2mg/ml NHS-S-S-Biotin at 4ºC and internalisation 
then allowed to proceed for 30 min at 37ºC in the presence of 2.5µg/ml fibronectin. Biotin remaining 
at the cell surface was removed by exposure to MesNa at 4ºC, then the cells were incubated for 
the indicated times at 37ºC. The quantity of biotinylated receptor remaining within the cells was 
determined by capture-ELISA using microtitre wells coated with antibodies recognising α5.  
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Appenix 4.3 Photoactivation of α5β1 in a region lacking CLIC3 vesicles. 
A2780-Rab25 cells were co-transfected with 1.2µg of Cherry-CLIC3 and 4.8µg of photoactivatable 
wild type α5 integrin; paGFP-α5. 2.5µg/ml of soluble fibronectin (FN) was used for 1.5 hours prior 
to photoactivation to increase colocalisation between CLIC3 and α5 integrin. Photoactivation was 
performed with 405nm laser aimed at CLIC3-negative regions, as indicated by the white arrows. 
Images were then captured with a confocal microscope every 2 seconds over a period of 120 
seconds. Movies were generated from these time-lapse images and stills corresponding to 
individual frames from a representative movie are presented. These include a frame prior to 
photoactivation, one immediately after photoactivation (0 sec) and subsequent ones at 15 second 
intervals after photoactivation, as well as full field activation that illuminates total pool of α5 integrin. 
Top panel shows α5 integrin in grey, bottom panel depicts merged images with α5 in green and 
CLIC3 in red. Scale bar, 10µm. 
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Appendix 6.1 Proteins identified to interact with CLIC3 by mass spectrometry. 
Protein names correspond to gene symbols listed in Figure 6.2. 
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